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Infectious diseases are one of tiie most common causes of morbidity and mortality in 
liumans. Development of antibiotic therapy has resulted in successful treatment of 
bacteria and fungal diseases. However, due to the excessive and indiscriminate use of 
drugs, emergence and spread of drug resistant strains have become a common problem 
today. Incidence of microbial infections has increased in recent decades; especially 
mycoses caused by various pathogenic and opportunistic groups are on the rise in the 
different parts of the world as a consequence of growing number of immunocompromised 
patients due to the HIV infections, cancer chemotherapy and organ or bone marrow 
transplantations (Aperis et al. 2006). Various fungal diseases caused by members of 
Aspergillus spp, Candida, spp and dermatophytes are classified as aspergillosis, 
candidiasis and dermatophytosis respectively. Other known pathogens are Cryptococcus 
spp, Fusarium spp and Rhizopus spp. These pathogens are mainly serious threats in 
immunocompromised individuals, however, Trichophyton spp, Epidermophyton spp, 
Histoplasma spp, Blastomyces spp, Sporothrix spp, Coccidioides spp, and 
Paracoccidioides spp, are capable of infecting healthy people as well. 
Infections of alveolar tissues by members of genus Aspergillus produce a spectrum of 
lung diseases known as aspergilloses. The disease involves pulmonary aspergilloma, 
invasive aspergillosis and allergic bronchopulmonary aspergillosis and is mainly caused 
by A. fumigatus and A. niger and less frequently by A. flavus and A. clavatus. Invasive 
aspergillosis caused hy Aspergillus spp is considered as a major cause of morbidity and 
mortality in immunocompromised hosts and mortality rates may range from 40 to 90% in 
high risk populations (Erjavec et al. 2009; Pfaller and Diekema 2010). 
Other chronic infections associated with the immunocompromised patients are of hair, 
skin and nails and are primarily caused by Trichophyton rubrum and other dermatophytes 
and had shown increased incidence in recent years especially in the tropical countries 
(Venkatesan et al. 2007; Vermount et al. 2008). Such infections are not life-threatening; 
however, both immunocompetent and immunosuppressed persons are affected. Such 
infections have increased considerably among pediatric and geriatric populations 
(Mukherjee et al 2003b; Monod 2008) and carry considerable morbidity and can become 
serious in immunocompromised patients resulting in invasive infections (Sokovic et al. 
2006). 
Opportunistic fungal infections are a serious threat to such patients and have been 
reported to occur at an alarming rate (Pinto et al. 2006). Candida species are 
opportunistic pathogens that cause superficial and systemic diseases in critically ill 
patients with weakened immunity (Richardson 2005). In such persons, Candida 
infections mainly caused by C. albicans are very common producing oral, vaginal and or 
systemic candidiasis (Claderone 2002), with the highest morbidity rate (30-50%) 
occurring with systemic Candida infections in neutropenic transplant patients (Tortorano 
et al. 2006). Furthermore, candidiasis is the most common invasive fungal infection in 
the critically ill non neutropenic patients (Eggimann et al. 2003). Candida spp are the 
most common agent of hospital acquired bloodstream infections (Citak et al. 2005) and 
accounting for 8 to 9% of all the bloodstream infections with a crude mortality rate of 
40% (Pfaller and Diekema 2007). Oropharyngeal candidiasis is generally common in 
AIDS patients who do not have access to highly active antiretroviral therapy (HAART) 
(De Repentigny et al. 2004) whereas oral candidiasis often affects cancer patients 
undergoing chemotherapy and/or radiotherapy (Davies et al. 2006). Around 75% of the 
adult women have at least one episode of vulvovaginal candidiasis (VVC) during their 
life, with the prevalence of C. albicans in 70-90% cases (Mardh et al. 2002; Mendling et 
al. 2004). 
The majority of manifestations of candidiasis are associated in one way or another with 
the formation of Candida biofilms on the surfaces of inert or biological materials, and 
this phenotype is associated with infections at both the mucosal and systemic sites 
(Crump and Collignon 2000). Biofilm-associated infections may be either persistent or 
recurrent (Fux et al. 2005). It has been speculated that biofilms account for as much as 
65% of all microbial infections (Potera 1999). C. albicans is the major fungus that 
colonizes medical implants such as dental implants, heart valves, vascular bypass grafts, 
ocular lenses, artificial joints, intravenous catheters and central nervous system shunts, 
stents, etc, causing device-associated infections with high mortality (Ramage et al. 2006). 
The biofilms on implants and other surgical devices may lead to failure of devices and 
furthermore, these biofilms serve as a source of recalcitrant infection. Hence, it is 
difficult to treat implant-mediated infections and the only chance is to remove the implant 
device, which may complicate the situafion in case of major surgeries. Candida infections 
are placed third in catheter related infections, second highest in colonization-to-infection 
rate, and overall highest in crude mortality (Crump and Collignon 2000). 
In addition to C. albicans, non albicans species of Candida have now been emerged as 
increasing cause of infection with mortality rate ranging from 15-35% (Krcmery and 
Barnesz 2002). Some reports from India have also highlighted the emergence of NAC 
causing candidiasis (Capoor et al. 2005). The reasons for this epidemiological shift are 
not clear; however, the decreased susceptibility of these species relative to C. albicans to 
commonly use antifungal agents such as fluconazole has been implicated as being at least 
partially responsible (Chavanet et al. 1994). On the other hand cryptococcosis is a 
leading cause of death among immunocompromised patients, and cryptococcal 
pneumonia is the next most frequent manifestation of cryptococcosis in AIDS patients 
and occurs as a primary infection in approximately 4% of cases (Sugar 1991). 
Cryptococcal meningitis is the fourth most commonly recognized cause of life 
threatening infection among AIDS patients (Kwon-Chung and Bennet 1992). Reports 
have indicated the high incidence of cryptococcal infections in developing countries 
including India (Banerjee et al. 2004). 
With the increasing number of immunosuppressed patients at an unprecedented rate, the 
management of these fungal infections would be a definite challenge to mankind. The 
antifungal drugs most commonly used against these diseases include amphotericin B, 
ketoconazole, fluconazole, terbinafine and flucytosine. On the past several years there has 
been an impressive increase in the antifungal armamentarium due to the advances in 
antifungal therapies (Sakagami 2010). But many problems remain to be solved for most 
of the commonly available antifungal drugs such as nephro and hepato toxicities 
associated with the use of amphotericin B (Groll and Kolve 2004). A lipid formulation of 
amphotericin B is less toxic but costly, and also, therapeutic response is slow in 
immunocompromised patients (Herbrecht et al. 2003). Azoles, particularly fluconazole, 
presenting decreased toxicity after oral and intravenous administration, are often 
employed (Groll and Kolve 2004). Fluconazole is considered to be one of the safest 
antifungals used in the treatment of fungal infections but the fungistatic nature and the 
development of resistance in fungi have restricted the use of fluconazole (Balkis et al. 
2002; Ishida et al. 2006). 
There are several reports on the increasing azole drug resistance in Aspergillus spp and 
dermatophytes (Ballcis et al. 2002; Howard et al. 2006; Santos and Hamdan 2007). 
Failure of azole therapy was observed due to intrinsic resistance in Candida spp. such as 
C. krusei and C. glabratu and acquired resistance in previously susceptible strains of C. 
albicans due to its continual use in the AIDS and cancer patients (Pfaller et al. 2006). 
About 3.6-7.2 % of C. albicans isolates from women with vaginitis are resistant to 
fluconazole (Sobel et al. 2003) and, oropharangeal candidiasis due to the fluconazole-
resistant Candida has long been a problem for patients infected with HIV (Revankar et 
al. 1996; Perea and Patterson 2002). In immunosuppressed patient the prolonged 
exposure to fluconazole has shifted the predominant vaginal yeast flora from C. albicans 
to more intrinsically azole-resistant species. 
The intrinsic low level and acquired high level azole-resistance in C. glabrata has likely 
contributed to its recent emergence as a pathogen (Katiyar et al. 2006). C krusei is 
another species of clinical importance, primarily because of its innate resistance to azole 
antifungal drugs (Hakki et al. 2006). Azole- and amphotericin B- resistance in C. 
neoformans is also reported to be inherent or acquired (Perfect and Cox 1999). 
Furthermore, Sessile (biofilm) cells display unique phenotypic traits in comparison with 
planktonic cells. The most notable of these is that sessile cells are notoriously resistant to 
antimicrobial agents and withstand host immune defenses (Douglas 2003), and this is the 
main reason why biofilm-associated infections are frequently refractory to conventional 
antibiotic therapy. Decreased susceptibility of sessile cells to antimicrobial agents 
including amphotericin B, fluconazole, itraconazole and ketoconazole compared to those 
planktonic cells has also been reported extensively over the past decade (Seneviratne et 
al. 2008). Newly developed echinocandins, less toxic and activity comparable to 
amphotericin B, display excellent inhibitory and cidal activity against isolates of C. 
albicans exhibiting higher levels of resistance to fluconazole (De Logu et al. 2005; 
Messer et al. 2006). These semisynthetic echinocandins inhibit synthesis of 1,3-P-D-
glucan, a main structural component of the fungal cell wall and extracellular materials of 
biofilms, and are quite effective against Candida biofilms (Bachmann et al. 2002). But 
therapy with echinocandins is still expensive and often not affordable, in particular, in 
developing countries (Onyewu and Heitman 2007). Therefore, considering the 
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importance of fungal infections, in particular in immunocompromised patients, and 
limitations of currently available antifungal drugs regarding their toxicities, fungistatic 
activities, treatment costs and increasing prevalence of pathogen resistance both in 
planktonic and biofilms leading to recalcitrant infections, the search for new alternative 
strategies or new drug formulation to combat fungal infections is justified and research in 
this direction is urgently needed. 
Therefore, to combat such infections novel anti-mycotic agents with broad spectrum of 
action and fewer dose limiting side effects are needed. Alternative strategies employed to 
overcome the problems include use of currently available antifungal drugs in 
combination with antifungal agent with newer mode of action (Baddley and Pappas 
2007). Targeting virulence attributes is an attracting attention to develop antifungal agent 
based on anti-pathogenic drug principle. Recent developments in fungal genomics have 
provided unprecedented opportunities for identifying new antifungal drug targets and 
subsequently exploiting in drug development. However, successful outcome from 
genomics is still awaited. 
In these perspectives, search for alternative mode of therapy and discovery of new anti-
infectives with novel modes of action with no or least toxicity from various sources 
including natural products is needed. Plant products especially essential oils, traditionally 
being used in ethnomedicine as effective antifungal agents against infectious diseases 
caused by yeasts and moulds, have been expected to deliver newer antifungal compounds 
and can be exploited as alternative therapy alone or in combination with known 
antifungals. Essential oils are volatile, natural, complex compounds characterized by a 
strong odour and are formed by aromatic plants as secondary metabolites. They are 
mixtures of different lipophilic and volatile substances, such as monoterpenes, 
sesquipterpenes, and phenylpropanoids. Furthermore, they are considered to be a part of 
the preformed defense system of higher plants (Bakkali et al. 2008) and therefore, 
expected to deliver active anti-microbial results in infectious diseases. In the past few 
decades interest in plant products has increased, and medicinal plants have been 
investigated for various biological activities and therapeutic potentials (Cowan 1999; 
Mehmood etal. 1999; Ahmad and Beg 2001; Aqil etal. 2010). 
Several in vitro and in vivo studies using plant products traditionally being used in 
ethnornedicine have shown promising antifungal activity, especially when plant essential 
oils are used (Mondello et al. 2003; Ishida et al. 2006; Park et al. 2007; Bansod and Rai 
2008; Bajpai et al. 2009). Recent scientific literatures have shown promising therapeutic 
activity from essential oils against a range of pathogenic yeasts, dermatophytes including 
Candida albicans, Trichophyton spp, and Aspergillus spp, associated with mucosal, 
cutaneous and respiratory tracts infections (Pina-Vaz et al. 2004; Cavaleiro et al. 2006; 
Sanguinetti et al. 2007; Fontenelle et al. 2008; Pinto et al. 2009; Zuzarte et al. 2011). 
Several workers have reported promising anti-candidal activity against mucosal 
candidiasis from various essential oils (Mondello et al. 2006; Zhang et al. 2006; Noumi 
e? a/. 2010). 
Combinations of two or more antifungal drugs have been exploited to achieve better 
therapeutic action against invasive and systemic mycoses. It is desirable to assess 
compounds with newer modes of action to existing antifungals and test these in 
combinations. Combination therapy has potential advantages over monotherapy in terms 
of reducing dose related toxicity and emergence of drug resistance. The problems 
associated with fluconazole and amphotericin B, might be overcome with combination 
therapy, however, it is still immature in many countries (Ahmad et al. 2010c). Some 
restrictions of combination therapy for chemical drugs are reported. The effective 
combination of calcineurin inhibitors such as cyclosporine A or tacrolimus (Onyewu and 
Heitman 2007) with azoles is being restricted due to the toxicity associated with the 
cyclosporine A (Wu et at. 2004). Even synergistic combinations of amphotericin B or 
fluconazole with echinocandins (Groll and Kolve 2004; De Logu et al. 2005; Onyewu 
and Heitman 2007) is discouraging due to its increased cost. In this perspective, there is a 
need for new cost effective fungicidal drug with no or lower toxicity in the therapy giving 
effective results alone or in combination with the available antifungal drugs. The 
essential oils showing promising activity might synergistically interact with antifungal 
drugs and therefore need to be explored. 
The phyto-products have been subjected to determine their potential modes of action and 
target sites. The mode of action of essential oils as an antifungal agent is less understood 
and is expected to be different than that of available antifungal drugs (Baby and George 
2008). Moreover, natural products are cheaper and considered safer, they could be better 
explored for their synergistic interaction with drugs of choice against fungal infections 
potentially resulting in more cost effective and safer formulations. Some in v/tro reports 
have suggested the synergistic interaction of certain oils with fluconazole and 
amphotericin B against candidal infections (Rukayadi et al. 2009; Khodavandi et al. 
2010; Mahboubi and Bidgoli 2010). However, no systematic screening or synergy studies 
on various plant essential oils against drug resistant strains of fungi have been conducted. 
This has prompted us to assess the possible synergy between essential oils and common 
antifungal drugs against drug-resistant strains of fungi. 
Another emerging approach for developing antifungal agent is to attack target enzymes or 
factors whose absence or inhibition, although not lethal for fungi, leads to a loss or 
decrease of virulence. In the recent years, virulence factors are considered as promising 
anti-infective drug targets and many researchers have attempted to obtain effective anti-
pathogenic drugs as a valuable approach against fungal infections (Gauwerky et al. 
2009). Establishment of infection by fungi depends on the host cell interaction with 
complex interplay of secretion of virulence factors mainly proteinases including 
elastinases, keratinases, gelatinases, lipases and phospholipases. These extracellular 
enzymes are probably essential for these organisms to degrade structural barrier and to 
obtain nutrient and in establishing infections (Voltan et al. 2008). Various virulence 
factors have been characterized in C. albicans such as germ tube formation, adherence, 
and phenotypic switching, production of extracellular enzymes such as proteinsaes, 
phospholipases, haemolysin and formation of biofilms and, have been shown to be 
involved in the pathogenesis of C. albicans (Claderone 2002; Douglas 2003; Gauwerky 
et al. 2009). 
Candidal colonization and infection depends on the initial ability to adhere to host 
surfaces; cell surface hydrophobocity and hyphal formation are required for adherence, 
colonization and tissue invasiveness (Claderone 2002). Nutrient uptake and invasiveness 
is also promoted by proteinases and phospholipases (Haynes 2001). C. albicans also 
secretes haemolytic factors that cause release of haemoglobin, which is then used as an 
iron source by the organism to grow in the host (Almeida et al. 2009). Little is known 
about the relative importance of individual virulence factors in superficial and systemic 
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infections. But it is established that several components combine to influence the 
virulence and pathogenicity. It is expected that compounds with the anti-pathogenic 
properties may reduce one or more virulence attributes and thus strain becomes non-
virulent. Several antifungal drugs such as fluconazole, ketoconazole, nystatin, 
amphotericin B and 5-fluorocytosine can also interfere with certain virulence factors 
(EUepola and Samaranayke 1998). Fluconazole and amphotericin B at sub-MICs can 
interfere with germ tube formation, adherence to buccal cells and interactions with 
phagocytic cells (Hazen et al 2000; Vale-Silva et al. 2007). The influence of essential 
oils on fungal virulence factors synthesis and activity are not yet explored or poorly 
known. And no systematic screening of plant essential oils have been made for inhibition 
of growth or virulence attributes especially in drug-resistant strains of fungi. 
In addition, plants are known to produce phytochemicals including essential oils that 
attenuate/inhibit biofilm development through specific mechanism (IMiu and Gilbert 
2004; Ramage et al. 2004). The essential oils of many aromatic plants are mixtures of 
various components (terpenes, aldehydes, alcohols, acyclic esters, etc.) with different 
chemotypes. They have antifungal effects and their specific ant\-Candida activity against 
planktonic forms is known (Knoblock et al. 1989; Mehmood et al. 1999; Pina-Vaz et al. 
2004). However, little is known about the spectrum of action of oils against Candida 
biofilm cells. Therefore, a systematic screening and evaluation of essential oils and active 
ingredients from essential oils against Candida biofilm is needed to identify promising 
novel anti-biofilm agent. 
Current antifungal therapy for such fungal infections has been threatened by the 
development of drug resistant strains, host toxicity of available polyenes and fungistatic 
mode of action of azoles. Therefore, to combat newly borne spectrum of fungal 
infections, steps should be taken to make the benefits of successful pharmaceutical 
research available to all and especially to those who are in the greatest need. In fact, it is 
the need of hour to search for new antifungal agents of herbal origin which are relatively 
economically affordable, safer and easily available to common men. Therefore, 
systematic screening and evaluation of plant essential oils and some of their active 
compounds against growth and virulence in fungi, and to explore their toxicity and 
mechanism of action for development as antifungal agent is justified. 
In lieu of this, the present study was proposed with the following aims and objectives: 
1. To characterize strains of Candida spp and filamentous fungi for their typical 
characteristics including production of virulence factors, susceptibility to 
antifungal drugs and formation of biofilms. 
II. To evaluate antifungal properties of certain essential oils against drug-resistant 
fungal pathogens. 
III. To examine the mode of antifungal action of essential oils. 
IV. To evaluate synergistic interaction between essential oils and antifungal drugs 
against drug-resistant fungal strains. 
V. To study the effect of potential antifungal essential oils on the production of 
certain virulence factors including extracellular enzyme activity in test fungi. 
VI. To determine the anti-biofilm activity of certain essential oils alone and in 
combination with antifungal drugs against C. albicans. 
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2.1. An introduction to human fungal infections 
Fungi are eukaryotic microorganisms that are more closely related to humans than 
bacteria at cellular level. They belong to group Eumycota and are chemoheterotrophs 
with a chitinous cell wall. More than 100,000 species have been described. Most species 
grow as multicellular filaments called hyphae forming mycelium such as molds; some 
species also grow as single cells like yeasts although some of them may grow as hyphae 
at room temperature and as yeast inside the host and are called as dimorphic. Some 
groups of fungi are pathogenic to humans, animals and plants, and require control 
measures. 
Human fungal pathogens belong to four main groups namely zygomycetes, ascomycetes, 
deuteromycetes and basidiomycetes. The fungal infections caused by these pathogens are 
categorized as (i) superficial; affecting nails, skin, scalp or mucous membrane, (ii) 
systemic; affecting deeper tissues and organs. Superficial infections are by far commoner 
and comprise the various types of tinea or ring worms affecting the skin, hair, and nails. 
The fungi causing such infections are specialized saprophytes, with the capacity to digest 
keratin viz. Pityriasis vesicolor, Cladosporum spp and dermatophytes like Trichophyton 
spp, Microsporum spp, Epidermophyton spp and Candida albicans. Systemic mycoses 
are caused by fungi that are mostly soil saprophytes. Systemic mycoses occur in varying 
degree of severity, ranging from asymptomatic infection to fungal diseases. The causative 
agents include Cryptococcus spp, Sporothrix spp, Paracoccidioides spp, Blastomyces 
spp, Histoplasma spp etc. A third type of fungal infections caused by opportunistic 
pathogen occurr in patients with debilitating diseases such as AIDS, cancer, diabetes or in 
whom the physiological state has been upset by immunosuppressive drugs. The causative 
agents are Candida albicans, Aspergillus spp, Mucor spp and Penicillium spp, Fusarium 
spp and Rhizopus spp, which are normally avirulent in healthy people but could be 
disseminated to deep tissue and cause fatal disease in unhealthy people (Pfailer and 
Diekema 2004; Chakrabarti 2005; Reedy et al. 2007). 
Over the past few years, major advances in healthcare have led to an unwelcome increase 
in the number of life-threatening infections due to true pathogenic and opportunistic 
fungi. These infections are increasing in number largely because of the increasing size of 
the population at risk. This population includes transplant recipients, cancer patients and 
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other individuals receiving immunosuppressive treatment. Furtliermore patients with 
burns, neutropenia, and HIV infections are now seriously exposed to fungal infections 
(Kuleta et al. 2009). Among such patients, novel and more intensive regimens have 
resulted in more profound levels of immuno-suppression that are sustained for longer 
periods. Likewise, the increasing use of invasive monitoring and aggressive therapeutic 
technologies in intensive care units has resulted in improved survival of individuals with 
life threatening illness, but contributing to an increase in the number of persons at risk for 
fungal infections (Richardson 2005). The increased incidence of fungal infections has 
coincided with a decrease in mortality from bacterial infections. This is probably the 
result of better antibiotic therapy, leading to increased survival of patients who are 
predisposed to fungal infections, as well as inappropriate broad spectrum antibiotic 
therapy disrupting the normal microbial flora on the skin and mucosal surfaces leading to 
opportunistic fungal pathogens to flourish. 
The estimated annual incidence of invasive mycoses is 72-228 infections per million 
populations for Candida species, 30-66 infections per million population for C. 
neoformans, and 12-34 infections per million populations fox Aspergillus species (Pfaller 
et al. 2006). The morbidity and mortality rates caused by species of Candida, 
Aspergillus, Fusarium and Trichosporum are relatively higher (Fluckiger et al. 2006). In 
Europe, the fungal infections are accounting for 17% cases associated with intensive care 
unit (Rupp 2007) while in USA it has become 7* most common cause of deaths among 
hospitalized patients (Martin et al. 2003). 
Data from the late 1950's and early 1960's indicates that invasive fungal infections were 
extremely rare, even in immunocompromised cancer patients (Chakrabarti 2005). 
Candidaemia rates increased rapidly in the 1980s, so that Candida spp became the fourth-
commonest cause of bloodstream infection in the USA (Edmond et al. 1999). The 
emergence of fungal rhinosinusitis, penicilliosis, marneffei and zygomycosis due to 
Apophysomyces elegans is unique in the Indian scenario. OPC is the most frequent 
opportunistic fungal infection among HIV-infected patients, and it has been estimated that 
more than 90% of HIV-infected patients develop this often debilitating infection at some 
time during progression of their disease (De Repentigny et al. 2004). Approximately 70% 
of woman experience vaginal candidiasis once in a life and 20% suffered from recurrence 
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(Fidel et al. 1999; Achkar and Fries 2010). Fungal infections now have also become more 
common in the healthy population. These diseases differ in their nature, causative agents 
and distribution. Description of such fungal diseases, their causative agents and major 
organs involved etc are summarized in table R-1. 
Table R-1 Examples of commonly caused fungal diseases (Source: Weitzman and Summerbell 
1995; Rappleye and Goldman 2006). 
Fungal diseases Causative agent Site of infection Transmission 
Dermatophytosis 
Histoplasmosis 
Blastomvcosis 
T. nibntm, T. 
menlagrophytes, E. 
floccosusm, M. gypseum, 
M. canis 
H. capsulatum 
B. dermatitidis 
Coccidioidomycosis C. immitis, C. posadasii 
Candidiasis 
Cryptococcosis 
Aspergillosis 
C. albicans, C. tropicalis, C. 
glabrata, C. knisei, 
C. diibliniensis 
C. neoformans 
A. fiimigatus, A. flavus, A. 
niger 
Hyalohyphomycosis Fusarium sp, Phecilomyces 
sp, Acremonium sp 
Zygomycosis Rhizopiis sp, Mucor sp and 
Absidia sp 
Skin, hair, nail, feet 
Lungs 
Lungs, skin, 
genitourinary tract, 
brain 
Lungs, bones, joints, 
meninges 
Intestinal tract, vaginal 
tract, skin, fingers, oral 
cavity 
Lungs, meninges, 
kidney, liver, prostate, 
bones 
lungs 
Keratin, nails, lungs 
Skin, cerebral, blood, 
lungs, genitourinary 
and gastrointestinal 
system 
Soil, contact with 
arthrospores or conidia 
from contaminated 
animals and humans 
Soil, inhalation of 
microconidia 
Soil, inhalation of 
conidia 
Soil, inhalation of 
arthroconidia 
Endogenous flora, 
contact with secretions 
from infected person 
Soil, contamination 
with bird feces 
Soil, inhalation of 
spores 
Soil, plant debris, 
ingestion of toxin 
contaminated plant 
parts 
Soil, decaying plant 
material, inhalation or 
percutaneous contact of 
spores 
2.1.1. Candidiasis 
Candidiasis is the secondary or opportunistic infections ranging from acute, subacute and 
chronic to life threatening mycoses. Healthy persons generally encounter superficial 
infections but in immunocompromised patients invasive infections could also occur. 
Superficial infections include vulvovaginal candidiasis, candiduria, onychomycosis and 
oropharaingeal candidiasis (OPC). Systemic candidiasis include infections of blood i.e. 
candidemia and disseminated candidiasis infecting multiple organs especially brain, 
myocardium, kidneys and eyes (Khan and Gyanchandani 1998). 
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A number of Candida spp are encountered in candidiasis like C. albicans, C. glabrata, C. 
tropicalis, C. krusei, C. dubliniensis, C. parapsilosis (Hayens and Westerneng 1996; 
Pfaller et al. 2006). Among the various species of Candida capable of causing human 
infections, C. albicans predominates in infections of genital, oral, and cutaneous sites, 
blood stream infections (BSI), intensive care unit, bone marrow transplantation and 
nosocomial infections (Pfaller et al. 2006). C. albicans is a member of commensal 
microflora of the intestine. It is pleomorphic and undergoes reversible morphogenic 
transitions between budding yeast, pseuodohyphal and hyphal growth forms. 
Among other Candida spp, C. glabrata has emerged as frequent pathogen due to 
increased use of immune suppressive agents. Importantly, more than one-third of 
CflwJ/fi^ a-associated BSIs among patients >60 years of age are due to C. glabrata (Malani 
et al. 2005). C. krusei is a pathogen of importance in patients with hematological 
malignancies and transplants. BSI due to C. krusei is associated with a high mortality rate 
(80% crude mortality and 40% attributable mortality), and possibly related to its poor 
response to standard antifungal therapy (Viudes et al. 2002). C. parapsilosis is 
frequently isolated from blood cultures due to insertive medical devises and it affects 
critically ill neonates and ICU patients likely because of its association with parenteral 
nutrition and central venous catheters (Sarvikivi et al. 2005), and is the most common 
species found on the hands of health care workers (Trofa et al. 2008). C. tropicalis is one 
of the causative agents of candidemia and isolated from patients with leukemia and who 
have undergone bone marrow transplantation. Among patients with neutropenia who are 
found to be colonized with C. tropicalis, as many as 60-80% eventually develop invasive 
infection (Wingard 1995; Pfaller and Diekema 2007). C. dubliniensis is found associated 
with oral and systemic infections in AIDS patients (Gutierrez et al. 2002; Loreto et al. 
2010). 
2.1.2. Aspergillosis 
Aspergilloses is the spectrum of diseases caused by fungi of the genus Aspergillus. The 
majority (approximately 80%) of invasive Aspergillus infections are caused by 
Aspergillus fumigatus. The second most frequent pathogenic species is Aspergillus flavus 
and to a lesser extent are Aspergillus niger and Aspergillus terreus (Krishnan et al. 2009). 
The most common forms are allergic bronchopulmonary aspergillosis (ABPA), 
pulmonary aspergilloma and invasive aspergillosis (lA). Aspergillosis develops mainly in 
individuals who are immunocompromised, either from disease or from 
immunosuppressive drugs, and is a leading cause of death in acute leukemia and 
hematopoietic stem cell transplantation (Dagenais and Keller NP 2009). ABPA occurs in 
patients suffering from atopic asthma or cystic fibrosis. ABPA occurs in approximately 1 
to 2% of asthmatic patients (15% of asthmatic patients sensitized to A. fumigatus) and 7 
to 35% of cystic fibrosis patients (Krasnick et al. 1995; Moss 2007). Aspergilloma, 
commonly referred to as "fungus ball," occurs in preexisting pulmonary cavities that 
were caused by tuberculosis, sarcoidosis, or other bullous lung disorders and in 
chronically obstructed paranasal sinuses (Ma et al. 2011). Transplant recipients are 
among the most significant subgroups of immunosuppressed hosts at risk for invasive 
aspergillosis. Aspergillus infections have been reported in 2 to 26% of hematopoietic 
stem cell transplant (HSCT) recipients and in 1 to 15% of organ transplant recipients. lA 
has become a leading cause of death, mainly among hematology patients. The average 
incidence of lA is estimated to be 5 to 25% in patients with acute leukemia, 5 to 10% 
after allogeneic BMT, and 0.5 to 5% after cytotoxic treatment of blood diseases or 
autologous BMT and solid-organ transplantation (Latge 1999; Singh and Paterson 2005; 
FuquaJre/fl/. 2010). 
2.1.3. Dermatophytosis 
DermatO'phytosis is generally a cutaneous infection (skin, hair, scalp and nails) and 
restricted to the nonliving comified layers because of the inability of the fungi to 
penetrate the deeper tissues or organs of immunocompetent hosts. These infections are 
mainly caused by a morphologically and physiologically closely related group of fungi 
such as species of Microsporum, Trichophyton and Epidermophyton which have the 
ability to utilise keratin as a nutrient source (Weitzman and Summerbell 1995). In 
humans, dermatophytoses are referred to as "tinea" infections, and are named with 
reference to the area of the body involved, for example, Tinea capitis (hair and scalp), 
Tinea corporis or ringworm (trunk, extremities and face), Tinea barbae (hairs and skin in 
the beard and mustache area), Tinea faciei (nonbearded parts of the face), Tinea cruris 
(groin), Tinea pedis or Athlete's foot (foot). Tinea manuum (hands), Tinea unguium 
(nail). Dermatophytes account for the majority (90%) of cases of fungal nail infections 
16 
(onychomycosis) in the United States and Europe (Ellis et al. 1997) and also prevailing in 
developing countries including India (Kannan et al. 2006). In immuno-compromised 
individual fungi of genus Trichophyton and Microsporum can invade the dermis or 
subcutaneous tissue causing sl<.in lesions and can cause disseminated mycoses (Galhardo 
etal. 2004; Marconi et al. 2010). 
2.2. Virulence and pathogenicity 
Pathogenesis is the ability of a microorganism to infect the host and produce disease 
resulting from interaction of pathogen with host via expression of certain factors on both 
sides, and virulence is the severity of disease produced by a pathogen causing harm to its 
host. Several numbers of determinants including genes or gene products like enzyme 
molecules known as virulence factors are involved in this relationship producing 
superficial to invasive infections in humans (Casadevall 2007). Virulence factors also 
facilitate pathogen to grov/ at elevated temperatures, adherence, penetration and 
dissemination, or assisting in resistance against innate immune defenses, e.g. 
phagocytosis and complement, evasion from adaptive immune defenses or it may be 
nutritional and metabolic factors, necrotic factors or morphology variation. Role of 
various virulence factors in the pathogenicity of pathogenic fungi is given in table R-2. 
Table R-2 Ro le o f v i ru lence factors in pa thogenic fungi (Source: Hogan etal. 1996; Ghannoum 
2000; Claderone and Fonzi 2001; Yang 2003; Blankenship and Mitchell 2006; Kuleta et al. 2009). 
Fungal pathogens Types of virulence factors Role in pathogenicity 
Dermatophytes 
Aspergillus spp 
Keratinase 
Elastase 
Acid proteinase 
Phospholipase 
Cell wall component, (3-1,3 
glucan 
Conidial size (2-3^) 
Adhesin, tronchin 
cAMP, rasA, rasB 
Elastase-alkaline serine 
proteinase 
Phospholipase C (plbl,2,3) 
Catalases (catA, catB and cat2), 
Superoxide dismutase 
Gliotoxin, helvolic acid 
Ribotoxin 
Siderophore (sidA gene) 
Damage of keratinous layer in epidermis 
Destruction of elastin in tissues 
Cleavage of peptide bonds in host cells to obtain 
nutrients and invasion 
Cleavage of phosphodiester bond in membrane lipids 
for invasion 
Cell adhesion 
Escape from mucocilliary extrusion 
Binding of conidiato lung tissue 
Nutritional uptake and growth of pathogen, 
germination of conidia, branching of hyphae 
Degradation of elastin in lung tissue 
Tissue damage and penetration 
Prevention from oxidative damage in macrophages 
Immunosppressive properties, prevention from 
oxidative burst of macrophages 
Cleavage of phosphodiester bond in eukaryotic 28s 
rRNA 
Uptake of iron from blood heme 
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Hisloplasma 
capsiilalum 
Coccidiodes immilis 
Blastomyces 
dermatitidis 
Cryptococcus 
neoformans 
Candida albicans 
Growth at 37°C, hspl, cgrA 
Dimorphism 
a-l,3-glucan in cell wall 
Growth inside macrophage 
Catalase 
Dimorphism 
Elastase 
Estrogen Binding Protein 
Dimorphism 
Adhesin(BADl) 
a-l,3-giucan in cell wall 
Capsule 
Melanin 
Mannitol 
Phosphlipases A,B,C,D 
(plbL23) 
Acid proteinases 
Adhesin (Als family, HWPl) 
Dimorphism (phrl, hyrl, chs2, 
chs3,rbri) 
Phenotypic switching (efgl) 
Secreted aspartyl proteinases 
(SAPsl-10) 
Phosphlipases A,B,C,D 
(plbl.2,3 
Farnesol 
Catalase, Superoxide dismutase 
SUN41,GCN4,MKclp 
Ability to invade host tissue and survival at elevated 
temperature of host 
Altered cell surface adhesion, tissue invasion by hyphal 
phase, dissemination by yeast phase 
Required for adhesion 
Evasion from immune cells, dissemination to other 
organ tissues 
Protection from oxidative killing 
Sheer size of spherule is required for dissemination, 
hyphal phase tolerate pH 2-12 
Destruction of lung insertium and blood vessels 
Acceleration of spherule maturation and endospore 
release 
Tissue invasion and dissemination 
Suppression of immune response 
Adhesion and masking of cell surface receptors being 
recognized by immune cells 
Inhibition to phagocytosis 
Prevention from oxidative damages 
Scavenging of hjdroxyl radical during respiratory burst 
Tissue invasion and adherence 
Tissue invasion and dissemination 
Adherence to epithelial cells, fibronectin, biofilm 
establishment 
Hyphal phase required for invasion and adherence, 
yeast phase for dissemination 
Conversion to more virulent forms showing increased 
ASP and adhesion production, evasion from host 
response 
Nutrient uptake, tissue invasion, adherence and 
dissemination 
Tissue invasion and adherence 
Quorum sensing, biofilm formation 
Prevention from oxidative damages 
Biofilm establishment 
2.2.1. Virulence factors involved in the pathogenicity o{ Candida albicans 
Like other fungal pathogens, C. albicans also regulate expression of certain genes and 
their products as virulence factors to produce disease. This is the most common 
opportunistic pathogens utilizing several kinds of virulence factors. Some of the 
commonly studied virulence factors in Candida albicans are briefly described here. 
2.2.1A. Adhesion and cell surface hydrophobicity 
Candidal adherence to various biological or non-biological surfaces is considered a 
prerequisite for colonization, and pathogenesis of candidal infections, and their relative 
cell surface hydrophobicity (CSH) is likely to be a possible contributory force involved in 
this process. Adherence of candidal cells to host tissues is a complex multifactorial 
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phenomenon utilizing several types of adhesins expressed on morphogenetically 
changing cell surfaces. Hydrophobic proteins embedded in the matrix of the C. albicans 
cell wall beneath the fibrillar layer provide the hydrophobic interactions needed to turn 
this initial attachment between fungus and the surface into a strong bond (Masuoka and 
Hazen 2004). Well known adhesins are agglutinin like sequences (ALS) that are member 
of a family of seven glycosylated proteins. Alslp, Als3p and Als5p (Alalp) on cell 
surface of hyphae adhere to human buccal epithelial cells (HBEC) and fibronectin, 
collagen, laminin, and endothelial cells (Hoyer 2001). Als6p and Als9p bind to collagen 
and laminin, respectively. Als4p binds to endothelial cells and Als5p is additionally 
needed for cell aggregation, however, the role of Als7p is unclear (Filler et al. 2006, 
Kuleta et al. 2009). 
2.2.1.2. IMorphogenesis 
Morphogenesis in C. albicans is defined as transition from unicellular yeast form to 
filamentous form (pseudohyphae or hyphae). Of all the species only C. albicans and C. 
dubliniensis are able to undergo morphogenesis. Their ability to grow in yeast, 
pseudohyphal and hyphal forms has an important role in causing disease by invading 
epithelial cells and causing tissue damage. Germ tube formation by Candida albicans is 
associated with its invasive capacity and is considered an important pathogenic 
mechanism (Comer and iVlagee 1997, Eckert et al. 2007). This transition is strongly 
required for pathogenesis. Yeast forms are more suited for dissemination in tissues and to 
other hosts whereas hyphal forms are requisite for tissue damage and invasion. Further, 
hyphal cells have stronger adherence capacity due to expression of ALS adhesins and 
also exhibit greater invasiveness to tissues. 
2.2.1.3. Phenotypic switching 
Unlike other pathogens, phenotypic switching in Candida is pleitropic by affecting 
several phenotypic and metabolic parameters subsequently a number of virulence traits 
like SAPs gene regulation. That allows Candida to adapt different host environment 
during infection (Soli 2002). Colonies of C albicans show morphological variation 
including smooth, rough, star, stippled, hat, wrinkle and fuzzy at high frequency. This 
switching is reversible and occurs spontaneously in stress and results in changes in cell 
surface behavior, colony appearance, metabolic, biochemical and molecular attributes to 
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become more virulent and effective during infection (Soil 2002, Odds et al. 2006). 
Presently, of all the phenotypes described, white-opaque system in strain WO-1 is most 
studied. This system is characterized by transition from smooth, white colonies to flat, 
gray opaque colonies. White cells are round ovoid while opaque cells are elongated or 
bean shaped (Soil 2002). Study of gene expression with WO-1 system revealed 
association of OPAl (SAPI) and SAPS in opaque cells whereas SAP2, WHI land EFGI 
in white cells (Miller and Johnson 2002; Whiteway and Oberholzer 2004). 
2.2.1.4. Extracellular enzymes 
2.2.1.4.1. Phospholipases 
Phospholipases are enzymes that hydrolyze ester linkages of glycophospholipids and 
hence impart tissue invasiveness to Candida cells. In Candida albicans, four types of 
phospholipases are classified by researchers on the basis of ester bond they cleaved viz. 
phospholipase A, B, C, and D. All types possess hydrolase activity but PLB in addition 
also possess lysophospholipase transacylase activity, therefore, able to release fatty acids 
from phospholipids and the remaining fatty acid from lysophospholipid and then transfer 
a free fatty acid to lysophospholipid producing phospholipids (Ghannoum 2000). Of 
these only PLB I, a 84 kDa glycoprotein isolated from hyphal tip in the course of tissue 
invasion, has been shown to be required for virulence in murine model of candidiasis 
(Ghannoum 2000, Yang 2003, Theiss et al. 2006). 
2.2.1.4.2. Proteinases 
Secretion of proteinases by pathogen is mandatory to degrade the tissue barriers and 
obtain nutrition at infection site. Secreted aspartyl proteinases (SAPs) from Candida have 
been reported that hydrolyze many proteins like albumin, hemoglobin, keratin, collagen, 
laminin, fibronectin, mucin, salivary lactoferin, interleukinip, cystatin A and 
Immunoglobulin A (Naglik et al. 2003). Till date ten proteins have been recognized as 
SAP family (SAPl-10) and found responsible for tissue invasion. Several workers have 
reported that production of SAPs is also correlated with hyphal formation, adherence, and 
phenotypic switching (Monod and Zepelin 2002; Naglik et al. 2003). Expression of SAPs 
has been found to be correlated with other virulence determinants to enhance the 
pathogenicity of Candida albicans. Correlation of SAPs with other virulence factors in 
Candida albicans is illustrated in figure R-1 
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Figure R-1. Correlation of secreted aspartyl proteinases with other virulence attributes in 
Candida albicans (Partially adapted from Naglik et al. 2004). 
2.2.1.4.3. Haemolysin 
The ability to utilize haemoglobin as an iron source is described as a strategy of C. 
albicans to exploit iron from host protein. The first step in haemoglobin iron utilization 
by C. albicans in vivo is probably via binding to erythrocytes. Candida albicans hyphae 
are able to rosette erythrocytes via complement receptor like molecules (Moors et al. 
1992). For erythrocyte lysis, C albicans possesses a haemolytic factor, called as 
haemolysin, probably a mannoprotein attached to the fungal cell surface (Watanabe et al. 
1999). Iron, as an essential cofactor for several proteins, is required for numerous 
biochemical processes including cellular respiration and metabolism, oxygen transport, 
drug metabolism and DNA synthesis (Welch et al. 2001). Because iron is an essential 
element for both the host and C. albicans, iron uptake during infection is considered a a 
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virulence attribute and even colonization and proliferation are possible only if sufficient 
iron is accessible to the fungus (Sutak et al. 2008). However, the mechanism by which C 
albicans causes haemolysis and the molecular basis of this mechanism remains unknown 
(Almeida et al. 2009). 
2.2.2. Virulence factors involved in the pathogenicity of Aspergillus spp and 
Trichophyton spp 
Like other pathogenic fungi, Aspergillus spp mainly A. fumigatus exhibit several 
structures and products which are considered as virulence factors such as adhesins, 
pigment production, toxic metabolites and extracellular enzymes (Alp 2006). The 
secretory proteins of A. fumigatus contain enzymes (such as proteases, peptidases and 
phospholipases), toxins, adhesins, and other molecules responsible to adhere to different 
host tissues components and to invade host immune systems and cause pathogenesis 
(Tomee and Kauffman 2000; Osherov 2007). Aspergillus and Trichophyton species 
secrete a variety of proteases that are evolved to degrade the tissue barrier to obtain 
nutrient and to increase pathogenicity (Hogan et al. 1996; Monod 2008). 
Elastase a well known protease secreted hy Aspergillus spp exhibits elastinolytic activity 
and considered as important virulence attributes infecting the lung tissues such as 
aspergillosis. A. fumigatus possesses two elastases, one a serine protease and the other a 
metalloproteinase. A. flavus produces a 23 kDa metalloproteinase and a 36 kDa serine 
proteinase of lesser elastinolytic activity that produced by A. fumigatus (Hogan et al. 
1996). In addition to proteases with elastinolytic activity, an aspartic acid proteinase has 
been purified from A. fumigatus and demonstrated role in invasive asepergillosis 
(Reichard et al 1994). An extracellular collagenolytic activity due to a metalloprotease of 
43 kDa has been reported for Aspergillus spp (Rementeria et al. 2005). Proteases secreted 
by Trichophyton spp are defined as keratinases that play a vital role in degrading 
keratinized tissues and increasing the pathogenicity. Several endo and exopetidases have 
been reported for Trichophyton and other dermatophytes such as a 43.5 kDa 
metalloprotease and 90 kDa serine proteinase (Monod 2008). The virulence caused by A. 
fumigatus may be augmented by its numerous secondary metabolites, including 
fumagillin, gliotoxin, helvolic acid etc. giving a general and significant 
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immunosuppressive effect on host defences (Rementeria et al. 2005). A. fumigatus also 
produce a haemolysin encoded by asp-HS gene (Rementeria et al. 2005). 
2.3. Biofiim formation in Candida albicans 
Biofiims are the organized structures involving microbial communities that are attached 
to some inanimate surfaces or tissues and circumvented in a self produced matrix of 
exopolymeric materials. Cells within the biofiims exhibit altered phenotype, growth rate 
and gene expression compared to planktonic cells. Recent advances in confocal 
microscopy and molecular genetics have provided evidence that biofiim formation 
represents the most common mode of growth of microorganisms in nature. This growth 
form presumably allows microbial cells to survive in hostile environments, enhances their 
resistance to physical and chemical pressures, and promotes metabolic cooperation 
(Jabra-Rizk et al. 2004). 
Biofiim formation in fungi is a well-organized process that progresses through 
coordinated early, intermediate, and maturation stages. It begins with attachment of a 
microorganism to a surface, followed by a cascade of differential gene expression 
resulting in biofiim formation. Mature C. albicans biofiims are complex three-
dimensional structures between 50 fim and 350 yim thick (Mukherjee and Chandra 2004). 
Studies with scanning electron microscopy of biofiims revealed presence of both 
adherent yeast cells and invasive hyphal forms constructing basal and upper layers, 
respectively, enclosed in extracellular polymer matrix consisting of polysaccharides, 
chitins, DNA and proteins and forming a three dimensional structures with water 
channels (Kojic and Darouiche 2004; Blankenship and Mitchell 2006). The persistence 
of fungal infections is promoted by the ability of fungi to form biofiims on a wide variety 
of implanted medical devices. The ability of Candida to form biofiims on catheters, 
endotracheal tubes, pacemakers and other prosthetic devices has contributed to its 
predominant prevalence in nosocomial infections (Douglas 2003; Ramage et al. 2005). 
Such devices, in addition to providing platform for candidal cells to form biofiim, growth 
and development, pose route through host barrier defenses for dissemination. 
Adherence is the critical property for biofiim forming cells and is mediated by a number 
of adhesins, encoded by ALSl, ALS2, ALS4, ALS5 (ALAl), HWPl, and EAPl. These 
mediate adhesion to organic and inorganic surfaces, extracellular matrix proteins, human 
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endothelial cells, and epithelial cells (Blankenship and Mitchell 2006; Filler et al. 2006). 
Biofilms are organized communities imder tight regulation of gene expression controlled 
through quorum sensing that in turn are regulated by famesol and tyrosol molecules 
(Ramage et al. 2002). This cell to cell communication prevents and controls unnecessary 
overpopulation, nutritional competition and has implication in dissemination and 
establishment of infection at distal site from old biofilm (Alem et al. 2006). Involvement 
of different virulence factors in forming biofilms and associated pathogenicity in 
C.albicans is depicted in figure R-2. 
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Figure R-2. Illustration of virulence factors involved in establishing biofilm and 
associated pathogenicity in Candida albicans (a) Planktonic yeast cells (b) 
initiation of biofilm formation on living tissues or inert object like 
polyvinyl chloride (PVC) by adherence of yeast cells forming basal layer 
(c) development of biofilm by initiation of upper invasive hyphal layer 
and production of exoploysaccharide (d) maturation of biofilm by more 
filamentation and exopolysaccharide production (Partially adapted from 
Blankenship and Mitchell 2006). 
A brief rveiw of literature reporting incidence of virulence factors including biofilm 
formation in Candida spp and other filamentous fiingi and their role in pathogenicity is 
given here. 
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Luo et al. (2001) examined a total of 80 Candida isolates representing 14 species for their 
respective responses to an in vitro hemolytic test. A group o^ e\g\\l Candida species which 
included Candida albicans (15 isolates), C. dubliniensis (2), C. kefyr (2), C. krusei (4), 
C. zeylanoides (1), C. glabrata (34), C. tropicalis (5), and C. lusitaniae (2) demonstrated 
both alpha and beta hemolysis at 48 h postinoculation. Only alpha hemolysis was 
detectable in four Candida species, viz., C.famata (3), C. guilliermondii (4), C. rugosa 
(1), and C. utilis{\), while C. parapsilosis (5) and C pelliculosa (1) failed to demonstrate 
any hemolytic activity after incubation for 48 h or longer. This was the first study to 
demonstrate the variable expression profiles of hemolysins by different Candida species. 
Viani et al. (2001) investigated the possible relationship between the clinical status of M 
canis infection and enzymatic activity of isolates. They studied the relationship between 
keratinase, elastase, lipase and DNase levels produced in vitro by different isolates and 
virulence as expressed in a guinea pig model. Samples isolated from symptomatic dogs 
and cats showed a statistically significantly (JP<0.05) higher keratinase activity than 
samples isolated from asymptomatic animals. Experimental infection of guinea pigs 
showed that a strain with high in vitro keratinase activity induced acute infection, which 
resolved clinically and mycologically faster than the infection induced by a strain with 
low keratinase activity. They suggested a strong correlation between high keratinase 
activity and the development of symptoms. The same correlation was not observed for 
other enzymes tested. 
Kantarcioglu and Yucel (2002) determined the in vitro phospholipase and protease 
activities in 95 clinical isolates of various Candida species (C. albicans, C. glabrata, C. 
guilliermondii, C. kefyr, C. krusei, C. lipolytica, C. lusitaniae, C. parapsilosis, C. rugosa 
and C. tropicalis). 59 (62.1%) of isolates examined were phospholipase positive and 75 
(78.9.9%) were protease positive. 56 (93.3%)) of C.albicans isolates tested were 
phospholipase producers, however only a few strains of C. glabrata and C. kefyr behaved 
in the same way. Protease activity was detected in 57 (95%)) of C. albicans strains tested 
and in a few strains of C. kefyr, C.lipolytica, C. parapsilosis and C. tropicalis- the 
remaining isolates were negative. 56 strains of C. albicans and 2 strains of C. kefyr tested 
produced both phospholipase and protease. 
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Luo and Samaranayake (2002) investigated in vitro the CSH of 34 oral isolates of C. 
glabrata and 15 isolates of C albicans. There were remarkable intraspecies differences in 
both the CSH and the adhesive ability of C glabrata strains (/'<0.00l). Compared with 
C. albicans, C glabrata demonstrated a four-fold greater CSH value (30.63±11.20% vs 
7.23±3.56%, P<0.0001) and a two-fold greater tendency to adhere to denture acrylic 
surfaces (75.18±39.96% vs 30.36±9.21%, i'<0.0001). A significant positive correlation 
between CSH and adhesion was also noted for both C. glabrata (r==0.674, P<0.000]) and 
C. albicans (r =.636, P<Q.05). These data have provided archival information on 
important pathogenic attributes of the two most common oral Candida species. 
Shin et al. (2002) compared clinical bloodstream isolates representing seven different 
Candida species to each other and to those from other anatomical sites for the capacity to 
form biofilms. Isolates included the following from nonneutropenic patients: 101 
bloodstream isolates (35 C. parapsilosis, 30 C. albicans, 18 C tropicalis, 8 C glabrata, 
and 10 other Candida species isolates) and 259 clinical isolates from other body sites 
(116 C. albicans, 53 C. glabrata, 43 C tropicalis, 17 C parapsilosis, and 30 other 
Candida species isolates). Biofilm production by C. albicans isolates was significantly 
less frequent (8%) than that by non-C. albicans Candida species (61%; /'<0.0001). The 
overall proportion of non-albicans Candida species isolates from the blood that produced 
biofilms was significantly higher than that of non- albicans Candida isolates obtained 
from other sites (79%) versus 52%; P^O.OOOl). Bloodstream isolates of C. parapsilosis 
alone were significantly more likely to be biofilm positive than were C. parapsilosis 
isolates from other sites (86% versus 47%; ^=0.0032). Non-albicans Candida species, 
including C. parapsilosis, were more likely to be biofilm positive if isolates were derived 
from patients whose candidemia was central venous catheter (CVC) related (95%; 
P<0.0001) and was associated with the use of total parenteral nutrition (TPN) (94%); 
?<0.005). These data suggested that the capacity of Candida species isolates to produce 
biofilms in vitro may be a reflection of the pathogenic potential of these isolates to cause 
CVC-related fungemia in patients receiving TPN. 
Basu et al. (2003) studied 85 isolates of Candida spp recovered from 350 diverse clinical 
sources, viz. respiratory tract (sputum, bronchial washing, bronchoalveolar lavage, 
tracheal aspirate), blood, urine, high vaginal swab, skin and plastic devices, for their 
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morphological and biochemical characters. Seven species of Candida were identified, 
viz., C. albicans (45.8%), C. tropicalis (24.7%), C. parapsilosis (10.5%), C. krusei 
(7.0%), C. kejyr (7.0%), C guilliermondii (3.5%), and C. glahrata (1.1%). C albicans 
was the predominant species isolated from all clinical specimens, except blood from 
which C. r^wj'e/ was most frequently (38.4%) recovered. Out of 39 isolates of C. 
albicans, 26 (66.6%) and 19 (48.7%) exhibited strong proteinase and phospholipase 
activity respectively. There was a higher prevalence of proteinase producing strains 
amongst the vaginal and skin isolates than that in urinary and respiratory isolates. Also a 
greater number of phospholipase producing strains was observed in the vaginal and 
urinary isolates than that in the respiratory and skin isolates. 
Kuriyama et al. (2003) determined the in vitro SAP activity of Candida albicans isolated 
from a variety of oral conditions, including healthy oral cavities, was determined. SAP 
activity was 0.28±0.33 for pseudomembranous candidosis isolates (n = 18), 0.35±0.46 for 
chronic erythematous candidosis isolates (« = 21) and 0.30±0.32 for chronic hyperplastic 
candidosis isolates (« = 50). SAP activity of 0.19±0.22 was recorded for isolates from 
squamous cell carcinoma {n-\S), 0.26±0.37 for burning mouth syndrome isolates 
(n = 29), 0.25±0.38 for isolates from xerostomia {n= 15) and 0.39±0.50 for isolates from 
lichen planus («=13). The SAP activity of isolates from oral disease states was 
significantly (?<0.05) higher than that recorded for 28 isolates from healthy mouths 
(activity of 0.04±0.03). However, there was no significant difference in the SAP activity 
between the three forms of clinical oral candidosis (P>0.05). These results have indicated 
that C. albicans strains associated with oral disease have inherently higher SAP activity. 
Schaufuss and Steller (2003) investigated the haemolytic activity in T. rubrum, T. 
mentagrophytes, T. equinum and T. verrucosum strains. Out of these, T. rubrum and T. 
equinum produce a zone of complete haemolysis followed by a small zone of incomplete 
haemolysis around the colony. T. mentagrophytes and T. verrucosum produce a zone of 
complete haemolysis. They concluded that haemolytic activity is pronounced in 
dermatophytes and may play an important role as virulence factor. 
Kumar et al. (2006) studied 61 isolates of Candida spp recovered from HIV seropositive 
and cancer patients for elaboration of putative virulence determinants-phospholipase (PL) 
and secreted aspartyl proteinase (Sap). Forty two (68.85%) isolates examined were PL 
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producers and 51 (83.6%) were positive for Sap. 57.37% (35/61) isolates produced botii 
enzymes. Enzymatic activity was more pronounced in Candida albicans with 100%o PL 
and 94.1%) Sap activity. In contrast, non-albicans Candida species demonstrated only 
29.6%) PL and 70.3%) Sap activity, indicating interplay of other virulence determinants in 
these yeasts in colonization and disease. 
Antony et al. (2007) determined the degree of expression of virulence factors such as 
adherence, CSH and production of proteinase by different morphological forms of 
Candida albicans causing oral candidiasis in HIV-infected individuals. It was found that 
proteinase production was greatest with the W type followed by the R type and 0 type. 
The S type produced the least proteinase. Expression of cell surface hydrophobicity and 
adherence was greatest in the 0 type followed by the R and then the W type and finally 
the S type. They suggested that the differential expression of virulence factors occurs 
with different phenotypic forms of C. albicans and this may provide a particular 
morphological type with a distinct advantage over other types in causing candidiasis. 
Tsang et al. (2007) studied phospholipase, proteinase and haemolytic activities of oral 
Candida albicans isolates from 210 Chinese patients with type 2 diabetes mellitus (DM) 
and 210 age- and sex-matched healthy controls. Seventy-six and 50 C. albicans isolates 
were obtained from type 2 DM patients and controls, respectively, using the oral rinse 
technique. Significantly higher proteinase and haemolytic activities were found in the 
isolates from the type 2 DM group (P<0.05). Proteinase activity was higher in isolates 
from patients with >10 years of DM history than those with <10 years (/'<0.05). 
Haemolytic activity was significantly higher in isolates from female DM patients than in 
those from male counterparts (/'<0.05). These data provide evidence of increased 
extracellular enzyme activity in Candida isolates taken from DM patients. 
Vinitha and Ballal (2007) aimed at demonstrating the formation of biofilm by Candida 
species isolated from blood samples collected from ICU patients and patients with 
indwelling devices. Thirty-four species oi Candida were isolated from the blood samples 
and the isolates include C. krusei (38.23%)), C albicans (20.58%o), C parapsilosis 
(11.76%), C. guilliermondii (5.88%), C. glabrata (11.76%), C. tropicalis (5.88%) and C. 
pseudotropicalis (5.88%)). The biofilm formation by C. albicans was less frequent 
(42.85%)), than that by non-albicans Candida (63.33%)). Their data suggested that the 
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capacity of Candida species to produce biofilm may be a reflection of the pathogenic 
potential of the isolates to cause central venous catheter related candidaemia in ICU 
patients and patients on dialysis. 
Alp and Arikan (2008) investigated the production of extracellular elastase, acid 
proteinase and phospholipase enzyme activities in clinical isolates of Aspergillus 
fumigatus, Aspergillus flavus and Aspergillus niger. In their study, a total of 73 strains 
(45 A. fumigatus, 23 A. flavus, 5 A. niger) isolated from patients with invasive 
aspergillosis (n = 55), superficial aspergillosis (n = 5), allergic bronchopulmonary 
aspergillosis (n = 1), and from those colonized with Aspergillus (n = 12) were included. 
The enzj/matic activities were tested on solid media supplemented with the corresponding 
substrates. Elastase activity was detected in 95.6, 82.6, and 0.0% of ^. fumigatus, A. 
flavus, and A. niger isolates, respectively. Acid proteinase activity was detected only for 
A. fumigatus and in 20 of 45 isolates belonging to this species. Phospholipase activity 
was present in all strains o^ A. fumigatus and A. niger but in none of the isolates of ^. 
flavus. 
Pinto et al. (2008) attempted to link the production of hydrolytic enzymes with the 
capacity to produce infection and therefore, they studied 232 clinical isolates of yeasts 
from the oral cavity of 140 individuals wearing removable maxillary protheses. The 
sample was composed of 70 patients with denture-related stomatitis (DRS) and 70 
individuals with normal palatal mucosa. In their study, Candida albicans was the only 
species producing phospholipase and germ tube. They observed a higher level of 
production of phospholipase in cases of infection over commensals. Significant 
differences between the two groups of C. albicans isolates were observed in terms of 
germ tube production. They suggested, it seems that several virulence attributes are 
involved in the infective process but no single factor contributes to Candida virulence. 
Antony et al. (2009) studied the phenotypic switching and its influence on the 
pathogenicity of 53 strains of C. albicans. It was found that proteinase activity was 
greatest with the W type followed by the R type then the 0 type. The S type produced the 
least proteinase. The phospholipase activity was greatest with 0 type followed by R type. 
The W and S types produced the least phospholipase. Expression of CSH and adherence 
was greatest in the 0 type followed by the R and then the W type and finally the S type. 
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Therefore, they concluded that, differential expression of virulence factors occurs with 
different phenotypic forms of C. albicans and this may provide a particular 
morphological type with a distinct advantage over other types in causing candidiasis. 
De Souza et al. (2009) evaluated the differences in the CSH of strains isolated from 
denture users with and without denture-related candidosis. The measures revealed that the 
yeasts from patients with candidosis had CSH values ranging from 4.52% to 12.24%, 
with an average of 8.22±2.92%. In the countergroup, the CSH ranged from 3.86% to 
14.36%, with an average of 8.38±3.76%. The difference between the groups were 
considered not relevant (/'=0.997). The results let to the inference that natural populations 
of C. albicans from patients with and without clinical manifestation denture-related 
candidosis do not differ one from the other regarding to CSH. Cells of C. albicans strains 
with higher CSH rates i.e. hydrophobic present higher adhesion success in different host 
tissues than cells with lower rates or even hydrophilic. 
Hasan et al. (2009) compared biofilm formation in 107 Candida isolates from 32 
candidemic patients with Candida isolates from oropharyngeal lesions of 19 AIDS 
patients. Biofilm formation varied among species and C albicans; C. lusitaniae and C 
krusei produced more biofilm than the other Candida species. Importantly, though 
biofilm formation was variable within a species it was stable in sequential isolates during 
chronic infection. Sequential isolates exhibited identical Karyotype pattern or RAPD 
patterns unless patients were co-infected with more than one strain. Murine infection 
studies demonstrated that, degree of in vitro biofilm formation was associated with 
virulence in mice, as mice infected both with no and low biofilm formers survived longer 
than mice infected with high biofilm former C. albicans (P=0.001). Based on their study 
they concluded that biofilm formation is a stable but strain specific characteristic that can 
greatly vary among C. albicans and non-albicans strains, and plays an important role in 
persistence of infection. 
Blanco etal. (2010) evaluated virulence factors involved in the adhesion process, such as 
CSH, adherence to plastic capacity, adherence capacity to BEC, and biofilm formation, in 
17 strains of C. albicans isolated from bronchial aspirates of critically ill patients. Their 
study showed that these factors are directly involved in adhesion, with variability in the 
degree of expression among them. Medium-high levels of CSH were found in 52.9% of 
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the strains. The percentage of strains with high values in adherence to plastic was 35.3%. 
The most hydrophobic strains were the most adherent to plastic, with a correlation 
coefficient of 0.76. Of the 12 biofilm-producing strains, 6 were high producers. These 
strains had also high levels of CSH and adherence to plastic, with significant results. All 
the strains studied adhered to BEC, with results ranging widely from 45 to 157 yeasts/ 
100 BEC although CSH was seen to be an indispensable prior requisite for adherence to 
cells. On the basis of their observation they concluded that CSH is a variable 
characteristic in C. albicans and is directly related to adherence to plastic and biofilm 
formation. 
Mahmoudabadi et al. (2010) studied extracellular phospholipase activities in different 
isolates of C. albicans isolated from vagina and urine samples from Ahvaz, Iran. In 
addition, phospholipase activities were compared in C. albicans isolated from two 
different sources. The phospholipase activity was detected in all tested isolates with a 
high level in Pz<0.70. In the present study phospholipase activity with higher Pz values 
was more common in vaginal isolates (84.7% isolates with Pz value <0.70) compared 
with 75% in urine isolates. In their study, 100% clinical isolates of C. albicans from 
vaginitis and urine samples demonstrated phospholipase activity. 
Negri et al. (2010) assessed the virulence factor profile and in vitro antifungal 
susceptibility of 27 hospital isolates of C. albicans; 19 of these were from infections (16 
urinary and three blood), and the other eight were isolated from sites of colonization (two 
from hands of health professionals, and six from central venous catheters). The virulence 
factors assayed were germ tube formation and production of extracellular products 
(hemolysins, proteinases, and phospholipases). Regarding the virulence factors, the 
infection isolates produced significantly more haemolysin and germ tubes than the 
colonization isolates (P<0.05). There were no significant differences in the production of 
other factors between isolates from the two sources {P>0.05). These results suggest that 
the capacity of C. albicans to produce hemolysins and germ tubes may be associated with 
its pathogenic potential. 
Villar-Vidal et al. (2011) aimed to compare the capacity of biofilm production by blood 
and oral isolates of C. albicans and C. dubliniensis. In their study all tested isolates 
produced biofilm. Biofilm formation by C. albicans isolates was statistically significantly 
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higher than biofilm formation by C. dubliniensis isolates at 24 h (/"^ O.OS) and 48 h 
(P^O.OOOl). There was a higher percentage (41.7%) of high producers of biofiims among 
C. albicans blood isolates than among oral isolates (31.3%), without statistically 
significant differences. They concluded that this capability may allow C. albicans and C. 
dubliniensis to maintain their oral ecological niches as commensal or pathogenic 
microorganisms and can be a major virulence factor during invasive candidiasis. 
2.4. Antifungal drugs and their modes of action 
The treatment of human fungal diseases relies primarily on the availability of antifungal 
agents. Antifungals used in medicines are divided into seven major different chemical 
classes including polyenes, pyrimidine analogues, azoles, candins, allylamines, 
thiocarbamates and morpholines (Sanglard et al. 2009). These have been categorized on 
the basis of their mechanism of action: (1) alteration of membrane function (2) inhibition 
of DNA or RNA synthesis (3) inhibition of ergosterol biosynthesis (4) inhibition of 
glucan, chitin and mannan synthesis (Perea and Patterson 2002). 
The polyenes, represented by amphotericin B and nystatin, were the first truly effective 
antifungal drugs introduced for treatment of life-threatening mycoses. The polyenes 
target ergosterol in the fungal membrane and create pores that allow small molecules to 
diffuse across the membrane, resulting in cell death (Canute and Redero 2002). The 
azoles are broad class of synthetic compounds that inhibit a cytochrome P450 dependent 
Lanosterol demethylase, ErgU or Cyp51, which is an essential step in ergosterol 
biosynthesis (Sanglard 2002). There are two classes of azoles (i) the imidazoles, 
including ketoconazole, miconazole and clotrimazole, and mainly used in topical 
application (ii) the traizoles, including fluconazole, voriconazole, itraconazole, 
ravuconazole and posaconazole, and mainly used systemically (Sanglard et al. 2009). 
Flucytosine (5-fluorocytosine, or 5-FC) is a fluorinated pyrimidine that, when 
metabolized to 5-fluorouracil by the target fungus, acts as an antimetabolite through the 
selective inhibition of fungal protein synthesis by replacing uracil with 5-fIurouraciI, 
which is then incorporated into fungal DNA and RNA and therefore inhibiting cellular 
function and divisions (White et al. 1998; Hector 2005). 
The sordarin antifungal class, although not developed for clinical use, merits mention 
among the new mechanisms of action. Sordarins inhibit protein synthesis by blocking the 
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function of fungal translation elongation factor 2 (EF2) (Odds et al. 2003). The 
allylamines are a class of synthetic compounds that also interfere with ergosterol 
biosynthesis in the fungal membrane, although at an earlier step in the enzymatic 
pathway compared to azoles (Hector 2005). Terbinafine (allylamines) and tolnaftate 
(thiocarbamates) inhibit the same enzyme, squalene epoxidase (Ergl). The morpholines 
(fenpropimorph) inhibit two different enzymes, ERG2 and ERG2, catalyzing sterol A'"*-
reductase and A -A7 isomerase, respectively. These agents are one of the main treatment 
options for dermatophyte infections in topical use (Niewerth and Korting 2000; Odds et 
al. 2003; Proia 2006). Griseofulvin, isolated from Penicillium ghseofulvum, alters a 
process vital to the sliding of microtubules necessary for the separation of the 
chromosomes and therefore interrupting fungal cell division during mitosis and other 
cytoplasmic functions. Griseofulvin's spectrum of activity is limited to dermatophytes as 
an oral medication, but has seen less use with the advent of the azole and allyamine 
classes (Bossche 1997; White et al. 1998; Hector 2005). 
Echinocandins namely caspofungin, micafungin and anidulafungin target the fungal cell 
wall by selective inhibition of [3-1,3-glucan synthesis by targeting enzyme complex P-1,3-
glucan synthase encoded by FKSl and FKS2 that is located in the plasma membrane of 
the fungal cells. Glucan is a critical cell wall polysaccharide; without it, the cell will lyse 
as a result of oxidative and osmotic stress. Other antifungals targeting cell wall synthesis 
are nikkomycins (chintin syntahse inhibitors), pradimicins (mannoprotein synthase 
inhibitors) (Odds et al. 2003; Proia 2006; Cowen 2008). The principle targets of 
antifungal drugs are described in figure R-3 and table R-3. 
2.5. Problems associated with the current antifungal therapy 
A number of factors affect and limit the use of some of the existing antifungal antibiotics, 
which necessitates a search for newer antifungal antibiotics to control existing problems. 
The problems associated with antifungal drugs mainly include host toxicity and rapid 
emergence of resistant strains, however, low potency, poor solubility, limited or 
inconvenient dosage forms may also be accounted (Balkis et al. 2002). 
2.5.1. Host toxicity 
Antifungal drugs target the eukaryotic cell functions and the similarity between fungal 
and mammalian cells is responsible for selective toxicity. Antifungal drugs are in general 
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Figure R-3. Illustration of antifungal drugs targets on the fungal cell (Partially adapted from 
Neely and Ghannoum 2000; Odds et al. 2003; Cowen 2008). 
more toxic than antibacterial drugs. Most commonly obser\'ed toxicity is associated with 
amphotericin B. Although amphotericin B maintains a higher affinity for ergosterol 
compared with other sterols, the host toxicity displayed by this drug is primarily the 
result of its binding to cholesterol, the main sterol of mammalian cell. It is believed to 
cause alterations in the membrane permeability of renal tubules and vasculature and has 
also been implicated as an inducer of phagocytic cells (Balkis et al. 2002; Onyewu and 
Heitman 2007; Laniado-Labori and Cabrales-Vargas 2009). 
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5-Fluorocytosine interferes with DNA synthesis and causes bone-marrow toxicity, 
leukopenia and liver enzyme elevations. It is used in adjuvant therapy with amphotericin 
B or azoles because if used in monotherapy leads to development of resistance (Vermes 
et al. 2000). The azoles have mainly shown pharmacokinetics problems including dose 
administration, metabolism and clearance (Graybill 2000; Groll and Kolve 2004). 
Ketoconazole significantly interfere with the human cytochrome P450 system while the 
drug carrier for miconazole has been associated with toxicity (Meeker et al. 1983; Farid 
et al. 2007). The triazoles (fluconazole, itraconazole, and voriconazole) have three 
nitrogen atoms in their azole ring and a greater affinity for fungal, rather than 
mammalian, cytochrome P450 enzymes. For this reason, the triazoles have fewer side 
effects than their imidazole (miconazole and ketoconazole) counterparts. Fluconazole is a 
first-generation triazole and one of the most commonly prescribed antibiotics in the world 
and considered as safest drug but its fungisatatic nature has led to the development of 
drug-resistance and even higher doses are reported to be hepatotoxic (Groll et al. 1998; 
Proia 2006). 
A recent review by Fanos et al. (2010) has indicated overall antifungal drug toxicity to 
childrens with defects in host defences and newborns where almost all antifungal drugs 
show varied level of toxicity. The echinocandins (glucan synthesis inhibitors) and 
nikkomycins (chitin synthesis inhibitors) target components of fungal cell wall that are 
not present in mammalian cell and thus make it less toxic and attractive for use in humans 
but costly in therapy (Denning 2002; Odds et al. 2003; Sable et al. 2008). 
2,5.2. Drug resistance 
The term "resistance" is used to describe a relative insensitivity of a microbe to an 
antimicrobial drug as tested in vitro and compared with other isolates of the same species 
(Loeffler and Stevens 2003). Resistance can be classified as microbiological or clinical 
according to the guidelines of the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST). 
2.5.2.1. Microbiological resistance 
Microbiological resistance refers to non-susceptibility of a fungus to an antifungal agent 
by in vitro susceptibility testing, In which MIC of the drug exceeds the susceptibility 
breakpoint for that organism. It is defined by the presence of an acquired or mutational 
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resistance mechanism to the drug that is being tested. It depends directly on the 
microorganism, and it can be divided into groups: (1) primary or innate, when fungi are 
intrinsically resistant prior to drug exposure such as intrinsic amphotericin B resistance 
observed in C. lusitaniae, C. guilliermondii and Fusarium species; resistance of C. krusei 
to fluconazole and of Ciyptococcus neoformans to echoncandins (2) secondary or 
acquired resistance, which appears during or after drug exposure in previously 
susceptible strain and is usually dependent on altered gene expression. This form of 
resistance has been frequently observed for C. albicans and C. neoformans in 
immunosuppressed persons who have undergone prolonged azole therapy for treatment 
of oropharangeal candidiasis and cryptococcosis (Vazquez 2003; Alcazar-Fuoli et al. 
2008; Kanafani and Perfect 2008). 
2.5.2,2. Clinical resistance 
Clinical resistance is denominated as treatment failure to eradicate a fungal infection 
despite the administration of an appropriate antimicrobial treatment i.e. antifungal agent 
with in vitro activity against the organism. Within this term, it is important to 
differentiate between an intermediate or resistant microorganism. A microorganism is 
defined as intermediate when the isolate that is causing infection is appropriately treated, 
but there is an uncertain therapeutic effect. A microorganism is defined as resistant when 
it denotes growth or lack of inhibition of the microorganism with persistence of fungal 
infection, even with appropriate antifungal drug therapy. Clinical resistance depends on 
the drug being used to treat the infection and the host response and pathogen involved. 
Microorganisms are categorized as intermediate or resistant using defined breakpoints by 
the appropriate phenotypic test system (Perea and Patterson 2002; Alcazar-Fuoli et al. 
2008; Kanafani and Perfect 2008). 
2.6. Mechanism of antifungal drug resistance 
Clinically relevant resistance to antifungal agents has emerged in several patient 
populations, and the elucidation of the basis of this process is of paramount importance. 
Antifungal drug resistance is a prominent feature in the management of mycoses and its 
epidemiological characteristics continue to evolve (Kanafani and Perfect 2008). The use 
of an antimicrobial drug always carries the risk that resistance will evolve in the pathogen 
(Cowen 2008). Clinical in vitro resistance, including intrinsic or acquired, to all 
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antifungal agents has been reported (White et al. 1998; Sanglard et al. 2009). Molecular 
mechanisms of drug resistance in fungi are as follows: 
(i) Drug import and modification or degradation of the drug. 
(ii) Target site alteration by mutations. 
(iii) Up-regulation of target enzyme. 
(iv) Decreased accumulation of drugs. 
(v) Utilization of compensatory and catabolic pathway. 
(vi) Presence of complex multicellular structures i.e. biofilms: Formation of 
biofilms by many pathogenic Candida spp is reported to confer higher level of drug 
resistance (Cannon et al. 2007; Sanglard et al. 2009). The mechanism of drug-resistance 
by biofilms involved (a) restricted penetrafion of drugs inside the exopolymer matrix, 
which can bind or restricts the diffusion of antifungals (b) a decreased growth rate or 
nutrient limitations (c) the expression of resistance genes, particularly those encoding 
efflux pumps (d) the presence of persister cells (Douglas 2003; Ramage et al. 2005). The 
mechanism of drug-resistance in pathogenic fungi is given in figure R-4 and table R-3. 
Drug 
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Figure R-4. Pictorial presentation of mechanisms by which microbial cells might 
develop resistance (Partially adapted from Ghannoum and Rice 1999; Yang and Lo 
2001; Prasad et al 2002; Cannon et al 2007). 
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2.6.1. Incidence of antifungal drug resistance in clinical isolates of fungi 
Inspite of avialble spectrum of antifungal drugs the incidence of drug resiatnce to azoles 
and other drugs is reported world wide. A brief summary of reports on emergence of drug 
reistant fungal pathogens especially Candida spp, Aspergillus spp and Trichophyton spp 
is reviewed here. 
Duran et al. (2003) carried out a retrospective study to investigate the antifungal 
susceptibility oi Candida spp isolates from blood cultures performed in the period from 
January 1997 to December 2001. None of the isolates presented an amphotericin B MIC 
>1 |Jg/ml. All the C. krusei isolates were resistant to fluconazole. Itraconazole resistance 
and dose-dependent fluconazole susceptibility was found in 80% of C. glabrata isolates. 
Only one C. parapsilosis isolate was resistant to flucytosine. On the basis of their 
observations they concluded that fluconazole and itraconazole resistance is commonly 
found among C. krusei and C glabrata isolates which accounted for 15% of the total 
Candida spp isolated from blood cultures in their hospital. 
Citak et al. (2005) studied resistance of Candida spp isolated from blood cultures of 
cancer patients to ketoconazole (KET), fluconazole (FLU), amphotericin B (AmpB), and 
flucytosine (FCU). Of the 56 Candida albicans isolates, 7 (12.5%) were resistant to FLU 
(MIC >64 ng/ml), 6 (10.7%) were resistant to KET (MIC >64 ^g/ml) and 3 (5.3%) were 
resistant to FCU (MIC >32 jag/ml). One (14.3%) of 7 C parapsilosis isolates was 
resistant to FLU (MIC >64 ^ig/ml). One (33.3%) of 3 C. tropicalis isolates was resistant 
to KET (MIC >64 microg/ml). None of the C. guilliermondii or C. pelliculosa isolates 
was resistant to KET, FLU, AmpB, or FCU. 
Yang et al. (2005) reported distribution of drug resistance in Candida spp. They 
determined susceptibilities to amphotericin B and fluconazole of 628 clinical yeast strains 
collected from 22 hospitals in Taiwan. A total of 53 isolates (8.4%o) were resistant to 
fluconazole. Each hospital had different resistance rate to fluconazole ranging from 0% to 
24%. None of the 186 isolates from eight of the 22 hospitals was resistant to fluconazole. 
In contrast, isolates from nine of the remaining 14 hospitals had greater than 10%) 
resistance rate to fluconazole. Consistently, 88.9% (8/9) fluconazole-resistant C. albicans 
isolates were from hospitals having a high resistance rate to fluconazole. The prevalence 
of various Candida spp in each hospital was different. A positive association was found 
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between the prevalence of C. tropicalis and the resistance rate to fluconazole for 
individual hospitals. Although only three isolates (0.5%) were resistant to amphotericin 
B, a co-resistance to both amphotericin B and fluconazole was observed, which 
highlights the emerging problem of drug resistance. 
Mohanty et al. (2007) carried out a prospective study to determine the susceptibility 
pattern to fluconazole of yeasts isolated from the vagina of symptomatic women. This 
prospective study was conducted in a rural primary health care center of north India from 
May 2003 to April 2004 and included 601 married, sexually active women (18-49 yr) 
with the self reported symptoms of vaginal discharge and/or genital itching and/or genital 
burning. In their study, susceptibility testing carried out on 30 representative isolates (15 
C. glabrata, 10 C. albicans, 4 C. tropicalis and I C. parapsilosis) revealed that 21 
isolates (70%) were susceptible (MIC, < 8 mg/ml) to fluconazole while 9 (30%) were 
susceptible-dose dependent (S-DD, MIC 16-32 mg/ml). On the basis of their findings 
they suggested that a low prevalence of fluconazole resistance in vaginal Candida 
isolates in their population. However, a high prevalence of non-albicans Candida species 
and increased dose-dependent resistance in these isolates necessitates vigilance since this 
may warrant a change in the optimal therapy of non-albicans Candida vaginitis. 
Snelders et al. (2008) investigated the prevalence and spread of azole resistance using/i. 
fumigatus isolates collected between 1994 and 2007. They investigated the prevalence of 
itraconazole (ITZ) resistance in 1,912 clinical A. fumigatus isolates collected from 1,219 
patients in our University Medical Centre over a 14-y period. The spread of resistance 
was investigated by analyzing 147 A. fumigatus isolates from 101 patients, from 28 other 
medical centres in The Netherlands and 317 isolates from six other countries. ITZ-
resistant isolates were found in 32 of 1,219 patients. All cases were observed after 1999 
with an annual prevalence of 1.7% to 6%. The ITZ-resistant isolates also showed 
elevated minimum inhibitory concentrations of voriconazole, ravuconazole, and 
posaconazole. The ITZ-sensitive isolates were not more likely to be responsible for 
invasive aspergillosis than the ITZ-resistant isolates. ITZ resistance was found in isolates 
from 13 patients (12.8%) from nine other medical centres. They concluded that azole 
resistance has emerged in A. fumigatus and might be more prevalent than currently 
acknowledged. 
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Yan et al. (2011) determined the drug suceptibility of Candida islates in patients with 
primary Sjogren's syndrome (SS). In their study susceptibilities of the 44 Candida 
isolates to 7 antifungal agents varied dramatically. The resistance to azoles was 
remarkable, and the phenomenon of cross-resistance between itraconazole and 
fluconazole was observed. 
2.7. Combating drug resistance in fungi 
Various approaches are now attempted and or employed to combat fungal infections. In 
order to develop new approaches to antifungal therapy, new targets, novel compounds 
and innovative delivery systems are required. In this regard, the cell membrane, cell well 
and associated virulence factors, and putative genes have been targeted. Some new 
targets for antifungal agents may be identified at the level of fungal cell wall a structure 
essential to fungi but lacking in mammalian cells. Their major macromolecular targets 
are chitin P-glucan and mannoproteins. Similarly, plasma membrane and targets based on 
synthesis of ergosterol, phospholipids, shingolipid and proton ATPase, efflux pump, 
protein synthesis, intermediary metabolism of nucleic acid, signal transduction and cell 
cycle; all can provide new antifungal drug target (Sangamwar et al. 2008). New 
molecular drug target have been identified and validated. However, new drug 
development is still awaited (Odds 2005, Ahmad et al 2010d). 
2.7.1. Use of combination therapy 
A possible approach to overcome antifungal drug resistance and high mortality rates due 
to severe fungal infections is to combine two or three classes of antifungals, especially 
the drugs having different mechanisms of action. The overall goal of combination 
antifungal therapy is to achieve increased clinical efficacy through drug synergy and to 
avoid or minimize toxicity to the patient. 
2.7.2. Targeting virulence and pathogenicity 
An advantage of using virulence factors as drug target is that they are usually pathogen 
specific and not found in human host. Fortunately, during the last few years, virulence 
factors of fungi and their inhibitors have, at least to some extent been discovered and 
characterized. This should provide new options for the developments of potential 
antifungal therapeutics as described by Gauwerky et al. (2009). 
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2.8. Role of plant products in alternative medicine 
In these perspectives, plant products especially essential oils traditionally being used in 
e.thnomedicine against fungal infections are suspected to deliver such kinds of antifungal 
agents with broad spectrum and newer modes of action. Medicinal plants are part and 
parcel of human society to combat diseases, from the dawn of civilization. There are 
2600 plant species of which more than 700 are noted for their uses as medicinal herbs. In 
folk medicine, medicinal herbs and plant products were used in treating a wide spectrum 
of infections and other diseases. Primitive people have used plants to cure a variety of 
human ailments. Even today, 85% of Indians use higher plants as effective anti-
microbials for the treatment of various diseases. A large number of anti-microbial agents 
derived from traditional medicinal plants are available for treating various diseases 
caused by microorganisms (Jain 1994, Kamboj 2000). They are used to eliminate the 
infecting micro-organisms. Today, a great number of different medicinal tea and other 
plant products are available in market (including cosmetics and pharmaceuticals), which 
contains biologically active substances. In recent years, there has been a gradual revival 
of interest in the use of medicinal and aromatic plants in developed as well as in 
developing countries, because plant-derived drugs have been reported to be cheaper, safe 
and'without side-effects (Bansod and Rai 2008). It is also expected that plant compounds 
with target sites other than those currently used by antimicrobials will be active against 
drug-resistant microbial pathogens. Yet, the information available regarding medicinal 
plants products that are active against such microorganism is not sufficient for effective 
formulations for human use (Agarwal et al. 2010). These products can be used alone or in 
support to existing antifungal agents for achieving effective therapeutic values. 
2.9. Essential oils 
Essential oils are the volatile, natural, complex compounds characterized by a strong 
odour and are formed by aromatic medicinal plants as secondary metabolites (Bakkali et 
al. 2008). The term essential oils was derived from the Latin phrase 'Quinta essential', 
meaning 'the effective component of a drug', coined in the sixteenth centuary by the 
Swiss physician and alchemist, Paracelsus von Hohenheim (Guenther 1948). Essential 
oils are well known since antiquity for their properties to possess biological activities 
notably antibacterial, antifungal, antioxidant, antiviral, anti-cancerous and anti-
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inflammatory activities, and are used for flavouring and preservating foods and drinks 
(Bounatirou et al. 2007; Bakicali et a!. 2008). The essential oils are obtained by hydro or 
steam distillation of different parts of the plants such as flowers, fruits, leaves, seeds, 
stems, barks, woods etc. The quality and composition of essential oils vary widely 
depending on the plant organs, age, vegetative cycle stage, season, location, geographical 
location, environmental and agronomic conditions, cultivation techniques, soil texture, 
climate etc and therefore variation in commercial and biological activities (Angioni et al. 
2006; Yesil et al. 2007). Table R-4 shows ethnomedicinal values of certain medicinal 
plants and their essential oils. 
2.9.1. Chemical composition of essential oils 
Most essential oils are primarily composed of terpenes and their oxygenated derivatives 
such as mono- and sesquiterpenoids, benzoids, phenylpropanoids, etc. and exert different 
biological actions on humans, animals, and other plants (Adorjan and Buchbauer 2010). 
Essential oils are very complex natural mixtures which can contain about 20-60 
components at quite different concentrations. They are characterized by two or three 
major components at fairly high concentrations (20-70%) compared to others components 
present in trace amount (Bakkali et al. 2008). Chemical structures of some of the selected 
components of essential oils depicted in figure R-5. Further detailed structure of various 
compounds from plants can be assessed from Harborne and Baxter (1995). 
2.9.2. Antifungal activity of essential oils alone 
Essential oils could be a potential source of novel bioactive compounds with new mode 
of action of various cellular and molecular targets. A survey of literature reveals that 
there are many essential oils which possess antifungal activity. 
Several workers form India and other countries have validated the use of essential oils in 
antifungal therapy and their studies have suggested their important antifungal activity 
against yeasts, dermatophyte and Aspergillus strains, and have therapeutic potential, 
mainly in fungal diseases involving mucosal, cutaneous and respiratory tract infections 
(Rai et al 2003). Reports on antifungal activities from essential oils are reviewd here in 
brief. 
Manohar et al (2001) reported antifungal properties of origanum oil under both in vitro 
and in vivo. Origanum oil at 0.25 mg/ml was found to completely inhibit the growth of C. 
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Figure R-5. Chemical structures of selected components of common essential oils. 
albicans in culture. Growth inhibitions of 75% and >50% were observed at 0.125 mg/ml 
and 0.0625 mg/ml level, respectively. In addition, both the germination and the mycelial 
growth of C. albicans were found to be inhibited by origanum oil and carvacrol in a dose-
dependent manner. The daily administration of 8.6 mg of origanum oil in 100 |al of olive 
oil/kg body weight for 30 days resulted in 80% survivability, with no renal burden of C. 
albicans as opposed to the group of mice fed olive oil alone who died within 10 days. 
Similar results were obtained with carvacrol. 
Hammer et al. (2002) have reported in vitro antifungal activities of tea tree oils against 
dermatophytes (n=106) and other filamentous fungi (n=78). Tea tree oils MIC was 
ranged form 0.004% to 0.25% v/v and MFC ranged from <0.03% to 8.0% v/v against all 
the tested fungi. They also showed that germinated conidia of Aspergillus niger were 
more susceptible to tea tree oil compared to non germinated conidia. 
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Mondello et al. (2003) studied tea tree oil (TTO) preparation of defined chemical 
composition, for its in vitro activity against 115 isolates of Candida albicans, other 
Candida species and Cryptococciis neoformans. Fourteen strains of C. albicans resistant 
to fluconazole and/or itraconazole were also assessed. They observed that TTO was 
active in vitro against all tested strains, with MlCs ranging from 0.03% (for C. 
neoformans) to 0.25% (for some strains of C albicans and other Candida species). 
Fluconazole- and/or itraconazole-resistant C. albicans isolates had TTO MIC50 and 
MIC90 of 0.25% and 0.5%, respectively. They also found that TTO was highly 
efficacious in accelerating C albicans clearance from experimentally infected rat vagina. 
Hammer et al. (2004) investigated the mechanism of action of tea tree oil and its 
components against Candida albicans, Candida glabrata and Saccharomyces cerevisiae. 
The treatment of C. albicans with tea tree oil and components at concentrations of 
between 0.25 and 1.0% (v/v) altered both permeability and membrane fluidity. 
Membrane fluidity was also increased when C. albicans was cultured for 24 h with 
0.016%)-0.06%) (v/v) tea tree oil, as compared with control cells. For all three organisms, 
glucose-induced acidification of the external medium was inhibited in a dose-dependent 
manner in the presence of 0.2%, 0.3% and 0.4% tea tree oil. Data from this study 
supported the hypothesis that tea tree oil and components exert their antifungal actions by 
altering membrane properties and compromising membrane-associated functions. 
Tampieri et al. (2005) have evaluated the in vitro inhibiting activity of sixteen 
commercial essential oils and forty-two pure constituents (alcohols, aldehydes, ketons, 
phenols and hydrocarbons), against a strain of Candida albicans. The essential oils of 
Origanum vulgare, Satureja montana, Mentha piperita, Cinnamomum verum, 
Cymbopogon flexuosus showed maximum inhibitory activity (MIC = 500 ppm) after 7 
days. According to the results of the examination of pure constituents, y5-phellandrene 
proved to be the most interesting component among cyclic monoterpenic hydrocarbons as 
it showed a strong activity (MIC = 50 ppm). The most active of phenols was carvacrol 
(MIC 100 ppm). The open-chain alcohol 1-decanol was the most active of alcohols at 50 
ppm. They also recorded that, among aldehydes, a strong activity was shown by trans-
cinnamaldehyde (MIC 50 ppm). 
Rukayadi et al. (2006) have reported anticandidal activity from xanthorrizol obtained 
from Curcuma xanthoirhiza Roxb. In their study all Candida species showed 
susceptibility to xanthorrhizol in the MIC range 1.0-15.0 mg/L for Candida albicans, 
i.O-IO mg/L for Candida glabrata, 2.0-8.0 mg/L for Candida guilliennondii, 2.5-7.5 
mg/L for Candida krusei. 2.5-25 mg/L for Candida parapsilosis and 2.0-8.0 mg/L for 
Candida tropicalis. Time-kill curves demonstrated that xanthorrhizol was able to kill the 
Candida strains with MFCs of 20 mg/mL, 15 mg/mL, 12.5 mg/mL, 10 mg/L, 30 mg/mL 
and 10 mg/'L for C albicans, C glabrata, C guilliermondii, C. krusei, C. parapsilosis 
and C tropicalis, respectively. 
Rasooli et al. (2006) evaluated the antifungal effects of essential oils from Thymus 
eriocalyx and Thymus x-porlock with emphasis to determine the mechanism of inhibition 
of Aspergillus niger growth at ultrastructural level. They determined MIC, MFC, and 
fungicidal kinetics of the oils. Transmission electron microscopy of ^. niger exposed to 
MIC levels of the oils showed irreversible damage to cell wall, cell membrane and 
cellular organelles. 
Park et al. (2007) investigated the potential of oils derived from Leptospermum petersonii 
Bailey and Syzygium aromaticum L. Merr. Et Perry as natural antifungal agents against 
the dermatophytes. The antifungal activities of 5'. aromaticum oil (clove oil) against the 
dermatophytes tested were highest at a concentration of 0.2 mg/ml, with an effectiveness 
of more than 60%. Hyphal growth was completely inhibited in T. mentagrophytes, T. 
rubrum, and M gypseum by treatment with clove oil at a concentration of 0.2 mg/ml. 
Eugenol was the most effective antifungal constituent of clove oil against the 
dermatophytes T. mentagrophytes and M canis. Morphological changes in the hyphae of 
T. mentagrophytes, such as damage to the cell wall and cell membrane and the expansion 
of the endoplasmic reticulum, after treatment with 0.11 mg/ml eugenol were observed by 
TEM. At a concentration of 0.2 mg/ml, L petersonii oil (LPO) was more than 90% 
effective against all of the dermatophytes tested, with the exception of T. rubrum. 
Geranial was determined to be the most active antifungal constituent of Z. petersonii oil. 
Taken together, the results of this study demonstrated that clove and tea tree oils have 
significant antifungal activities against the dermatophytes tested in this study. 
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Sokovic et al. (2008) performed in vivo evaluation of the toxicological and antifungal 
activity of the essential oil of Thymus vulgaris L. and its main component thymol on two 
month old male Wistar rats. They examined the therapeutic potency against 
experimentally induced dermatomycoses in rats, using the most frequent 
dermatomycetes, Trichophyton mentagrophytes, T rubrum, and T. tonsurans. The 
therapeutic efficacy of a 1% solution of the essential oil of Thymus vulgaris and thymol 
as well as the commercial preparation bifonazole was evaluated. They found that during 
the 37-day observation period the oil-treated animals were cured. 
Bajpai et al. (2009) undertaken to assess the in vitro antifungal potential of the essential 
oil and n-hexane, chloroform, ethyl acetate, and methanol extracts of Nandina domestica 
Thunb. against dermatophytes. The oil (1,000 |ig/disc) and extracts (1,500 ^ig/disc) 
revealed 31.1-68.6% and 19.2-55.1% antidermatophytic effect against Trichophyton spp., 
along with their respective MlCs ranging from 62.5 to 500 and 125 to 2,000 ng/mi. Also, 
the oil had strong detrimental effect on spore germination of all the tested dermatophytic 
fungi as well as concentration and time-dependent kinetic inhibition of T. rubrum KCTC 
6375. Their results demonstrated that N. domestica mediated oil and extracts could be 
potential sources of natural fungicides to control certain important dermatophytic fungi. 
Pinto et al. (2009) studied the composition and antifungal activity of clove essential oil 
(EO), obtained from Syzygium aromaticum and its main constituent eugenol against 
Candida, Aspergillus and dermatophytes. The EO and eugenol showed inhibitory activity 
against all the tested strains. Mechanism of action of these oils on yeasts and filamentous 
fungi was determined using flow cytometric and inhibition of ergosterol synthesis 
studies. They observed that propidium iodide rapidly penetrated the majority of the yeast 
cells when the cells were treated with concentrations just over the MlCs, meaning that the 
, fungicidal effect resulted from an extensive lesion of the cell membrane. Clove oil and 
eugenol also caused a considerable reduction in the quantity of ergosterol. Germ tube 
formation by Candida albicans was completely or almost completely inhibited by oil and 
eugenol concentrations below the MIC values. Their study indicated that clove oil and 
eugenol have considerable antifungal activity against clinically relevant fungi, including 
fluconazole-resistant strains. 
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Agarwal et al. (2010) tested inhibitory effect of 30 different plant oils on Candida 
albicans isolated from clinical samples. Of the 30 plant oils tested, 18 were found to be 
effective and 12 were ineffective. Based on their MFCs, effective oils were placed into 
three categories: most effective, moderately effective and least effective. Eucalyptus 
globulus and Mentha piperita oils were most effective, with MFC values of 0.12% and 
0.15% (v/v), respectively. Whereas, Cymbopogon martini, Eugenia caryophyllous, 
Ocimum sanctum, Melaleuca alternifolia were moderately effective (0.15-1.0%). The 
significant antifungal activity of these oils suggested that they could serve as a source of 
compounds with therapeutic potential against Candida-vdated infections. 
Ahmad et al. (2010b) performed in vitro studies to assess the antifungal activity of 
eugenol and methyl eugenol on various Candida isolates. Insight studies to mechanism 
carried out by this group suggested that both eugenol and methyl eugenol exerts their 
antifungal activity by targeting sterol biosynthesis. Furthermore, it was also observed that 
additional methyl group to eugenol increases its antifungal activity. The observed 
fungicidal characteristics of both eugenol and methyl eugenol indicated that both the 
compounds might be promising antifungal agents defining a new class of antimycotics. 
Ahmad et al. (2011) also attempted to examine antifungal activity of thymol and 
carvacrol against 111 fluconazole -sensitive and -resistant Candida isolates. In their 
study, both these compounds were found to be effective to varying extents against all 
isolates, including the resistant strains. Significant impairment of ergosterol biosynthesis 
was pronouncedly induced by these agents. Carvacrol and thymol show strong fungicidal 
effect against all of the Candida isolates. 
Neelofar et al. (2011) evaluated curcumin, an important Asian spice, for their antifungal 
activity against 14 strains of Candida. In their study, curcumin displayed antifungal 
properties against all tested Candida strains, with MICs varying from 250 to 2000 
Hg/mL. At MIC, curcumin inhibited H"^  extrusion in 2 species of Candida by 42% and 
32% in the absence of glucose and by 28% and 18% in the presence of glucose. 
Respective inhibition of H"^  extrusion caused by the MIC of fluconazole was 85%) and 
89%) in the absence of glucose and 61% and 66%) in its presence. Ergosterol content 
decreased by 10% and 53% for the 2 strains following exposure to curcumin at MIC; 
comparative values for fluconazole at MIC were 93% and 98%). Curcumin and 
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fluconazole decreased proteinase secretion by 49% and 53%, respectively, in C, albicans 
and by 39% and 46%), respectively, in C. glabrata. In conclusion, they suggested that 
curcumin is active against all tested strains and antifungal activity might be originating 
from alteration of membrane-associated properties of ATPase activity, ergosterol 
biosynthesis, and proteinase secretion. 
2.9.3. Antifungal activity of essential oils in combination with antifungal drugs 
Combination of drugs may result in different outcomes defined as synergy, antagonism, 
additivity and indifference. When combinational activity of drugs is greater than 
individual's, it is defined as synergy and if lower, than antagonism. Additivity is 
observed when efficacy in combination is no higher than sum of individual drugs 
whereas, indifference for no enhancement in efficacy at all. There are several advantages 
and reasons to be considered in combination therapy as described by Baddley and Pappas 
(2005) such as (a) increased potency and extent of fungal killing (b) broader spectrum of 
activity targeting potentially resistant pathogens (c) counter emergence of drug resistance 
(d) reduction of individual drug dosages to minimize their toxicities. 
Combination of drugs may be based on their mode of action of two antifungal drugs. 
Using a combination of drugs that act at different site, theoretically, may result in 
synergistic killing of fungal pathogen and several examples are based on this principle 
(Johnson et al. 2004; Johnson and Perfect 2007). But caution is still needed since some 
antifungal combinations have also demonstrated antagonistic activity. Well-controlled 
clinical trials are required to define the most efficacious antifungal regimen. Furthermore, 
these trials should evaluate the side effect potential of combination therapy and the 
pharmaco economic impact (Vazquez 2007). In recent years, several authors have 
described both in vitro and in vivo antifungal combinations in treatment of various fungal 
infections (Cuenca-Estrella 2004, Baddley and Pappas 2007, Espinel-Ingroff 2009). 
Combinations of new agents along with more traditional antifungals have shown to 
possess some synergistic or at least additive activity against many pathogenic fungi 
in vitro and in vivo. A review on studies made on combination of essential oils with 
antifungal drugs against fungal pathogens is given here. 
Giordani et al. (2004) evaluated the antifungal effect of the essential oil from Satureja 
montana L., Lavandula angustifolia Mill., Lavandula hybrida Reverchon, Syzygium 
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aromaticum (L.) Merril and Perry, Origanum vii/gare 1.,., Rosmarinus officinalis L. and 
six chemotypes of Thymus vulgaris L. on Candida albicans growth. The most efficiency 
was obtained with the essential oil from Thymus vidgaris thymol chemotype (MIC 80% = 
0.016 i^ L/mL and A^ aff = 296 fa.L/mL). The presence in the culture medium of essential oil 
from Thymus vulgaris thymol chemotype (0.01, 0.1, 0.2, 0.3 |ig/mL) and amphotericin B 
involved a decrease of the MIC 80% of amphotericin B. In contrast, the combination of 
amphotericin B and low concentrations (0.00031-0.0025 )ag/mL) of essential oil was 
antagonistic. The strongest decrease (48%)) of the MIC 80%) was obtained with the 
medium containing 0.2 ).iL/mL of essential oil. There findings signified that the essential 
oil of Thymus vulgaris thymol chemotype potentiates the antifungal action of 
amphotericin B. 
Hirasawa and Takada (2004) evaluated the susceptibility of Candida albicans to catechin 
and the synergism of the combination of catechin and antimycotics. Among catechins, 
pyrogallol catechin showed stronger antifungal activity against C. albicans than catechol 
catechin. The addition of 6.25-25 or 3.12-12.5 mg/L EGCg to amphotericin B 0.125 or 
0.25 mg/L (below MIC) at pH 7.0 resulted in enhancement, respectively, of the 
antifungal effect of amphotericin B against amphotericin B-susceptible or -resistant C. 
albicans. Combined treatment with 3.12-12.5 mg/L EGCg plus amphotericin B 0.5 mg/L 
(below MIC) markedly decreased the growth of amphotericin B-resistant C. albicans. 
When fluconazole-susceptibie C albicans was treated with 25-50 mg/L EGCg and 
fluconazole 0.125-0.25 mg/L (below MIC), its growth was inhibited by 93.0%-99.4% 
compared with its growth in the presence of fluconazole alone. The combined use of 12.5 
mg/L EGCg and fluconazole 10-50 mg/L (below MIC) inhibited the growth of 
fluconazole-resistant C. albicans by 98.5%>-99.7%). They suggested that EGCg enhances 
the antifungal effect of amphotericin B or fluconazole against antimycotic-susceptible 
and -resistant C. albicans. 
Giordani el al. (2006) investigated the antifungal activity of the essential oil from 
Cinnamomum cassia, alone or combined with amphotericin B. The essential oil of 
Cinnamomum cassia exhibited strong antifungal effect (MIC 80%) -=0.169 ^L/mL and 
K^^= 18,544 |iL/mL). A decrease of the MIC 80% of amphotericin B was obtained when 
the culture medium contained essential oil concentrations ranging from 0.08 to 0.1 
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^L/mL. The strongest decrease (70%) was obtained when the medium contained 0.1 
[iL/mL of essential oil. This potentiation of amphotericin B has highlighted the effective 
therapies involving Cmnamomum cassia oil in combination. 
Sim and Shin (2008) studied the antifungal activities of ligustilide and butylidene 
phthalide, which are major oil components comprising the essential oil of Ligusticum 
chiianxiong, in combination with antifungal drugs against Trichophyton species, T. 
ehnacei, T. mentagrophytes, T. rubrum, T. schoenleinii, T. tonsurans and T. soudanense. 
Susceptibility of these Trichophyton species to L. chiianxiong essential oil differed 
distinctly. The fractional inhibitory concentrations (FlCls) against Trichophyton species 
ranged between 0.27 and 0.56 for ketoconazole combined with ligustilde or butylidene 
phthalide, indicating synergism or additive effects between the antibiotic and essential oil 
compounds. In their study, testing by itraconazole instead of ketoconazole, similar 
combination effects were observed with FICls from 0.31 to 0.63 against the tested strains 
of T. mentagrophytes, T. rubrum, T. schoenleinii, and T. soudanense. Thus, data reported 
by this group had showed that Trichophyton susceptibility to ketoconazole and 
itraconazole could be notably improved by ligustilde and butylidene phthalide. 
Rukayadi et al. (2009) have exploited Xanthorrhizol, a sesquiterpene compound isolated 
from Curcuma xanthorrhiza Roxb in combination with ketoconazole or amphotericin B 
against Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, 
Candida parapsilosis, and Candida tropicalis. In their study, mostly, xanthorrhizol in 
combination with ketoconazole or amphotericin B exhibited the synergistic anticandidal 
effects against all species of Candida tested. In combination with xanthorrhizol, the 
concentration of ketoconazole or amphotericin B for inhibiting the growth of the tested 
Candida species could be reduced by >50%. Time-kill curves showed that 1/2 MIC dose 
of xanthorrhizol, amphotericin B, or ketoconazole alone against each of the six Candida 
species did not inhibit the growth of all Candida species tested. However, 1/2 MIC dose 
of xanthorrhizol in combination with 1/2 MIC dose of ketoconazole or 1/2 MIC dose of 
amphotericin B exhibited growth inhibition of all Candida species tested and reduced 
viable cells by several logs within 4 h. These results supported the potential use of 
xanthorrhizol as an anticandidal agent, and it can be used complementarily with other 
conventional antifungal agents. 
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Ahmad et al. (2010a) assessed the in vitro antifungal activity of eugenol (EUG) and 
methyleugenol (MEUG) alone and in combination against 64 FLC-sensitive and 34 FLC-
resistant clinical Candida isolates. All the strains were susceptible to both the naturally 
occurring phenyl propanoids. FICI values depicted a high synergism of PLC with both 
compounds, which was greatest with MEUG. FLC-resistant Candida isolates showed 
high sensitivity to both compounds. No antagonistic activity was seen in the strains tested 
in the present study. From these results they suggested that EUG and MEUG have great 
potential as antifungals, and that FLC can be supplemented with EUG and MEUG to treat 
FLC-resistant Candida infections. 
Saad et al. (2010) investigated a possible synergistic effect of the EOs of two Moroccan 
endemic thymes {Thymus broussonetii and T. maroccanus) with amphotericin B (Amp B) 
and fluconazole against Candida albicans. The FICI of T. maroccanus and T. 
broussonetii EOs combined with AmpB and fluconazole were 0.49, 0.27, 0.37 and 0.3, 
respectively. Also, their results indicated that the synergistic effect of EOs with 
fluconazole was stronger than the combination with Amp B. All these data highlighted 
that the EOs tested potentiate the antifungal action of Amp B and fluconazole, suggesting 
a possible utilization of these EOs in addition to antifungal drugs for the treatment of 
some candidiasis due to C. albicans. 
Silva et al. (2011) evaluated the antifungal activity of coriander essential oil against the 
Candida strains. The MLC values equal to the MIC value and ranging from 0.05 to 0.4% 
(v/v). Flow cytometric evaluation of BOX, PI and DRAQ5 staining indicates that the 
fungicidal effect is a result of cytoplasmic membrane damage and subsequent leakage of 
intracellular components such as DNA. Also, concentrations below the MIC value caused 
a marked reduction in the percentage of germ tube formation for C. albicans strains. A 
synergetic effect between coriander oil and amphotericin B was also obtained for C. 
albicans strains, while for C. tropicalis strain only an additive effect was observed. 
Zore et al. (2011) evaluated ant\-Candida potential of six terpenoids against various 
isolates of Candida a/bicans (n=39) and non-albicans Candida (n==9) that were 
differentially susceptible to fluconazole. In their study, all the six terpenoids tested, 
showed excellent activity and were equally effective against isolates of Candida spp 
tested. Linalool and citral were the most effective ones, inhibiting all the isolates at 
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<0.064% (v/v). Five among the six terpenoids tested were fungicidal. Time dependent 
i<.ili curve assay showed that MFCs of linaiool and eugenoi were highly toxic to C. 
albicans, l<illing 99.9% inoculum within seven min of exposure, while that of citronellal, 
linalylacetate and citral required 15 min, 1 h and 2 h, respectively. FlC index values 
(Linalool-0.140, benzylbenzoate-0.156, eugenol-0.265, citral-0.281 and 0.312 for linalyl 
acetate and citronellal) and isobologram obtained by checkerboard assay showed that all 
the six terpenoids tested exhibited excellent synergistic activity with fluconazole against 
a fluconazole resistant strain of C. albicans. Linaiool, citral, citronellal and benzyl 
benzoate caused more than 50% inhibition of germ tube induction at 0.008%, while 
eugenoi and LA required 0.032 and 0.016% (v/v) concentrations, respectively. 
2.9.4. Anti-pathogenic and anti-biofilm activity of essential oils 
A variety of virulence factors have been observed in fungal pathgenesis and reported to 
be targeted in vitro and in vivo for possible new approach for describing new antifungals. 
Hydrolytic enzymes such as SAPs, phospholipases, catalases, and adhesions, melanin, 
calcineurin, lipid signaling molecules and several other putative virulence factors 
including biofilm formation in one or other pathogenic fungi candidate are in the 
development of new antifungal drugs targeting virulence. Several inhibitors of virulence 
factors have been reported by various workers. Didanosine (an antiretroviral agent) and 
squinavir (HIV proteinase inhibitors) were found effective in clearance of oral 
candidiasis resulting in HIV patients. Squinavir, retnovir and indinavir being HIV 
proteinase inhibitors also inhibited Candidal SAPs in vitro (Zingman 1996; Cauda et al. 
1999). In addition, some natural products like tacrolimus, cyclosporine A inhibits 
calcineurin in C. albicans and C. neoformans (Liu et al. 1991; Huai et al. 2002). 
Furthermore, Aureobasdin A and Khafrefungin have been shown to inhibiting inositol 
phosphoryl ceramide synthase in Candida spp, C. neoformans and Aspergillus spp 
(Gauwerky et al. 2009). Also, olive extracts and saponins are reported to be inhibitors of 
elastases and hyphal formation, respectively, in Candida infections (Battinelli et al. 2006; 
Zhang et al. 2006). A brief review of the literature describing anti-pathogenic potential of 
essential oils against fungi is given below. 
Hammer et al. (2000) examined the effect of tea tree oil (TTO) on the formation of germ 
tubes by Candida albicans. Two isolates were tested for germ tube formation (GTF) in 
54 
the presence of TTO concentrations (%v/v) ranging from 0.25% (1/2 minimum inhibitory 
concentration [MIC]) to 0.004% (1/128 MIC). GTF at 4 h in the presence of 0.004 and 
0.008% (both isolates) and 0.016% (one isolate) TTO did not differ significantly 
(P>0.05) from controls. At all other concentrations at 4 h, GTF differed significantly 
from controls (P<0.01).They further tested eight isolates for GTF in the presence of 
0.031% TTO, and at 4h the mean GTF for all 10 isolates ranged 10.0-68.5%. Two 
isolates were examined for their ability to form germ tubes after 1 h of pre-exposure to 
several concentrations of TTO, prior to induction of germ tubes in horse serum. Cells pre-
exposed to 0.125 and 0.25% TTO formed significantly fewer germ tubes than control 
cells at 1 h (i'<0.05), but only those cells pre-exposed to 0.25% differed significantly 
from control cells at later time points (P<0.01). Based on this study it was suggested that 
GTF by C. albicans is affected by the presence of, or pre-exposure to, sub-inhibitory 
concentrations of TTO. 
Ishida et al. (2006) investigated the antifungal activity of a crude extract, fractions and 
sub fractions from Stryphnodendron adstringens (Mart.) Coville, known as 'barbatimao'. 
They reported that sub fraction F2.4 had the best antifungal action at concentrations 
above 7.80 mg/L. CSH and the capacity for adhering to Vero cells and a glass surface 
were lower in treated yeasts. In addition, the inhibition of formation of the germ tube, the 
increase in the number of buds and changes in the cell wall ultrastructure of C. albicans 
were also demonstrated. Sub fraction F2.4 is composed of proanthocyanidin polymers of 
prodelphinidin and prorobinetinidin units and gallic acid of molecular weight 2114 Da. 
Therefore, they concluded that the antifungal action of sub fraction F2.4 on C. albicans 
can be attributed to condensed tannins. 
He et al. (2007) investigated the effects of eugenol on preformed biofilms, adherent cells, 
subsequent biofilm formation and cell morphogenesis of C. albicans. Eugenol displayed 
in vitro activity against C. albicans cells within biofilms, when MIC50 for sessile cells 
was 500 rng/L. They observed the effect of eugenol on morphogenesis of C. albicans 
cells by scanning electron microscopy (SEM). Their results indicated that the effect of 
eugenol on adherent cells and subsequent biofilm formation was dependent on the initial 
adherence time and the concentration of this compound, and that eugenol can inhibit 
filamentous growth of C. albicans cells. In addition, using human erythrocytes, eugenol 
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showed low hemolytic activity. They concluded that eugenol possess potent activity 
against C. albicans biofilms in vitro and has potential therapeutic implication for biofilm-
associated candidal infections. 
Agarwal et al. (2008) evaluated the inhibitory effect of 30 plant oils against biofilm 
forming Candida albicans strain (CA I) isolated from clinical samples, which was 
sensitive to 4 fig/ml of fluconazole, used as a positive control. The standard strain 
(MTCC 2,27, CA II) used in their study was found to be highly resistant to fluconazole, 
3,000 ng/ml of which was required to inhibit the growth of this strain partially, and 
complete inhibition could not be achieved. Eighteen among the 30 plant oils tested were 
found to show anti-Candida activity by disc diffusion assay. Effective plant oils were 
assessed using XTT reduction assay for biofilm quantification. Four oils eucalyptus, 
peppermint, ginger grass and clove showed 80.87%, 74.16%, 40.46% and 28.57% 
biofilm reduction respectively. Scanning electron microscopic (SEM) analysis further 
revealed reduction in C. albicans biofilm in response to effective oils. Therefore, the 
substantial antifungal activity shown by these plant oils suggests their potential against 
infections caused by C. albicans. 
Braga et al. (2008) investigated whether thymol can interfere with biofilm formation as 
well as acting on mature biofilms. Tests of C. albicans strains ATCC 3153A and ATCC 
MYA 2876 showed that thymol interferes with the starting phases of biofilm production 
as well as with mature C. albicans biofilms. The metabolic activity of sessile cells was 
reduced by >90% at twice the minimum inhibitory concentration of planktonic cells. 
They suggested that as biofilm is a multifactorial phenomenon, the multiple mechanisms 
of thymol (terpenes) could act on different steps in the evolution of mature biofilm. 
Dalleau et al. (2008) tested in vitro the antibiofilm activity of 10 terpenes against three 
Candida species by 24-h treatment of biofilms aged 1 -5 days. Treatment of 24-h-old 
Candida albicans biofilms with carvacrol, geraniol or thymol (0.06%) resulted in >80% 
inhibition. Carvacrol (0.03%)) inhibition was >75%) independent of the age of the C. 
albicans biofilm. Carvacrol (0.125%)) inhibition was >75% against Candida glabrata and 
Candida parapsilosis biofilms. Geraniol (>0.125%)) and thymol (0.06%) or 0.125%)) 
inhibition was >75% against C. parapsilosis biofilms whatever their age. This study 
demonstrated the antibiofilm activity of terpenes and pointed out the exceptional 
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efficiency of carvacrol, geraniol and thymol, which could represent candidates in the 
treatment of candidiasis associated with medical devices. 
Pozatti et al. (2010) investigated the effects of essential oils extracted from some spices 
in the inhibition of germ tube formation on Candida albicans and C. dubliniensis. They 
studied susceptibility of C. albicans fluconazole-susceptible (n == 30), Candida albicans 
fluconazole-resistant (n = 30) and C. dubliniensis fluconazole-susceptible (n = 30) 
isolates to essential oils through the inhibition of germ tube formation assay. The 
minimum essential oil concentration able to inhibit germ tube formation ranged from 
66.07 )J.g/ml (oregano) to above 3200 |ag/ml (rosemary). Furthermore, the profile of 
activity was the same for three groups of fungi: oregano > Mexican 
oregano > thyme > cinnamon > ginger > basil > sage > rosemary. They concluded that C. 
albicans fluconazole-susceptible were more susceptible than C albicans fluconazole-
resistant, requiring lower concentrations of essential oils to inhibit germ tube, whereas C. 
albicans was more susceptible than C. dubliniensis. 
Furletti et al. (2011) evaluated the efficacy of extracts and essential oils from Allium 
tuberosum, Coriandrum sativum, Cymbopogon martini, Cymbopogon winterianus, and 
Santolina chamaecyparissus against Candida spp isolates from the oral cavity of patients 
with periodontal disease. The most active oil was fractionated and tested against C. 
albicans biofilm formation. The best activities against planktonic Candida spp. were 
observed for the essential oil and the grouped F8-10 fractions from C. sativum. The crude 
oil also affected the biofilm formation in C. albicans causing a decrease in the biofilm 
growth as observed unde SEM. Chemical analysis of the F8-10 fractions detected as 
major active compounds, 2-hexen-l-ol, 3-hexen-l-ol and cyclodecane. Standards of these 
compounds tested grouped provided a stronger activity than the oil suggesting a 
synergistic action from the major oil constituents. The activity of C. sativum oil 
demonstrated its potential for a new natural antifungal formulation. 
Taweechaisupapong et al. (2011) evaluated MIC and MFC of lemomgrass oil against 
planktonic and biofilm cells oi Candida dubliniensis. In their study MIC and MFC were 
0.43 and 0.86 mg/ml, respectively. Employing XTT reduction assay for biofilm study, the 
results showed that the average percentage inhibition of lemongrass oil (0.43 mg/ml) on 
biofilm formation was 91.57±1.31%, while it exhibited more than the average killing 
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activity against C. dubliniemis in biofllm at concentrations of 1.7 mg/ml. In addition, a 
significant reduction (P=0.03) of candidal adhesion to acrylic occurred after a 15 min 
exposure to 1.7 mg/ml of lemongrass oil. Moreover, limited exposure of yeasts to 
lemongrass oil at subcidal concentration can suppress growth for more than 24 h. 
Altogether, there results obtained had indicated that lemongrass oil possess antifungal 
and antibiofilm activities and could modulate candidal colonization. 
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3.1 Materials used in the study 
3.1.1. Chemicals and culture media used 
A number of chemicals and culture media were used in this study as described below in 
table M-l. 
Table M-l List of chemicals/reagents/microbiological media used in the study. 
Chemicals/ biochemicals/drugs Source 
Acetic acid (glacial) 
Acetone 
Agar powder 
Amido black 
Ammonium sulphate 
Aniline blue 
Asparagine 
Barium chloride dehydrate 
Biotin 
Bovine serum albumin 
Bromocresol purple 
Calcium carbonate 
Calcium chloride 
Chloramphenicol 
Chloroform 
Citric acid monohydrate 
Dimethyl sulfoxide 
Dextrose 
Ethylene diamine tetraacetic acid 
Egg-yolk emulsion 
Elastin 
Elastin-congo red 
Eosin Methylene Blue agar 
Ergosterol 
Ethanol 
Gelatin 
L-glutamine 
Glycerol 
Glutaraldehyde 
rt-Hexane 
Hicrome Candida differential agar base 
Hydrogen chloride 
L-histidine 
Histidine hydrochloride 
Hydrochloric acid 
India ink stain 
Inositol 
Kovac's reagent 
Lactic acid 
Magnesium sulfate 
Menadione 
Methanol 
3-(N-morpholino)propanesuifonicacid 
a-naphthylamine 
DL-methionine 
Qualigens, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Qualigens, India 
Qualigens, India 
Qualigens, India 
Merck, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Merck, India 
Merck, India 
Merck, India 
SRL, India 
Hi-Media, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Sigma, India 
Sigma, India 
Hi-Media, India 
Sigma, India 
Merck, India 
Hi-Media, India 
Hi-Media, India 
Qualigens, India 
Hi-Media, India 
SRL, India 
Hi-Media, India 
Merck, India 
Hi-Media, India 
Hi-Media, India 
Qualigens, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Qualigens, India 
Sigma, India 
SRL, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
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Peptone 
Phenol 
Polysorbate 80 
Potassium dichromate 
Potassium nitrate 
Phenol red 
Dipotassium hydrogen phosphate 
Potassium dihydrogen phosphate 
Pyridoxine 
RPMI 1640 
Safranin 
Sulfanilic acid 
Sodium chloride 
Sodium citrate 
Sodium dodecyl sulfate 
Sodium hydroxide 
di-sodium hydrogen phosphate 
Sodium tetraborate 
Sorbitol 
Sulfuric acid 
Thiamine 
Trichloroacetic acid 
Triton X-100 
Trypan blue 
Tween 80 
Urea 
DL-tryptophan 
Xylene 
(2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) 
Yeast carbon base 
Yeast extract 
Zn powder 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Qualigens, India 
Qualigens, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Sigma, India 
Hi-Media, India 
Hi-Media, India 
Qualigens, India 
Qualigens, India 
Qualigens, India 
Qualigens, India 
Merck, India 
Merck, India 
Sigma, India 
Merck, India 
Hi-Media, India 
Merck, India 
Hi-Media, India 
Hi-Media, India 
Hi-Media, India 
Merck, India 
Hi-Media, India 
Qualigens, India 
Sigma, India 
Hi-Media, India 
Hi-Media, India 
Qualigens, India 
3.1.2. Composition of microbiological media; (ingredients in g/1) 
Corn meal agar: Corn meal infusion (2.0), polysorbate 80 (10.0 ml), agar (15.0) 
(pH 5.8). 
Eosin methylene blue agar: Peptone (10.0), lactose (10.0), dipotassium 
hydrogen phosphate (2.0), eosin Y (0.4), methylene (0.065), tetracycline (0.1), 
agar (20.0) (pH 6.9) 
Hicrome Candida differential agar: peptone (15.0), yeast extract (4.0), 
dipotassium hydrogen phosphate (1.0), chromogenic mixture (7.22), 
chloramphenicol (0.5), agar (20.0) (pH 6.3). 
Nitrate broth: Peptone (5.0), beef extract (3.0), potassium nitrate (5.0) (pH 7.2). 
Nutrient broth: Peptone (5.0), beef extract (3.0) (pH 7.0). 
Nutrient agar: Peptone (5.0), beef extract (3.0), agar (20.0) (pH 6.8). 
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Starch agar: Peptone (5.0), beef extract (3.0), starch soluble (2.0), agar (20.0) 
(pH 7.0). 
Sabouraud dextrose broth: Peptone (10.0), Dextrose (40.0) (pH 5.6). 
Sabouraud dextrose agar: Peptone (10.0), Dextrose (40.0), Agar (20.0) (pH 5.6). 
Staib's medium: Guizotia abyssinica seeds (70.0), creatinine (0.78), dextrose (10.0), 
chloramphenicol (0.05), agar (20.0) (pH 6.9). 
Trypan blue agar medium: Mycological agar (25.0), disodium phosphate (2.5), 
trypan blue (0.1), chloramphenicol (0.02), gentamicin (0.01) (pH 7.2). 
Urea broth: Yeast extract (0.1), potassium dihydrohen phosphate (0.09), 
disodium hydrogen phosphate (0.095) urea (20.0) phenol red (0.01) (pH 6.9). 
Yeast fermentation broth: Yeast extract (5.5), peptone (7.5), specific 
carbohydrate (60.0), bromocresol purple (0.04), (pH 7.1). 
Yeast carbohydrate assimilation broth: 100 ml of Yeast nitrogen base (with out 
amino acids and ammonium sulphate) was prepared in lOX concentration. Dissolve 1.7 g 
base in 100 ml distill water. Add ammonium sulphate (5.0 g) L-histidine (0.01 g), DL-
methionine (0.02 g), and DL-tryptophan (0.02 g) (pH. 7.0) and sterilize through 
membrane filtration. Prepare final medium by mixing the lOX sterile medium into sterile 
distill water in 1:9 ratio. Add autoclaved 0.04% (w/v) bromocresol purple dye. 
Yeast nitrogen assimilation broth: 100 ml of Yeast nitrogen base (with out amino 
acids and ammonium sulphate) was prepared in lOX concentration. Dissolve 1.7 g base 
in 100 ml distilled water. Add dextrose (1.0 g), L-histidine (0.01 g), DL-methionine (0.02 
g), and DL-tryptophan (0.02 g) (pH. 7.0) and sterilize through membrane filtration. 
Prepare final medium by mixing the lOX sterile medium into sterile distill water in 1:9 
ratio. Add autoclaved 0.04% (w/v) bromocresol purple dye. Nitrogenous compounds 
were added as ammonium sulphate (0.1% w/v), potassium nitrate (0.078% w/v), 
asparagine (0.1 %> w/v), peptone (0.132 % w/v). 
3.1.3. Composition of reagents/buffers/solutions 
Lactophenol cotton blue: Concentrated phenol (20%o v/v) is added to mixture of 
glycerol (40%), lactic acid (20%) and water (20%), followed by the addition of 
aniline blue (0.05 g). 
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Nitrate reduction test Solution: Solution A: Sulfanilic acid (5.0 g), acetic acid, 
5M (500 ml); Solution B: a-naphthylamine (5.0 g), acetic acid, 5M (500 ml). 
25% ale. KOH: KOH (25.0 g) in 35 ml distil water and 65 ml ethanol 
Cacodylate buffer: Prepare a 0.2 M stock solution of sodium cacodylate [Na(CH3)2 
ASO2.3H2O] in water (4.28 g/100 ml). Add amounts of 0.2 M HCl per 100 ml cacodylate 
stock solution, followed by the addition of distil water to a final volume of AOO ml, to 
obtain 0.05 M cacodylate buffer at the desired pH 
Phosphate buffer saline: Mix equal volume of 0.02M K2HPO4 (pH 7.8) and 
0.02M KH2PO4 (pH 5.6) and add 0.6% (w/v) sodium chloride (final pH 7.0). 
Sodium borate buffer: Dissolve sodium tetraborate in distill water to obtain 50 mM (pH 
8.5). 
Sodium citrate buffer: Mix equal volumes of 0.2M sodium citrate and 0.2M citric acid 
(pH 3.2). 
McFarland standards: 0.5 McFarland standard (Mix 0.5 ml of 1% barium 
chloride dehydrate with 9.95 ml of 1% sulfuric acid); 4.0 McFarland standard 
(Mix 0.4 ml of 1% barium chloride dehydrate with 9.6 ml of 1% sulfuric acid). 
3.1.4. Antifungal drugs used 
For conducting antifungal drug sensitivity of test strains and other experiments, 
the below mentioned (table M-2) antibiotic discs and powders were used. 
Table M-2 Antifungal drugs used in the study. 
Antifungal drugs 
Discs 
Amphotericin B 
Clotrimazole 
Fluconazole 
ItraconJizole 
Ketoconazole 
Nystatin 
Powders 
Amphotericin B 
Fluconazole 
Itraconazole 
Ketoconazole 
Abbreviation 
AMB 
CLT 
FLC 
ITC 
KTC 
NYT 
-
-
-
-
Potency/disc 
20 ng 
10 ng 
10 ng 
10 MS 
10 Hg 
100 unit 
-
-
-
-
Solubility 
-
-
-
-
-
-
1%DMS0 
-do-
-do-
-do-
Source 
Hi-Media Laboratory, 
Mumbai, India 
-do-
-do-
-do-
-do-
-do-
Hi-Media Laboratory, 
Mumbai, India 
Pfizer Co., Mumbai, India 
Jansen Co., Mumbai, India 
Hi-Media Laboratory, 
Mumbai, India 
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3.2. Methodology used in the study 
3.2.1. Isolation and collection of yeasts and filamentous fungi 
Yeasts: 
(a) A total of 23 clinical strains of Candida spp. and one isolate of C. neoformans 
were isolated form diseased samples of patients attending the Department of 
Microbiology, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim 
University, Aligarh. Clinical conditions of samples are mentioned in table 2. 
(b) In addition to above strains of clinical origin, four reference strains of 
Candida spp and one strain of C. neoformans were obtained from national or 
intem>ational culture collections. The details are given in table 2. 
Filamentous fungi (molds): 
(c) The two clinical strains one each of Aspergillus niger and Trichophyton 
rubriim were collected from Institute of Ophthalmology, Aligarh Muslim 
University, Aligarh. Clinical conditions of samples are mentioned in table 3. 
(d) Also, six reference strains of filamentous fungi including three strains of 
Aspergillus spp., and one strain each of Alternaria solani, Fusarium oxysporum, 
Mucor rouxii and Trichophyton ruhrum were included in the study (table 3). 
3.2.2. Morphological, cultural and biochemical characterization of Yeasts 
3.2.2.1. Morphological and cultural characterization 
Isolates oi Candida spp, Cryptococcus spp. were morphologically and culturally 
identified by examining the colony colour, shape and texture. 
Use of Hicrome Candida differential agar: The diseased specimen was streaked 
on to Hicrome Candida differential agar media plates and incubated at 30 °C for 
24-48 h. The species of Candida were identified on the basis of manufacturer's 
recommendation for colony texture and colour. Such as light green colour and 
smooth colonies (C. albicans), blue to purple and raised colonies (C tropicalis), 
small, convex and creamy white colonies (C. glabrata), large, spreading pink 
colonies v/ith matt surface (C krusei). 
Use of Eosin methylene blue agar medium: C. albicans was differentiated from 
other non-albicans Candida (NACs) by growth on EMB agar media. Culture 
inoculated plates were incubated at 37 °C in 10% CO2 for 24-48 h. C. albicans 
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was identified by characteristic spidery or feathery colourless colony indicating 
formation of germ tubes and presence of pseudohyphae and budding yeast cells. 
Whereas, NAC colonies appeared as smooth, circular and cream colour 
indicating presence of classical yeasts cells. 
Use of Staib's medium (bird seed agar)/phenol oxidase test: For selective 
isolation and differentiation of C neoformans and other yeasts, sample specimen 
was streaked on bird seed agar plates and incubated at 30 °C for 3-6 days. Brown 
colour colonies were considered as C. neoformans and creamy white colour 
colonies were as Candida spp and other Cryptococcus spp. 
Use of Trypan blue agar medium: Further, to differentiate C. neoformans from 
Candida spp and other yeasts, trypan blue agar media was used. Culture 
inoculated plates were incubated at 25 °C for 3-6 days. Colonies of dark blue 
colour were identified as C. neoformans and light blue colour colonies as 
Candida spp. 
3.2.2.2. Microscopic examination 
Use of Corn meal agar media using Dalmau plate culture technique: This 
enrichment media was used for differentiation of C albicans from NACs and 
Cryptococcus spp. Loopful of culture growth was streaked on to media plates and 
inoculum was covered by flame sterilized cover slip. Plates were sealed with 
parafilm and incubated at 30 °C for 3 days. Reverse side of cover slip was 
examined for diagnostic structures such as pseudohyphae, blastoconidia, hyphae, 
chlamydospores and arthrospores at 40X and lOOX under light microscope 
(Olympus BS60, Japan) 
Production of germ tubes: The method of Taschdjian et al (I960) with little 
modifications was adapted to evaluate the germ tube formation. Candida cells were 
allowed to grow in Sabouraud dextrose broth at 37 °C for 24 h. Next, 0.5 ml of yeast 
suspension (1.0x10^ cfu/ml) was mixed with 0.5 ml of serum and incubated at 37 °C for 
3 h. Loopful of sample was examined after staining with lactophenol cotton blue for 
the production of germ tubes at 40X and lOOX underlight microscope (Olympus 
BS60, Japan). 
65 
India ink staining: To visualize the characteristic capsules of C. neofromans, the 
india ink staining was performed. Loopful of culture inoculum was mixed with 1-
2 drops India ink and smear was prepared and microscopically examined at 40 X 
under light microscope (Olympus BS60, Japan). 
The yeast strains differentiated and identified on various differential medium 
were subjected to study their morphological and cultural characteristics on 
Sabouraud dextrose agar (SDA) media at 35 °C for 24-48 h. The strains were 
examined for colour, texture and shape of colonies grown on media. 
3.2.2.3. Biochemical characterization 
The yeasts strains were subjected to biochemical characterization on the basis of 
fermentation and assimilation of carbohydrates, assimilation of nitrogen compounds, 
nitrate reduction, urease and phenol oxidase tests. Reference methods of Land et al. 1975; 
Cooper and Silva-Hunter 1985; Warren and Shadomy 1991 and Barnett et al. 2000, were 
used for different organism. 
Carbohydrate fermentation: Briefly, 3 ml of yeast fermentation broth in sugar tubes 
containing 6% w/v of different sugars (viz. glucose, lactose, maltose, sucrose and 
galactose) and having Durham's tube in inverted position were inoculated with 10 |al of 
yeast suspension (1.0 McFarland). The inoculated tubes were incubated at 37 °C up to 7 
days. Colour change from blue to yellow and production of gas were observed at 
different time interval (1, 3, 5, and 7 day). Change of colour with or without gas 
production was indicated as positive reaction. 
Carbohydrate assimilation: The ability of yeasts to assimilate carbohydrates was 
determined by dye pour plate auxanographic (DPPA) technique. Briefly, plates of yeast 
nitrogen base containing bromocresol purple dye were prepared. Further, 100 1^ of yeast 
suspension (4.0 McFarland) was spread and allowed to absorb on to media for 10 min. 
Carbohydrate discs (25 mg/disc) were mounted on to the surface of media and plates 
were incubated at 30 °C for 3 days. Plates were examined for development of growth 
surrounding the discs as indicated by change in colour from blue to yellow. 
Nitrogen assimilation: Yeast nitrogen base containing bromocresol purple dye was used 
for nitrogen assimilation. Briefly, tubes containing 3 ml of this medium amended with 
different nitrogenous compounds were inoculated with 100 ^1 of yeast suspension (4.0 
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McFarland) and incubated at 30 °C for 3 days. Tubes were examined for change in colour 
of medium from blue to yellow if growtli occurs. 
Nitrate reduction test: Tubes containing 3 ml of nitrate broth and inverted Durham's 
tubes were inoculated with 100 |ul of yeast suspension (1.0 McFarland) and incubated at 
35 °C for 24-48 h. After incubation, 3 drops of solution A was added followed by 
addition of 3 drops of solution B. Development of red colour with in 30 min indicated the 
reduction of nitrate into nitrite. To the colourless solution a pinch of Zn powder was 
added. Further, development of red colour indicated negative reaction but culture broth 
still remained colourless, indicated positive reaction showing reduction of nitrate beyond 
nitrite into ammonia or nitrogen gas. 
Urease test: Loopful culture of test was inoculated in to 0.5 ml of urea broth in sugar 
tubes and incubated at 35 °C. Colour change were observed at different time intervals 
(15, 30, 60 min and up to 4 h). The development of deep pink colour indicated positive 
reaction. 
3.2.3. Morphological and cultural characterization of filamentous fungi 
3.2.3.1. Morphological characterization 
Isolates of Aspegillus spp., A. solani, F. oxysporum, M. rouxii, T. rubrum were 
morphologically identified by examining the colony colour, shape and texture 
grown on SDA plates at 25 °C for 7-14 days and as described by Larone (2002). 
3.2.3.2. Cultural characterization 
Test fungi were grown on SDA at 25 °C for 5-7 days. The growth from periphery of 
vegetatively growing mycelia were subjected to lacto-phenol cotton blue staining and 
observed for the differential vegetative and reproductive structures at 40 X under light 
microscope (Olympus BS60, Japan). 
3.2.4. Identification of C. albicans by ISSrRNA gene sequencing 
Molecular characterization of strain C. albicans 04 was performed at Macrogen 
Incorporation, Seoul, South Korea to confirm the identity of strain using 18S rRNA gene 
sequencing using following protocols. 
PCR amplification 
The primers ITSl primer (5 - TCCGTAGGTGAACCTGCGG - 3) and 1TS4 primer (5 -
TCCTCCGCTTATTGATATGC - 3) were used for the PCR. The PCR reaction was 
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performed with 20 ng of genomic DNA as the template in a 30 |ii reaction mixture by 
using a EF-Taq (SolGent, Korea) as follows: activation of Taq polymerase at 95 °C for 2 
min, 35 cycles of 95 °C for 1 min, 55 °C, and 72 °C for I min each were performed, 
finishing with a 10 min step at 72 °C. 
Sequence analysis 
The amplification products were purified with a multi-screen filter plate (Millipore Corp., 
Bedford, MA, USA). Sequencing reaction was performed using a PRISM Big Dye 
Terminator v3.1 Cycle sequencing Kit. The DNA samples containing the extension 
products were added to Hi-Di formamide (Applied Biosystems, Foster City, CA). The 
mixture was incubated at 95 °C for 5 min, followed by 5 min on ice and then sequences 
were determined by ABI Prism 3730XL DNA sequencer (Applied Biosystems, Foster 
City, CA). 
3.2.5. Preservation of fungal cultures 
The well characterized and identified strains of Candida spp, Cryptococuus spp, 
Aspergillus spp, A. solani, F. oxysporum, M. rouxii and T. rubrum are deposited to 
the culture collection of department of Agricultural Microbiology, Aligarh^ 
Muslim University, Aligarh. The strains were maintained on SDA at 4 °C and 
subcultured on SDA slants/SDB prior to use in assays. 
3.2.6. Detection of extracellular production of virulence factors in yeasts 
3.2.6.1. Formation of germ tubes 
The method of Taschdjian et al. (1960) with little modifications was adapted to evaluate 
the germ tube formation. Candida cells were allowed to grow in SDB at 37 °C for 24 h. 
Next, 0.5 ml of yeast suspension (1.0x10^ cfu/ml) was mixed with 0.5 ml of serum and 
incubated at 37 °C for 3 h. A random 100 yeast cells from each sample were selected to 
count the number of germ tubes using haemocytometer (Axiva Co., New Delhi, India) at 
40X magnification under light microscope (Olympus BS60, Japan). Each experiment was 
performed three times with three replicates per experiment and the mean values were 
considered for calculation of percent formation of germ tubes in untreated and treated 
samples. 
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3.2.6.2. Cell surface hydrophobicity 
The method of microbial adhesion to hydrocarbons (MATH) as described by Rosenberg 
et al. (1980) with some modifications was used to determine CSH of Candida cells. 
Briefly, Candida cells were grown on SDA at 25°C for 48 h. Yeast suspensions were 
made in PBS (A520 of 0.400) and allowed to contact with xylene in 5:1 ratio. The 
mixtures were vortexed for 1 min at room temperature and then allowed to separate the 
two phases for 10 min. The absorbance of aqueous phase was read at 520 nm. The 
percent CSH was calculated as follows; %CSH- [(A,-At)/A,]x]00. Where, Aj and Af are 
the absorbance values of aqueous yeast suspension at 520 nm before and after contacting 
yeast suspension to the organic phase. 
3.2.6.3. Phospholipase assay 
The extracellular secretion of phospholipase was measured by the modified method of 
Polak (1992). A base medium was prepared using dextrose (20.0 g/l), peptone (10.0 g/1), 
yeast extract (5.0 g/l), sodium chloride (58.5 g/l), calcium chloride (0.55 g/l) and agar 
(20.0 g/l) and autoclaved. To the basal medium, 8% egg-yolk emulsion (Hi-Media) was 
added and plates were prepared. Amounts of 10 |il of yeast suspension (1.0x10^ cfu/ml) 
were spot inoculated on the egg-yolk agar plates and incubated at 37 °C for 72 h. 
Phospholipase activity (pZ values) was measured in terms of the ratio of the diameter of 
the colony to the total diameter of colony plus zone of precipitation. 
3.2.6.4. Proteinase assay 
Production of extracellular proteinase was assessed by the method of Aoki et al. (1990) 
using BSA agar plates. Briefly, 60 ml of a solution containing MgS04.7H20 0.04 g, 
K2HPO4 0.5 g, NaCl 0.2 g, yeast extract 0.2 g, glucose 4.0 g and BSA (Hi-Media) 0.5 g; 
was prepared and the pH was adjusted to 3.5 with IN HCL. This solution was filter 
sterilized and mixed with 140 ml of autoclaved melted agar to prepare the BSA agar 
plates. Amounts of 10 ^1 of yeast suspension (1.0x10^ cfu/ml) were spot inoculated on 
the BSA agar plates and incubated at 37 °C for 5 days. After incubation, the plates were 
stained with 0.1% amido black dye and destained with 15% acetic acid, and the clear 
zone was measured. Proteinase activity (pZ values) was calculated in terms of the ratio of 
the diameter of the colony to the total diameter of colony plus zone of solubilization. The 
proteinase production in liquid medium was determined using the modified method of 
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Kuriyama et al. (2003). Briefly, 50 ml Erlenmeyer flasks containing 10 ml of induction 
medium as described by MacDonald and Odd (1980) was inoculated with 100 |il of 
Candida cells (l.OxlO'' cfu/ml) and incubated at 26 °C for 7 days at 160 rpm. The broth 
culture was centrifuged at 5000 rpm for 30 min to obtain supernatant. Furthermore, 200 
\i\ of supernatant was mixed with 800 1^ of substrate [1% (w/v) BSA in 0.025 M sodium 
citrate buffer, pH 3.2] and incubated at 37 °C for 3 h. The reaction was halted by the 
addition of 2.0 ml of 5% trichloroacetic acid (TCA) resulting in precipitation of 
undigested BSA. Tubes were kept at ice for 30 min and centrifuged at 2000 rpm for 20 
min. Proteolysis was determined by measuring the absorbance of soluble peptides at 280 
nm. A control was run by mixing substrate to supernatant and immediately reaction was 
stopped by adding TCA. The absorbance value of control was subtracted from test 
samples to obtain values for enzyme activity. 
3.2.6.5. Haemolysis assay 
Haemolysin production was evaluated using a modified method of Luo et al. (2001). The 
blood agar plates were prepared by adding 7 ml of fresh sheep blood suspended in sterile 
phosphate buffer saline (PBS) to 100 ml of SDA supplemented with 3% (w/v) glucose. 
Amounts of 10 )il of yeast suspension (l.Ox 10^  cfu/ml) were spot inoculated on the blood 
agar plates and incubated at 37 °C in 5% CO2 for 48 h. After incubation, plates were 
scored for the presence of transluscent ring and or a greenish black halo circumscribing 
the inoculum growth. Haemolysin activity (pZ values) was calculated in terms of the ratio 
of the diameter of the colony to the total diameter of colony plus zone of halo.' 
The haemolysin production in liquid medium was determined using the method of Manns 
et al. (1994) with some modifications. The erythrocytes were harvested by centrifugation 
of freshly obtained sheep blood for 10 min at 3000 rpm, and washed three times in PBS. 
To the pellet, PBS was added to yield a 10% (v/v) erythrocytes/PBS suspension. The 
10% suspension was then diluted 10 times in PBS. Candida cells were grown in SDB 
[8% (w/v) glucose] for 4 days at 37 °C. The broth cultures were centrifuged at 5000 rpm 
for 30 min to obtain supernatant. Furthermore, the culture supernatant and RBC 
suspension were mixed in 1:1 ratio and incubated at 37 °C for 4 h. Triton X-100 [0.1% 
(v/v) in PBS] was used as a positive control whereas 1% DMSO and PBS were used as 
negative controls. Tubes were centrifuged at 2000 rpm for 10 min and the absorbances of 
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supernatants were read at 540 nm. The percentage of haemolysis was calculated as: [{(A-
B)/(C-B)}xlOO]. Where, A and B are the absorbance values of supernatant from the test 
sample and PBS (solvent control) respectively and C is the absorbance value of 
supernatant from the sample after 100% lysis. 
3.2.7. Detection of extracellular production of virulence factors in 
filamentous fungi 
3.2.7.1. Lipase production 
The lipase assay was carried out according to the method as described by Muhsin 
et al. (1997). The basal medium consisted of peptone (1%, w/v), sodium chloride 
(5%), calcium chloride (0.01%) and agar (2%) (pH 5.5). Tween 80 (as a lipid 
substrate) was autoclaved separately and added to sterile and cooled (up to 50 °C) 
basal medium at a final concentration of \% (v/v). 10 |al of spore suspension (cell 
density of 1.0x10^ cfu/ml) of test fungi was inoculated on to the plates and 
incubated at 25 °C for up to 15 days. Formation of a precipitate around the 
colonies demonstrated lipase production. 
3.2.7.2. Phospholipase production 
The extracellular secretion of phospholipase was measured by the method of Muhsin et 
al. (1997). The basal medium consisted of sodium chloride (IM), calcium chloride 
(0.005M), and agar {2%), (pH 5.0). The medium was autoclaved, and cooled and 
amended with egg yolk (8%i, v/v). The plates were inoculated with 10 fil of spore 
suspension (1.0x10^ cfu/ml) of test fungi and incubated at 23 °C for 15 days. The 
formation of a dense white zone of precipitation around the colony indicated the 
production of phospholipase enzyme. 
3.2.7.3. Gelatinase production 
The method of Muhsin et al. (1997) was used for determination of gelatinase 
production. The basal medium contained gelatin (0.8%), w/v), agar (2%), (pH 
7.40). 8%i (w/v) gelatin solution was sterilized separately and, 5 ml was added to 
sterile and cooled 100 ml basal medium. The plates were inoculated with 10 |il of 
spore suspension (1.0x10^ cfu/ml) of test fungi and incubated at 29 °C for 15 days. 
Presence of clear halo around the colony indicated the production of gelatinase. 
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3.2.7.4. Proteinase production 
Proteinase production of test fungi was evaluated on BSA agar plates and as 
described by Staib (1965). The BSA media contained glucose (2%, w/v), KH2PO4 
(0.1%), MgS04 (0.05%) and BSA (1%) (pH 4.5). The medium was filter 
sterilized and amended with sterile melted agar (2%, w/v). The plates were 
inoculated with 10 [\.\ of spore suspension (1.0x10^ cfu/ml) of test fungi and incubated 
at 35 °C for 15 days. Presence of clear halo around the colony indicated the production of 
proteinase. 
3.2.7.4.1. Production and assessment of elastase activity 
Method of Kothary et al. (1984) was adapted for elastase production by Aspergillus 
isolates. Briefly, 250 ml of liquid medium (1.17% yeast carbon base, 0.2%o elastin and 
0.5% CaCOs) in 500 ml Erlenmeyer flask was inoculated with 2 ml of spore suspension 
(1.0x10^ cfu/ml) and incubated at 37 °C for 14 days at 120 rpm. Biomass was filtered 
through cheese cloth, whatman filter paper No. 1 and finally through 0.45 |im membrane 
filter to obtain cell free broth and used as source of crude enzyme in the assays. 
Further, a colorimetric assay of Sachar et al. (1955) with some modifications was used 
employing elastin congo red (Sigma) as substrate to determine the elastase activity. 
Briefly, 250 i^l each of 50 mM sodium borate buffer (pH 8.5) and elastin congo red (20 
mg/ml in 50 mM sodium borate buffer, pH 8.5) was mixed and vortexed at room 
temperature for 5 min. Next, 250 \i\ of test sample was added and incubated at 37 °C for 3 
h at 180 rpm. Test sample was replaced by 250 \i\ of buffer as control. After incubation, 
750 |j,l of 10%) trichloro acetic acid was added to stop the reaction and kept for 30 min on 
ice. Insoluble material in the assay mixture was removed by centrifugation at 20,000 rpm, 
30 min and absorbance was read at 495 nm using double beam uv-vis spectrophotometer 
(UV5704SS, India). 
3.2.7.4.2. Production and assessment of keratinase activity 
Test fungi were cultivated in SDB following the methods of Muhsin and Aubaid (2000). 
Briefly, 5 ml of spore suspension (1.5x10^ cfu/ml) was added to 500 ml of SDB in 1000 
ml Erlenmeyer flask and incubated at 27 °C for 4 weeks. Mycelial biomass was harvested 
and washed three times with 0.03M phosphate buffer (pH 7.8) and finally dispensed in to 
500 ml 0.03M phosphate buffer (pH 7.8) supplemented with glucose (0.02g), MgS04 
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(0.28g), thiamine (0.004g), pyridoxine (0.004g), inositol (0.02g) and fibrous protein 
(5.0g). Flasks were incubated for 3 weeks at 27 °C. Culture filtrate was passed through 
filter paper and 0.45 lam membrane filter and centrifuged at 20,000 rpm for 30 min and 
the obtained cell free supernatant is used as crude enzyme in the assays. 
Further, estimation of keratinase activity in test fungi was performed using modified 
method of Muhsin and Aubaid (2000). In brief, 500 [i\ of supernatant was mixed with 50 
mg of guinea pig hair in 5 ml of 0.03M phosphate buffer (pH 7.8) and incubated at 37 °C 
for 3 h, 150 rpm. Test sample was replaced by buffer to run the control. Reaction mixture 
was stopped by adding 5 ml of 10% TCA and kept at ice for 30 min and centrifuged at 
5000 rpm for 20 min. The hair was removed by filtration and absorbance was read at 280 
nm using double beam uv-vis spectrophotometer (UVS5704SS, India). 
3.2.8. Detection of biofilm formation in Candida spp. 
3.2.8.1. Visual detection of biofilm formation 
The strains of Candida spp were screened for their ability to form biofilm under static 
condition in polystyrene tubes by the method as described by Gokce et al. (2007) Briefly, 
10 mL of SDB supplemented with glucose (final concentration 8% w/v) was inoculated 
with loopful of organism and incubated at 37 °C for 48 h. After incubation, the broth in 
the tube was aspirated gently and decanted. Tubes were washed thrice with sterile PBS 
and then stained with 1% (w/v) safranin for 10 min and examined for the adherent 
biofilm layer. Biofilm formation ability was tentatively scored as strong (+++), moderate 
(++), weak (+) and negative (-) by visually comparing the thickness of adherent layer. 
3.2.8.2. Quantitative determination of biofilm formation in microtiter plate 
The strains oi Candida spp were also evaluated by 96 well microtiter plates based XTT 
reduction assay for biofilm formation using the method as described by Ramage et al. 
(2001) with little modifications. Briefly, Candida cells were grown in SDB (glucose 8% 
w/v) at 37 °C for 24 h. Cells were harvested and re-suspended in RPMI 1640 medium 
with L-glutamine but without bicarbonate and buffered to pH 7.0 with MOPS to a cell 
density of 1.5x10^ cfu/mL. Biofilms were formed by adding 100 pi of this standardized 
cell suspension to wells of microtiter plates and incubating at 37 °C for 48 h. Thereafter, 
the medium was aspirated gently, and non-adherent cells were removed by washing the 
biofilms thrice in sterile PBS. Further biofilm formation was analysed by XTT reduction 
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assay. Briefly, 0.091 mi of XTT (Sigma, N. Dellii) (1 mg/1 in PBS) and 0.009 mi of 
menadione (Sigma, N. Dellii) (1 m mol/1 in acetone) was added to each well and 
incubated in the dark for 4 h. The colorimetric change was measured at 492 nm using a 
Labsystem Multiskan Ex MTP Reader. Each assay was performed three times with three 
replicates per experiment and the mean absorbance values were used to measure the 
biofilm formation. 
3.2.9. Sensitivity of fungi to antifungal drugs 
All the test fungi were tested for their susceptibility to six antifungal drugs namely 
amphotericin B, clotrimazole, ketoconazole, fluconazole, itraconazole and nystatin using 
their standard discs (Hi-Media, Mumbai). Whereas, for determination of MIC and other 
assays, stock solutions of amphotericin B, ketoconazole, fluconazole and itraconazole 
were prepared in 1% dimethyl sulphoxide (DMSO) at a concentration of 25 mg/ml and 
stored at -20 °C until used. 
3.2.9.1. Disc diffusion assay 
A disc diffusion assay as recommended by Clinical and Laboratory Standards Institute 
(CLSI) M44-A2 (for yeasts) and M51-P (for filamentous fungi) was used with some 
modifications for determining drug susceptibility. Briefly, 100 |al of yeast suspension (0.5 
McFarland) or spore suspension (1.5x10^ cfu/ml) was spread onto SDA plates and then 
antifungal drug discs (10-20 )ig/disc), were placed over the agar surface and the plates 
were incubated at 37 °C for 24 h for yeasts and at 35 °C for 48 h for filamentous fungi. 
3.2.9.2. Broth macrodilution assay 
The MIC of drugs was determined against the yeasts by CLSI reference method for broth 
macrodilution M27-A3 and as modified by Colombo et al. (1995), whereas, CLSI 
reference method for broth macrodilution M38-A2 with some modifications was used 
against filamentous fungi. Briefly, yeast suspension (0.5 McFarland) or spore suspension 
of (1.5x10^ cfu/ml) was prepared in RPMI 1640 medium with L-glutamine but without 
bicarbonate and buffered to pH 7.0 with MOPS. 0.1 ml of two-fold serial dilutions of test 
drugs (lOX concentrations) were made in the test tubes and 0.9 ml of diluted inoculum 
medium was added to each tubes and incubated at 37 °C for 48 h (for yeasts) or at 35 °C 
for 48 h (for filamentous fungi). Drug free control was included. For the azoles such as 
fluconazole, itraconazole and ketoconazole, the MIC was established as the lowest 
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concentration that inhibited 80% of the control growth. For amphotericin B, MIC was 
defined as the lowest concentration that inhibited visible growth. 
3.2.10. Plant essential oils used in the study 
A total of 19 essential oils and 4 major active compounds were used in the study as 
described below in the table M-3. All the essential oils or active compounds were diluted 
ten times in 1% DMSO before use in assays. 
Table M-3 List of essential oils and active compounds used in the study. 
Plant essential oils Common 
name 
Parts used Source 
Apiitm graveolens 
Carum copticum 
Cinnamomum verum 
Citrus limon 
Citrus paradisi 
Citrus sinensis 
Cynibopogon citratus 
Cymbopogon martini 
Eucalyptus sp 
Foeniculum vulgare 
Mentha piperita 
Myristica fragrans 
Petroselinum crispum 
Rosmarinus officinalis 
Santalum album 
Syzygium aromaticum 
Thymus vulgaris 
Zea mays 
Zingiber officinale 
Active compounds 
Cinnamaldehyde 
Citrai 
Eugenol 
Geraniol 
Celery 
Ajowan 
Cinnamon 
Lemon 
Grape 
Orange 
Lemongrass 
Palmarosa 
Eucalyptus 
Sweet fennel 
Peppermint 
Nutmeg 
Parsley 
Rosemary 
Sandalwood 
Clove 
Thyme 
Corn 
Ginger 
Seeds 
Seeds 
Bark 
Fruit 
Fruit 
Fruit 
Leaf 
Leaf 
Leaf 
Seeds 
Leaf 
Seeds 
Leaf 
Leaf 
Heartwood 
Flower 
bud 
Leaf 
Kernels 
Roots 
Wyndmere Naturals Inc., USA 
Fragrance and Flavour Development Centre, 
Kannauj, India 
Himalaya drug Co, Dehradun, India 
Himalaya drug Co, Dehradun, India 
Wyndmere Naturals Inc., USA 
Wyndmere Naturals Inc., USA 
Fragrance and Flavour Development Centre, 
Kannauj, India 
Fragrance and Flavour Development Centre, 
Kannauj, India 
Hi-Media Laboratory, Mumbai, India 
Wyndmere Naturals Inc., USA 
Hi-Media Laboratory, Mumbai, India 
Himalaya drug Co, Dehradun, India 
Wyndmere Naturals Inc., USA 
Wyndmere Naturals Inc., USA 
Wyndmere Naturals Inc., USA 
Dabur India Ltd, Delhi, India 
Fragrance and Flavour Development Centre, 
Kannauj, India 
Wndmere Naturals Inc., USA 
Wyndmere Naturals Inc., USA 
Hi-Media Laboratory, Mumbai, India 
Fragrance and Flavour Development Centre, 
Kannauj, India 
Hi-Media Laboratory, Mumbai, India 
(minimum assay 98%) 
Fragrance and Flavour Development Centre, 
Kannauj, India (minimum assay 98%) 
3.2.10.1. Evaluation of physico-chemical properties of essential oils 
Physical and chemical properties of essential oils and active compounds such as colour, 
refractive index, specific gravity, optical rotation and solubility in alcohol were 
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determined at Flavour and Fragrance Development Centre, kannauj, India using standard 
protocols. Colour of oils was noted from physical appearance at 25 °C. Refractive index, 
extent of optical activity and specific gravity of oils was determined at 27 °C using 
Abbe's refractometer, polarimeter and specific gravity bottle respectively. Solubility of 
oil was determined at 27 °C by mixing increment volumes of the oil in specified volumes 
ofthe 90% alcohol. 
3.2.10.2. Gas chromatography and gas chromatography-mass spectrometry analysis 
of essential oils 
The percentage composition of oils and compounds was determined by GC-FID and the 
compounds were identified by GC-MS. GC analysis was carried out on a Shimadzu 2010 
Gas Chromatograph equipped with an FID and 25 m x 0.25 mm x 0.25 ^m WCOT 
column coated with diethylene glycol (AB-Innowax, 7031428, Japan). Injector 
temperature was set at 270 °C and detector at 280 °C. Nitrogen was used as a carrier gas 
at a flow rate of 3.0 ml/min at a column pressure of 74.9 kPa. 0.2 |il of sample were 
injected into column with a split ratio of 90.0. The linear temperature program of 60 °C to 
230 °C set at a rate of 3 °C min'' with hold time at 230 °C for 10 minutes. The samples 
were then analyzed on the same Shimadzu instrument fitted with the same column and 
following the same temperature program as above. MS parameters used were: ionisation 
voltage (EI) 70eV, peak width 2 s, mass range 40-600 amu and detector voltage 1.5 V. 
Results were based on GC-FID. Peak identification was carried out by comparison ofthe 
mass spectra on the basis of GC retention time and comparing with MS reference with 
database of NIST05, NBS75K and Wiley 8 libraries. Identification of compounds was 
confirmed by comparison of their relative retention indices with literature values (Davies 
1990). 
3.2.11. Antifungal activity of essential oils against yeasts and filamentous fungi ^ 
3.2.11.1. Disc diffusion assay 
The method of Sokovic and van Griensven (2006) was adapted with slight modifications 
to determine the susceptibility of test strains against essentia! oils or active compounds. 
For this, 100 ^1 of yeast suspension (0.5 McFarland standard) or spore suspension 
(1.5x10^ cfu/ml) was spread onto SDA plates and then paper discs (8 mm, HiMedia) 
impregnated with 10 fj,l of essential oils/active compounds, were placed over the agar 
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surface and the plates were incubated at 37 °C for 24 h (for yeasts) at at 28±2 °C for 48 h 
(for filamentous fungi). The diameter of the zone of inhibition was recorded in mm 
around the discs. Each experiment was conducted three times in triplicate and average 
zone size was measured and data are presented as mean ± SD. 
3.2.11.2. Broth macrodilution assay 
For MIC determination of essential oils/active compounds, the method of Sokovic and 
van Griensven (2006) was adapted with some modifications. Briefly, 10 |LII of yeast 
suspension (0.5 McFarland) or spore suspension (1.5x10^ cfu/ml) was added to 1 ml SDB 
containing serially diluted essential oils, active compounds along with 0.1% (v/v) Tween 
80 and incubated at 37 °C for 24 h (for yeasts) or at 28±2 °C for 48 h (for filamentous 
fungi). MIC was defined as the lowest concentration that inhibited visible growth. Each 
experiment was repeated three times with each experiment in triplicates and mean values 
were calculated for MIC and MFC. 
3.2.11.3. Time kill assay 
Test strains C. albicans 01, 09, C. tropicalis 01 and C. neoformam 01 were randomly 
selected to assess time dependent killing by the most potent essential oils,, active 
compounds and antifungal drugs namely amphotericin B and fluconazole, using the 
modified method of De Logu et al. (2005). Briefly, 2X MIC concentrations of essential 
oils, active compounds and drugs were selected for assay. Twenty milliliters of PBS 
solution containing desired concentrations of test agents were inoculated with 1 ml of 
yeast suspension (0.5 McFarland). The control solution contained PBS with yeast 
inoculum but no essential oils, active compounds or drugs. Immediately after inoculation 
100 1^1 was collected from the solutions for viable count. Furthermore, test and control 
solutions were incubated at 37 "C for 48 h. Viable counts were obtained from 10-fold 
serial dilutions of test and control solutions at 2, 4, 6, 8, 12, 24, 36, and 48 h by plating 
100 ^1 of 10-fold dilution onto SDA plates and incubating at 37°C for 24 h. Whereas, the 
time-dependent killing of ^. fumigatus MTCC2550 and T. rubrum IOA-9 was evaluated 
using the modified method of Hammer et al. (2002). Briefly, 20 mL of PBS solution 
containing IX MFC of test agents and 0.001% (v/v) Tween 80 was inoculated with 1 mL 
of spore suspension (1.5x10^ cfu/ml). The control solution contained phosphate buffer 
saline with Tween 80 and fungal inoculum but no essential oils or active compounds or 
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fluconazole. Immediately after inoculation 100 |il was collected from solutions for viable 
count and, test and control solutions were further incubated at 30 "C at 120 rpm. Viable 
counts were obtained from ten-fold serial dilutions of test and control solutions at 2, 4, 6, 
8, 10 and up to 24 h by plating 100 |il of ten-fold dilution onto SDA plates and 
incubating at 30 °C for 24 h. Each experiment was conducted three times with three 
replicates per experiment and the mean colony count for each experiment was converted 
to values relative to the mean colony count at 0 h to normalize the data and correct the 
variation in starting inocula concentrations. The relative viable count was plotted against 
time on a log scale. • ' . ' ' ' '• 
3.2.11.4. Determination of inhibition of biomass production in filamentous fungi 
Method described by Shafique et al. (2011) with slight modification was adapted. 
Briefly, 50 ml Sabouraud dextrose broth (SDB) containing different concentrations of 
oils (0.005-0.32% v/v) was inoculated with 500 \i\ of freshly prepared spore suspension 
(1.5xl0^cfu/ml) of test fungi. In the corresponding control an equal amount of distilled 
water was added. Fluconazole in the concentration range of 1.25-200 ng/ml was also 
tested as a positive control. The flasks were incubated at 28±2 °C for 5 days. Thereafter, 
mycelial biomass from triplicate samples for each treatment was collected on pre-
weighed Whatman filter paper No.l. Mycelial yield was determined after drying the 
mycelial mat at 80 °C for 24 h and percent loss in mycelial dry weight was calculated 
over untreated control. 
3.2.11.5. Determination of inhibition of mycelial radial growth in filamentous fungi 
Method of Quiroga et al. (2004) with little modification was adapted. Briefly, a 5 mm 
diameter disc of inoculum of the test fungi was cut from the periphery of an actively 
growing culture and placed onto the SDA petriplates amended with test oils (0.005-
0.32% v/v). Fluconazole amended plates (1.25-200 ng/ml) were included as positive 
control. The SDA plates without oils and inoculated with corresponding fungi were 
served untreated controls. All the inoculated plates were incubated at 28±2 °C for 5 days. 
Three replicates for each combination of test fungi and oils concentrations were used. 
The mean diameter of the radial growth of the fungi was recorded at the end of the 
incubation period and percent growth inhibition was calculated over untreated control. 
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3.2.11.6. Determination of toxic effect of essential oils on fungal hyphae 
The time and concentration dependent toxicity of essentia! oils against the test fungi was 
observed under light microscopy. Briefly, 500 1^ of spore suspension (I.SxJO^cfu/ml) of 
test fungi were inoculated into 50 ml of SDB in 100 ml Erlenmeyer flasks containing a 
range of concentration of essential oils or active compounds (0.005 to 0.32 %v/v) and 
incubated at 28±2 °C for 48 h at 120 rpm. Sample was collected at different time intervals 
(0, 2, 4, 8, 16, 24, 32, 48 h) on to microscopic slides and observed for morphological 
alterations at 40X under Light microscope (Olympus BS60, Japan). 
3.2.11.7. Determination of inhibition of ungerminated and germinated conidia 
growth 
The assay comprising the activities against ungerminated and germinated conidia of test 
fungi employed the modified method of DeLucca et al. (1997). For ungerminated conidia 
susceptibility assay, 90 \i\ of freshly obtained conidial suspension (1.5x10^ cfu/mI) was 
added to eppendorf tubes containing SDB (final volume 1 ml) with a range of 
concentration of test agent (5-320 |ag/ml). Control sample contained no test agent. Mixed 
samples were incubated at 30 °C for 30 min. Viable count was enumerated by plating 100 
1^1 onto SDA plates and incubating at 28±2 °C for 24 h. For germinated conidia 
susceptibility assay, freshly obtained conidial suspension was first allowed to incubate at 
30 °C for 8 h (A.fumigatus MTCC2550) and for 10 h (T. rubrum 10A9) at 120 rpm and 
then treated as for ungerminated conidia susceptibility assay. 
3.2.12. Determination of effect of essential oils on morphology and ultrastructure of 
fungal cell 
3.2.12.1. Scanning electron microscopy 
For scanning electron microscopy of yeasts, 100 \\\ of cell suspension (0.5 McFarland) 
was inoculated into 10 ml SDB treated with sub-MICs of cinnamaldehyde or eugenol and 
incubated at 37 °C for 48 h at 120 rpm and harvested to obtain cell pellets. Whereas, in 
case of filamentous fungi, 500 ^1 of spore suspension (1.0x10^ cfu/ml) of test fungi was 
inoculated into 50 ml SDB in 250 ml Erlenmeyer flask containing sub inhibitory 
concentration of cinnamaldehyde or eugenol. Flasks were incubated at 28±2 °C at 120 
rpm for 48 h at 120 rpm and mycelial biomass was harvested. Untreated sample served as 
control. Furthermore, harvested cell pellets or mycelial biomass placed in to vials 
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containing 3% glutaraldeiiyde in 0.05 M phosphate buffer (pH 6.8) at 4 °C and fixed for 
48 h and then dehydrated in an ethanol series (30 %, 50 %, 70 %, and 95 %) for 20 min in 
each alcohol dilution and finally with absolute alcohol for 45 min. The samples were then 
dried at critical point in liquid Carbon dioxide and mounted on standard V2 inch 
Cambridge SEM stubs and coated with gold-palladium electroplating (60s, 1.8 mA, 2.4 
kV) in a Polaron SEM coating system sputter coater. The samples were examined in a 
LE0435VP SEJVl at 15 kV to assess the changes in cell or hyphal morphology. 
3.2.12.2. Transmission electron microscopy 
Structural changes produced by test oils towards fungal cell were evaluated using 
transmission electron microscopy at sub inhibitory concentration. For Candida cells, 10 
ml of SDB treated with sub-MICs of cinnamaldehyde or eugenol was inoculated with 100 
i^l of yeast suspension (0.5 McFarland) and incubated at 37 °C for 48 h at 120 rpm. For 
filamentous fungi, 50 ml of SDB treated with sub-MICs of cinnamaldehyde or eugenol in 
250 ml Erlenmeyer flask was inoculated with 500 f^ l of spore suspension (1.0x10^ 
cfu/ml) and incubated at 28±2 °C for 48 h at 120 rpm. Control sample did not receive 
treatment. The obtained cell pellets or mycelial biomass was fixed with 2.5% 
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) for 24 h at room temperature. Post 
fixation was carried out in 1% osmium tetroxide in cacodylate buffer. Samples were 
dehydrated in acetone and embedded in epon. Ultra thin sections were stained with 12.5 
% alcoholic uranyl acetate and viewed under Morgagni 268D transmission electron 
microscope at 80 kv. Ultrastructure of treated and untreated cultures was compared to 
assess the effect of oils. 
3.2.13. Determination of effect of essential oils on fungal cell wall 
Sorbitol assay was performed as described by Frost et al. (1995) using the broth 
microdilution procedure for yeasts and with some modifications for filamentous fungi. 
Briefly, duplicate plates containing test samples were prepared; one containing two-fold 
dilutions of test oils and the other containing test agents plus 0.8 M sorbitol as an 
osmoprotectant. All the wells were inoculated with 100 i^l of yeast suspension (0.5 
McFarland) or and plates were incubated at 37 °C. The final assay volume was 200 \i\. 
The plates were read at 2 and 7 days. For filamentous fungi, broth macrodiiution 
procedure was adapted. Briefly, duplicate flasks containing 20 ml SDB were prepared; 
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one containing two-fold dilutions of test oils and the other containing test agents plus 0.8 
M sorbitol. All the flasks were inoculated with 200 |ul of spore suspension (1.5x10^ 
cfu/ml). MIC was determined as the lowest concentration of test agents inhibiting the 
visible growth and evaluated after 5 and 10 days of incubation. Each experiment was 
repeated three times in triplicates and mean values were calculated for MlCs. 
3.2.14. Determination of effect of essential oils on fungal cell membrane 
permeability and integrity 
3.2.14.1. Release of cellular material 
Analysis of loss of cellular material absorbing at 260 nm from the Candida cell was 
performed using the method of Bennis et al. (2004) with little modifications for yeasts 
and method of Wang et al. (2010) with some modifications was used for filamentous 
fungi. Briefly, Candida cells were grown in SDB at 37 °C for 48 h and ceil suspension of 
(2.5X10' cfu/ml) was prepared in 10 ml PBS. Whereas for A.fumigatus MTCC2550, 5 ml 
of spore suspension (l.Oxlo' cfu/ml) was inoculated into 50 ml of SDB and incubated at 
25 °C at 140 rpm for 3 days. Mycelia were harvested at 10,000 rpm for 10 min and 
washed three times with sterile PBS and suspended in 20 ml of PBS. Furthermore, this 
suspension was treated with different concentrations of test agents (amphotericin B was 
used as positive control) for 1 h or at fixed concentration (4X MIC) for different time 
intervals up to 2h. The untreated sample was considered as control. After treatment 
samples were centrifuged at 10, 000 rpm for 10 min, and the supernatant was removed 
and the absorbance was read at 260 nm using uv-vis spectrophotometer (UV5704SS, 
India). --/ 
3.2.14.2. Etracellular leakage of potassium 
Estimation of extracellular K"^  leakage from the fungal cell was performed using the 
method of Watanabe et al. (2006) with little modifications for yeasts and method of 
Wang et al. (2010) with some modifications for filamentous fungi. Briefly, Candida cells 
were grown in 100 ml SDB at 30 °C at 120 rpm for 24 h, whereas, 5 ml of spore 
suspension (1.0x10* cfu/ml) of A. fumigatus MTCC2550 was inoculated into 50 ml of 
SDB and incubated at 25 °C at 140 rpm for 3 day. Cell pellets or mycelial biomass were 
harvested ait 5,000 rpm for 5 min and washed three times with sterile PBS and suspended 
in 10 ml of PBS. 500 |il of the cell suspension was used to determine dry cell weight. 2 
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ml of cell suspension was mixed with 2 ml of PBS containing desired concentration of 
test agents (amphotericin B was used as positive control) and incubated for 4 hr or at a 
fixed concentration (4X MIC) for different time intervals up to 4 h. After treatment 
samples were centrifuged at 10,000 rpm for 10 min, and the supernatant was removed 
and stored for the determination of extracellular K"^  content released into the medium. 
The K"^  concentration was estimated by Flame Photometer (Evans Electroselenium LTD, 
Halsted Essex, England) using potassium filter. 
3.2.14.3. Flow cytometry analysis for determination of membrane damage 
Lesion of cytoplasmic membrane of Candida cell was determined by Flow cytometry 
analysis using propidium iodide. The method of Pinto et al. (2006) was adapted with 
some modifications. Briefly, Candida cells (LOxlO^cfu/ml) were grown in SDB at 35 °C 
up to mid exponential phase (8 h). The cell suspension was then treated with IX MIC, 2X 
MIC and 4X MIC of test agents for 1 h at 35 °C. Untreated sample was run as negative 
control and sample treated with amphotericin B was considered as positive control. The 
suspensions were centrifuged at 5000 rpm, 5 min and washed three times and re-
suspended in PBS. The PBS suspension was stained with PI (1 lag/ml) at 35 °C in dark 
for 30 min. Unstained cells were always included as auto fluorescence controls. Dead cell 
associated fluorescence was measured using a FACS Calibur flow cytometer (Beckman 
Coulter, MOFIO, USA) using a blue argon laser at 488 nm. The results were analysed 
using Sumit 4.3V software. Flouresence in the FL2 channel (Log red fluorescence, Long 
pass 630-nm filter) for PI were acquired and recorded, using a logarithmic scale, for 
10,000 events per sample. Scattergram analysis was performed to evaluate morphological 
alterations (size and complexity). For data analysis, quadrants were adjusted in raw data 
density plots of the fluorescence intensity of control samples in order to include a 
maximum of 5% of the cells in the upper-right quadrant of plots and then used in the 
analysis of the remaining samples to quantify the percentage of stained cells in the upper-
left quadrant in comparison to agent free controls. 
3.2.15. Ergosterol quantitation assay 
To determine the mode of action of test oils as inhibitor of ergosterol biosynthesis in 
Candida cells, the total intracellular ergosterol amount was quantified in the absence and 
presence of test oils using the method of Arthington-Skaggs et al. (1999) with slight 
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modifications. Briefly, 200 \i\ of Candida cells (0.5 McFarland) were inoculated into 20 
ml of SDB with and without IX MIC, 0.5X MIC and 0.25X MIC of test agents and 
incubated at 35 °C for 48 h at 120 rpm. Fluconazole was used as a control. Cells were 
harvested by centrifugation at 5000 rpm, 5 min and washed once with distill water, dried 
at room temperature and weight of cell pellet was determined. Further, 3 ml of 25% ale. 
KOH was added to each pellet and vortexed for I min. Suspension was transferred to 
borosilicate glass tubes and incubated at 90 °C for 1 h in water bath and allowed to cool 
at room temperature. Sterol was extracted by addition of 1 ml of distill water and 3 ml of 
n-Heptane. Mixture was vortexed vigorously for 3 min and allowed to stand for 30 min. 
The heptane layer was transferred to clear glass tubes and stored at -20 °C for 24 h. Prior 
to analysis 1 ml of sterol aliquot was diluted 5 fold in 100% ethanol and scanned between 
230 to 300 nm using uv-visible spectrophotometer (UV5704SS, India). The presence of 
ergosterol and the late sterol intermediate 24(2*) DHE in the extraxcted sample resulted 
in a characteristic four peaked curve. The absence of detectable ergosterol content in 
extract was indicated by a flat line. The ergosterol content was calculated as a percentage 
of the wet weight of the cell by the following equations: 
% ergosterol + % 24(28) DHE = [{A28i.5/290}xF]/pellet weight 
% 24(28) DHE = [{A230/518}xF]/pellet weight 
% ergosterol = [% ergosterol + %24(28) DHE] - %24(28) DHE 
Where, F is the factor for dilution in ethanol and 290 and 518 are the E values (in 
percentages per centimeter) determined for crystalline ergosterol and 24(28) DHE, 
respectively. 
3.2.16. Ergosterol binding assay 
To assess the target site of test oils as binding to membrane ergosterol in Candida cells, 
the MIC of test oils was determined in the absence and presence of external ergosterol in 
the growth medium using the method as described by Escaiante et al. (2008). Briefly, 
triplicate plates containing test samples were prepared; one containing two-fold dilutions 
of test oils and the others containing test agents plus ergosterol at a concentration of 100 
|ig/ml and 200 \ig/m\. All the wells were inoculated with 100 ^1 of yeast suspension (0.5 
McFarland) and plates were incubated at 37 °C. The final assay volume was 200 \i]. The 
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plates were read after 48 h and MIC was determined as the lowest concentration of test 
agents inhibiting the visible growth. 
3.2.17. Determination of m vitro interaction of essential oils with antifungal drugs 
A checkerboard microtiter test was performed to evaluate the interaction of essential oils 
or active compounds with fluconazole and amphotericin B against C. albicans 01, 02, 09, 
C albicans NRRLY12983 and A. fumigatus MTCC2550 and T. nibrum IOA-9. The 
method of Vitale et al. (2005) was adapted with some modifications. Briefly, series of 
two-fold dilutions of each oils and drugs was made in SDB and DMSO, respectively to 
obtain four limes the final concentration being achieved in the microtiter well. 
Furthermore, 50 \i\ of each dilution from oil was added to the 96 well microtiter plates in 
the vertical direction while 50 |al of each dilution of antifungal drugs was added in the 
horizontal direction, so that various combinations of essential oils or active compounds 
and fluconazole or amphotericin B could be achieved. Also, 100 |al of inoculum from 
yeast suspension (0.5 McFarland) or spore suspension (1.5x10'' cfu/ml) was added to 
each well and plates were incubated at 37 °C for 48 h (for yeasts) and at 30 °C for 48 h 
(for filamentous fungi). The nature of interaction was defined quantitatively by the means 
of fractional inhibitory concentrations (FlC) that was calculated as the MIC of the 
combination of essential oils or active compounds with fluconazole or amphotericin B 
divided by the MIC of essential oils or active compounds or fluconazole or amphotericin 
B alone. An FIC index (FICI) was obtained by adding both FlCs. The combination result 
was interpreted as follows: FICI < 0.5, synergistic; >0.5-4.0, no interaction; >4.0, 
antagonistic as described by Odds (2003). 
3.2.18. Determination of inhibition of virulence factors production in yeasts by 
essential oils and antifungal drugs 
3.2,18.1. Determination of viability oi Candida strains at sub-MICs of essential oils 
and antifungal drugs 
The test strains (1 .Ox 10^  cfu/ml) were inoculated into 10 ml of SDB containing sub-MICs 
(0.5 X and 0.25 X MIC) of oils, compounds or drugs for 24 h at 37 °C. A control was run 
without test agents but containing yeast inoculum. The grown cells were 10-fold serially 
diluted in sterile normal saline and O.I ml was spread onto SDA plates to determine the 
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number of viable cells. Each experiment was done three times in triplicates and data are 
presented as mean log cfu ± SD. 
3.2.18.2. Inhibition of Germ tube formation in C. albicans 
Candida cells were allowed to grow in SDB in the presence of 0.5X and 0.25X MIC of 
oils or drugs at 37 °C for 24 h. Agent free SDB was used as untreated control and further 
germ tube formation was determined by the method of Taschdjian et al. (1960) with little 
modifications as mentioned earlier. 
3.2.18.3. Changes in the cell surface hydrophobicity of Candida spp 
Candida cells were grown on SDA plates amended with 0.5X and 0.25X MIC of test 
agents at 25 °C for 48 h. Candida cells grown on SDA plates without amendment of test 
agents were considered as untreated control. Further, the method of microbial adhesion to 
hydrocarbons (MATH) as described by Rosenberg et al. (1980) with some modifications 
as mentioned earlier was used to determine inhibition of CSH of Candida cells. Percent 
reduction in CSH of treated strains was calculated over untreated control. Each 
experiment was conducted three times with three replicates per experiment and the mean 
values were considered for calculation of percent CSH. 
3.2.18.4. Inhibition of proteinase production 
50 ml Erlenmeyer flasks containinglO ml of induction medium as described by 
MacDonald and Odds (1980) with and without sub-MlCs (0.5X and 0.25X MIC) of test 
agents were inoculated with 100 |xl of Candida cells (l.Ox 10^  cfu/ml) and incubated at 26 
°C for 7 days at 160 rpm. The inhibition of proteinase production by oils and drugs were 
determined using the modified method of Kuriyama et al. (2003) as mentioned earlier. 
The absorbance value of untreated control was subtracted from treated samples to obtain 
values for enzyme activity. Each experiment was conducted three times with three 
replicates per experiment and data are presented as percent reduction of absorbance 
values in treated sample over untreated control. 
3.2.18.5. Inhibition of haemolysin production 
Candida cells were grown in SDB [8% (w/v) glucose] containing 0.5 X and 0.25 X MIC 
of test agents for 4 days at 37 °C. The solution without test agents was considered as 
untreated control. Further, the inhibition of haemolysin production by oils and drugs were 
carried out using the method of Manns et al. (1994) with some modifications as 
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mentioned earlier. Eacii experiment was conducted three times with three replicates per 
experiment and mean absorbance values were used to calculate the percent reduction of 
haemolysin in treated samples over untreated controls. 
3.2.19. Determination of inhibition of virulence factors production in filamentous 
fungi by essential oils and antifungal drugs 
3.2.19.1. Inhibition of elastase production 
The method of Kothary et al. (1984) as mentioned earlier was adapted to detect the 
production of elastase among test isolates treated with sub-MlCs of test agents (0.5X 
MIC and 0.25X MIC) as described earlier. The untreated sample was considered as 
control. Further, elastase activity was determined by colorimetric assay of Sachar et al. 
(1955) with some modifications employing elastin Congo red (Sigma) as a substrate as 
mentioned earlier. All the experiments were done in triplicate and the mean test 
absorbance value was subtracted from the mean untreated control absorbance value to 
obtain the percent reduction in elastase activity. 
3.2.19.2. Inhibition of keratinase production 
Test fungi were cultivated in SDB containing sub-MICs of test agents (0.5X MIC and 
0.25X MIC) and following the methods of Muhsin and Aubaid (2000) as mentioned 
earlier. The untreated sample was considered as control. Further, keratinase activity was 
performed using modified method of Muhsin and Aubaid (2000) as mentioned earlier. 
All the experiments were done three times with three replicates per experiment 
and inhibition of keratinase activity was calculated in terms of percent reduction in mean 
absorbance value of test sample compared to untreated control. 
3.2.20. Determination of inhibition of virulence activity in filamentous fungi by 
essential oils 
3.2.20.1. Inhibition of elastase activity 
The method of Kothary et al. (1984) as mentioned earlier was adapted to detect the 
production of elastase among test isolates and inhibition of elastase activity by test agents 
(oils at 1:10 dilution) was evaluated using the modified method of Okumura etal. (2007). 
The known inhibitors of proteinases namely, phenyl methyl sulfonyl fluoride (PMSF), 1 
mM; ethylene diamine tetra acetic acid (EDTA), 5 mM; and metal ion Mg "^^  (MgS04), I 
mM; were also used in the study. In the assay, 200 pi of test sample was mixed with 50 
86 
[i\ of inhibitor solution and incubated at 37 °C for 45 min before adding to elastin congo 
red substrate mixture. Further, procedure was followed as performed for elastase activity 
by colorimetric assay of Sachar et al. (1955) as mentioned earlier. Test sample without 
exposure to inhibitor was run as control. All the experiments were done three times in 
triplicate and the mean absorbance value of treated sample was subtracted from the mean 
absorbance value of untreated control to obtain the percent reduction in elastase activity. 
3.2.20,2. Inhibition of keratinase activity 
The method of Muhsin and Aubaid (2000) as mentioned earlier was used to evaluate 
production of keratinase. Inhibitory effect of test agents was evaluated by the method of 
Okumura et al. (2007) with some modifications, and employing known inhibitors of 
proteinases as used in elastase inhibition assays. In the assay, 400 \i.\ of test sample was 
mixed with 100 f^ l of inhibitor solution and incubated at 37 °C for 45 min. The control 
was run without treating with inhibitors. Further, estimation of keratinase activity in 
treated and untreated sample was determined using the modified method of Muhsin and 
Aubaid (2000) as mentioned earlier. Each experiment was performed three times in 
triplicates and inhibition of keratinase activity was calculated in terms of percent 
reduction in mean absorbance value of treated sample compared to untreated control. 
3.2.21. Anti-biofilm activity of essential oils and antifungal drugs against C. albicans 
3.2.21.1. Determination of MIC of essential oils and antifungal drugs against 
planktonic Candida cells 
MIC of compounds and drugs was determined against the test isolates by CLSI reference 
method of broth microdilution M27-A3 with some modifications. Briefly, overnight 
grown culture was adjusted to 0.5 McFarland standards in RPMl 1640 medium with L-
glutamine but without bicarbonate and buffered to pH 7.0 with MOPS. 0.1 ml of two-fold 
serial dilutions of test agents (2X final concentration) were made in RPMI 1640 medium 
in the wells of microtiter plates. O.I ml of diluted inoculum medium was added to each 
well and incubated at 37 °C for 48 h. Agent free control was also included. MIC of 
amphotericn B and fluconazole was established as the lowest concentration that inhibited 
50% and 80% of the control growth, respectively. MIC of oils/compounds was defined as 
the lowest concentration that inhibited visible growth. 
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3.2.21.2. Determination of effect of essential oils and antifungal drugs on sessile 
Candida cells 
For susceptibility of sessile cells to oils/compounds and drugs the method of Ramage et 
al. (2001) was used with some modifications. Biofilms were allowed to form in 
microtiter plates as described earlier. Further, 0.1 ml of two-fold serial dilutions of test 
agents made in RPMI 1640 medium was added to each biofilm wells of microtiter plates 
and incubated at 37 °C for next 48 h. A series of antifungal agent-free wells and biofilms-
free wells were also included to serve as positive and negative controls, respectively. 
Sessile MIC (SMIC) was determined by XTT reduction assay. Each experiment was 
repeated three times in triplicates and antifungal effect was measured by comparing the 
reduction in the mean absorbance of the antifungal-challenged biofilm to that of the 
unchallenged control and expressed as the MIC of agent at which 80% of the sessile cells 
were inhibited. 
3.2.21.3. Determination of kinetics of inhibition of sessile cells by essential oils and 
antifungal drugs 
Efficacy of oils/compounds and drugs was evaluated against sessile Candida cells by the 
time-dependent killing assay. Biofilms of test Candida strains were allowed to form in 
microtiter plate as described above and challenged with 2X SMIC of test agents. Over a 
series of time intervals of 0, 2, 4, 8, 12, 24 and 48 h inhibition of biofilms was measured 
with the XTT reduction assay and total viable cell counts. For the plate count assay, 
following antifungal challenge and subsequent washing, the sessile cells were removed 
from bottom of well by scraping with sterile scalpel. Further, sessile cells were added to 
sterile PBS and vortexed vigorously to disperse the cells. Cell counts were enumerated by 
ten-fold serially diluting this suspension in PBS and spreading 0.1 ml from each dilution 
on to SDA plates and incubating at 37 °C for 24 h. Each experiment was performed three 
times and mean log cfu count for each experiment was converted to values relative to the 
mean log cfu count at 0 h to normalize the data and correct the variation in starting 
inocula concentrations. Data were presented by plotting the relative log cfu against time. 
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3.2.21.4. Determination of effect of essential oils and antifungal drugs on biofilm 
formation in C. albicans 
The effect of different sub-MICs of compounds and drugs (0.5 X MIC and 0.25 X MIC) 
on the ability of Candida ceils to form biofiim was determined by the modified method 
of Ramage et al. (2001) with some modifications. 0.1 ml of test agents (2 X final 
concentrations) in RPMl 1640 medium was added to each well of microtiter plates. 
Subsequently, 0.1 ml of standardized yeast cell suspension was added and plates were 
incubated at 37 °C for 48 h. Antifungal agent-free wells served as positive controls for 
biofilm growth. After incubation, the medium and non-adherent cells were removed from 
wells and washed three times with sterile PBS. Further biofilm formation was analysed 
by XTT reduction assay. Each assay was performed three times in triplicates and mean 
absorbance values were used to measure the inhibition of biofilm formation as follows: 
(mean OD492 of treated well / mean OD492 of untreated control well)x 100. 
3.2.21.4.1. Light microscopy of biofilm formed in the presence of essential oils 
Polyvinyl chloride catheter discs (15 mm diameter) were placed in 6 well tissue culture 
plates. Wells of the plates were dispensed with 1 ml of RPMl medium containing 2X of 
sub-MICs of test agents. Further, 1 ml of standardized yeast cell suspension was added to 
each well and incubated at 37 °C for 48 h. Well without test agents served as positive 
control. After the formation of biofilm, medium was discarded and discs were washed 
three times with sterile PBS and air dried. The discs were visualized under bright field 
light microscope (Olympus, Japan) at 40 X. 
3.2.21.4.2. Scanning electron microscopy of biofilm formed in the presence of 
essential oils 
For examination by SEM, Candida biofilm cells were grown on discs in the presence of 
sub-MICs of test agents for 48 h at 37 °C as described in the preceding section. Biofilms 
grown in the absence of test agents served as control. After washing with PBS, discs 
containing biofilms were placed in a fixative solution of 5% glutaraldehyde in cacodylate 
buffer in a graded series of ethanol, immersed in hexamethyldisilazane, and finally air 
dried overnight at room temperature. The samples were than mounted on aluminum stubs 
with silver paint, sputter coated with gold, and examined under a LE0435VP SEM at 15 
kV. 
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3.2.21.5. Determination of combination effect of active compounds and antifungal 
drugs on established biofilms 
A checkerboard microtiter test was performed to evaluate the interaction of essential oils 
with antifungal drugs against inhibition of preformed Candida biofilms. Briefly, bioflims 
of test strains were allowed to form in the wells of microtiter plates as described above. A 
series of two-fold dilutions of compounds and drugs were made in RPMl 1640 medium, 
to obtain two times the final concentration being achieved in the microtiter well. 
Furthermore, 0.05 ml of each dilution from oils/compounds was added to the wells in the 
vertical direction while 0.05 ml of each dilution of antifungal drugs was added in the 
horizontal direction, so that various combinations of compounds and drugs could be 
achieved. Plates were incubated at 37 °C for 48 h. The SMICs in the combination of oils 
and drugs were evaluated by XTT reduction assay as described above. The nature of 
interaction was defined quantitatively by the means of fractional inhibitory 
concentrations (FIC) that was calculated as the SMIC of the combination of compounds 
and drugs divided by the SMIC of compounds or drugs alone. An FIC index (FICI) was 
obtained by adding both FICs. The combination result was interpreted as follows: FICI 
<0.5, synergistic; >0.5-4.0, no interaction; >4.0, antagonistic as described by Odds 
(2003). 
3.2.22. Statistical analysis 
All the experiments were performed three times and data were expressed as mean ± 
standard deviation (n=3x3). Statistical analysis was performed using Minitab (V.11.0 for 
Windows, Minitab, Inc., USA). Reduction in %CSH in the presence of oils or drugs was 
compared to untreated control by one way ANOVA using Duncan's method. The log 
cfu/ml of treated samples (0.5 X and 0.25 X MIC) was compared to untreated control. 
Similarly, reduction in the ungerminated and germinated conidia count in fungi treated 
with test agents was compared to untreated control. P-values of <0.05 were considered as 
statistically significant. 
90 
4. 1. Isolation, characterization and identification of fungi 
In the present study, a total of 29 strains of yeasts including clinical and reference strains 
and belonging to Candida albicans (21), non-albicans Candida (6), Cryptococcus 
neoformans (02), and eight strains of filamentous fungi viz. Aspergillus spp (03), 
Trichophyton rubrum (02), Alternaria solani (01), Fusarium oxysporum (01), Mucor 
rouxii (01) were isolated/obtained from various sources. All the clinical and reference 
strains of yeasts were subjected to morphological, cultural and biochemical 
characterizaition to check their identity. The characteristics of yeasts are presented in the 
tables l.a,b and 2.a,b and figures 1,2,3. Similarly, filamentous fungi were identified and 
confirmed on the basis of their cultural, morphological and microscopic examination of 
vegetative and reproductive structures as given in table 3, figures 4,5). Further, molecular 
characterization of C albicans 04 was performed using 18S rRNA gene sequencing. 
These sequences were compared with similar sequences of the reference organisms using 
Basic Local Alignment Search Tool (BLAST; a genome database of the National Center 
for Biotechnology Information). Our sequences showed 99.9% conformity with the I8S 
rRNA gene sequences of C. albicans isolate Kw946 (GenBank accession number 
FN652297.1) (figure 6). 
4.2. Virulence factors in test fungi 
As presented in table 4 and figure 7, out of 21 strains of C. albicans tested for 
extracellular production of phospholipase, proteinase and haemolysin on solid medium, a 
maximum number of strains (15) were positive for proteinase production followed by 
production of haemolysin (11) and phospholipase (7). However, higher activity index 
(0.35) was recorded for phospholipase production in both C albicans 03 and 04 strains. 
Among 6 strains of non-albicans Candida (NAC) production of phospholipase, 
proteinase and haemolysin was recorded in 3 different strains with the highest activity 
index (0.31) for phospholipase production in C. tropicalis 01 (figure 8). 
Cell surface hydrophobicity (CSH), germ tube formation (GTF), and production of 
proteinase and haemolysin in liquid medium maong the strains of C. albicans is depicted 
in table 5. As expected, all the test strains of C. albicans produced germ tubes in the 
range of 52.33% to 89.33%. However, 76%) of test strains were positive for CSH (in the 
range of 24.76% to 66.21% CSH). Production of proteinase was recorded in 15% of the 
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test strains of C. albicans. Seven strains form different clinical origin and three reference 
strains exhibited higher proteolytic activity with absorbance values (>1.0). Haemolysin 
production was recorded in 52% of the C. albicans strains. Interestingly, 4 strains of C. 
albicans (01, 03, 06 and 09) produced significant amount of both proteinase and CSH 
whereas strain C. albicans Q\ in addition also produced significant amount of haemolysin 
(41.52%). Among the NACs, three strains out of 6 were hydrophobic with % CSH 
ranging from 41.22 to 65.39. Strain C. glabrata 01 was maximum hydrophobic with % 
CSH of 65.39. Four test strains exhibited haemolysin production in the range of 15.96 to 
60.42%). Strain C tropicalis 01 produced maximum haemolysin. Moreover, three strains 
exhibited production of proteinase. Strain C. tropicalis 01 was highly proteolytic with 
absorbance values of 0.98. All the strains producing protease on solid medium could also 
produce in liquid medium except three strains C. albicans MTCC12983, C. glabrata 01 
and C. tropicalis 02. Similar variation could also observe in the production of haemolysin 
on solid and liquid medium (table 5). 
As evident from table 6, out of eight strains of filamentous fungi, A. niger I0A3 and T. 
rubrum I0A9 showed the extracellular production of lipase, phospholipase, gelatinase 
and proteinase enzymes on solid medium whereas, strains A. solani 1VITCC2101, F. 
oxysporum MTCC284, M. rouxii MTCC386 could not produce these enzymes. When the 
production of elastase and keratinase was evaluated in liquid medium, only A. niger 
I0A3 could produce elastase (OD495 of 0.085) and keratinase was produced by T. rubrum 
I0A9 and T. rubrum MTCC296. 
4.3. Biofllm forming ability of Candida spp 
Out of 18 clinical and 3 reference strains of C. albicans, 13 strains formed moderate to 
strong biofilms as determined by safaranin staining assay using polystyrene tubes. Three 
strains produced weak biofilms and two strains could not form biofilms (table 7 and 
figure 9). C. albicans NRRLY12983 and C albicans SC53I4 strains formed strong 
biofilms. Strain visually exhibiting strong biofilms showed absorbance values of >1.0 
when assessed by XTT reduction assay in 96 well microliter plates (figure 10). No strain 
of non-albicans Candida forms biofilm except C. tropicalis 01 which formed weak 
biofilm. In overall, 27 strains of Candida spp tested for the production of virulence 
factors, the order of expression of various virulence factors was maximum for biofilms 
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(74.07%) followed by CSH (70.37), proteinsae (66.66), haemolysin (51.85) and 
phospholipase (37.03) as presented in table 8. 
4.4. Susceptibility of fungal strains to antifungal drugs 
Table 9 shows the susceptibility behavior of strains of C. albicans, NACs and other 
yeasts to six antifungal drugs as determined by disc diffusion method. Zone of inhibition 
of fluconazole, itraconazole and clotrimazole varied from nil to <16 mm against test 
strains of C. albicans. Whereas, nystatin, amphotericin B and ketoconazole could show 
zone of inhibition ranging from >16 mm to 32 mm against two, seven and nine strains, 
respectively. A varying level of sensitivity behavior in terms of zone of growth inhibition 
of test NACs and Cryptococcus strains against six antifungal drugs was recorded. No or 
marginal zone of inhibition was recorded for itraconazole against test strains except C. 
albicans NRRLY12983 (12.33 mm) and C. albicans SC5314 (29.33 mm). Based on the 
antifungal sensitivity behavior maximum number of yeasts strains were resistant to azoles 
in the order of fluconazole ^ itraconazole >ketoconazole >clotrimazole. 
Further MIC and MFC of amphotericin B, ketoconazole, itraconazole and fluconazole 
was determined against these strains using the broth macrodilution method to assess the 
level of resistance. The strains were considered resistant at the MIC value > 1.0 ^g/ml for 
itraconazole, and > 64.0 ng/ml for fluconazole as established by CLSI breakpoints. Due 
to the lack of consensus on MIC breakpoints for amphotericin B and ketoconazole, the 
MICs for these drugs were established following the criteria suggested by other workers. 
The limit of resistance was considered as > 2.0 ng/ml for amphotericin B (Yang et al. 
2005) and > I.O fig/ml for ketoconazole (Milan et al. 1998). As presented in table 10 and 
11, all test strains of C albicans were resistant to fluconazole (MIC in the range of 128-
256 |ig/ml), itraconazole (4-128 ng/ml) and ketoconazole (2-256 ng/ml). Thirteen strains 
were resistant to amphotericin B with the MIC ranging from 32-128 i^g/ml, whereas 
susceptible strains exhibited an MIC range of 0.25-1.0 |ig/ml. Moreover, MIC50 of 
ketoconazole, amphotericin B, itraconazole and fluconazole was found to be 32, 64, 128 
and 256 |ig/ml, respectively, against test strains. These data further indicated the higher 
level of resistance in the test strains of C. albicans against azoles and surprisingly, co-
resistance to amphotericn B was also evident. The strains of NACs and other yeasts were 
considered resistant at the MIC value as described for C. albicans, however, breakpoints 
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for C. neoformam were determined as described by Perfect and Cox (1999). As presented 
in table 10, all the strains were resistant to itraconazole (MIC range of 16-128 |Jg/ml). 
Strains C. iropicalis 01, 02 and C. neoformans MTCC4424 were susceptible dose 
dependent (8-32 )ig/ml) and others were resistant (128-512 ]xglm\) to fluconazole. 
Moreover, strains of C. tropicalis 01, 02 and C. neoformans 01 were susceptible (0.25-
0.5 ng/ml) and others were resistant (16-128 |ig/ml) to ketoconazole. In general, 51.72% 
isolates of yeasts tested were multi-drug resistant to amphotericin B, ketoconazole, 
itraconazole and, fluconazole (table 12). 
Susceptibility of filamentous fungi to antifungal drugs is presented in table 13. All the 
test strains were resistant to fluconazole as well as itraconazole showing zone of 
inhibition <9.0 mm. Nystattin was most effective followed by ketoconazole and 
clotrimazole. The MIC and MFC data of antifungal drugs amphotericin B, ketoconazole, 
itraconazole and fluconazole against test fungi is presented in table 14. The level of 
resistance was higher against flucoanzole compared to itraconazole with MIC and MFC 
values in the range of 100-200 ftg/ml and 200-400 i^g/ml, respectively. A. niger IOA-3 
showed the highest level of resistance to fluconazole, with MIC and MFC at 800 and 
1600 [ig/ml, respectively. All the test fungi were resistant to both three or four different 
antifungal drugs and displayed multi-drug resistant behavior (table 15). 
4.5. Physico-chemical properties of essential oils 
Test oils displayed physico-chemical properties such as colour, refractive indices, 
specific gravity, optical rotation and solubility in alcohol in the range of quality refernce 
for respective oils. The data obtained for some of the most active essential 
oils/compounds is given in annexure-1. The test oils of C. copticum, C. martini, S. 
aromaticum, cinnamaldehye, citral and eugenol appeared to be pale yellow in colour and 
others were reddish brown, yellow or colourless. Refractive indexes for test oils were in 
the range of 1.48 to 1.54 and specific gravity in the range of 0.88 to 1.05. S. aromaticum 
and C. copticum exhibited optical rotation of-0.153 and +05.25, respectively. All these 
test oils were soluble in 95% alcohol. 
Furthermore, the major active ingredients of oil of C. copticum were p-cymene (33.67%), 
thymol (22.82), y-terpine (21.61) and p-pinene (12.30) and a-pinene (4.59) as analyzed 
by GC and GC-MS (figure 11 and table 16). Major constituents of Oil of C. citratus was 
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mainly comprised of a-citral (43.95%) and P-citral (28.87%) as presented in (figure 12, 
table 17). Geraniol (43.84%)) and geranyl acetate (26.91) were the most prominent 
constituent of C. martini (figure 13, table 18). Cinnamaldehyde was the predominant 
component (79.10%) of C. verum (figure 14, table 19). Oil of S. aromaticum was 
predominately composed of eugenol (74.32%) and caryophyllenes (27.97%)) (figure 15, 
table 20). Oil of T. vulgaris was primarily comprised of thymo (44.71%)), y-terpinene 
(26.01) and a-cymene (21.22) (figure 16, table 21). Minimum assay for active 
compounds citral and geraniol were 81%) and 85 %, respectively (figures 17,18). 
4.6. Susceptibility of fungal strains to essential oils 
The screening result for antifungal activity of essential oils and active compounds against 
the drug-resistant strains of yeasts using a disc diffusion method is given in table 22 and 
figure 19.a,b. Out of the 23 tested essential oils and active compounds, cinnamaldehyde 
and oil of C. martini were highly active against all the test strains followed by others in 
the order of citral >eugenoI >C. verum >C. citratus >S. aromaticum =C. copticum 
=geraniol >T. vulgaris, exhibiting zone of inhibition >20 mm against majority of strains. 
Oils of Eucalyptus sp, M. piperita, C. sinensis, C. paradisi and C limon were least active 
against majority of the strains exhibiting zone of inhibition <16 mm. Oils of A. 
graveolens, F. vulgare, P. crispum, R. officinalis, S. album, Z.mays, M. fragrans and Z 
officinale were found inactive at tested concentrations. 
Further, a total often essential oils and active compounds exhibiting the highest activity 
against the test yeasts strains by disc diffusion method were assessed for their potency of 
inhibitory activity in terms of MIC using broth macrodilution method. As evident from 
table 23, test oils were highly active in the order of C. martini (MIC50 90 |Jg/ml) 
>cinnamaldehyde >citral =C. citratus -C. copticum >eugenol =S. aromaticum =C. verum 
>T. vulgaris =geraniol. 
As shown in table 24 and figure 19.c,d, essential oils, namely C. copticum, C. verum, S. 
aromaticum, C. martini, and T. vulgaris exhibited strong and broad spectrum activity 
against all the strains of filamentous fungi with a zone of inhibition ranging from 11.00 
mm to 38.66 mm. Cinnamaldehyde, citral, eugenol and geraniol showed broad- spectrum 
antifungal activity with a zone of inhibition ranging from 21.66 mm to 42.66 mm against 
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all eight test strains. Cinnamaldehyde exhibited the highest zone of inhibition (42.66 mm) 
against T. rubrum MTCC296. 
Further, antifungal activity of essential oils and active compounds were determined in 
terms of MIC and MFC presented in table 25. Oils of C, copticum, C. verum, S. 
aromaticum, C. martini and T. vulgaris exhibited strong inhibitory activity against the 
test strains (MIC range of 72-288 |ag/mland MFC range of 144-576 |ag/ml). Peppermint 
oil was strongly active aga'msl A. Ji4migatus MTCC2550 and moderately active against T. 
rubrum MTCC296 (MIC of 288 and 576 |ag/ml, respectively). Active compounds namely 
cinnamaldehyde, eugenol and geraniol, showed activity higher than essential oils with 
MICs ranging from 40 to 160 |ug/ml. Cinnamaldehyde was most active against/i. solani 
MTCC2101, T. rubrum IOA-9 and T. rubrum MTCC296 strains, with MICs and MFCs 
of 40 and 80 i^ g/ml, respectively. 
4.7. Time-kill assay for fungal strains 
The potency of killing the strains of C. albicans by most active essential oils viz. S. 
aromaticum, C. copticum, C. verum, C. citratus, C. martini, T. vulgaris and active 
compounds namely eugenol, cinnamaldehyde, citral, and geraniol was evaluated against 
4 strains namely C. albicans 01, C. albicans 09, C. tropicalis 01 and C. neoformans 01. 
Amphotericin B and fluconazole were used as positive controls. The time dependent 
killing of C. albicans 01 by the essential oils and active compounds revealed a decrease 
of >llogio in the viable count compared to the control at 8 h by citral, cinnamaldehyde 
and eugenol followed by C. verum oil (between 9-10 h), geraniol and C. martini (between 
19-20 h), and C. citratus, S. aromaticum (24 h). Amphotericin B showed a similar effect 
by 34 h and fluconazole could not even up to 48 h (figures 20.a,b). However, citral was 
most active against C. albicans 09 by reducing the viable count >llogio in a 6 h followed 
by cinnamaldehyde and eugenol (8 h) (figure 20.c). Oils of C. verum and S. aromaticum 
exhibited activity similar to as against C. albicans 01 (figure 20.d). Oils of C. martini and 
C. citratus produced the same effect in 18 h and geraniol in 22 h, whereas, treatment with 
amphotericin B resulted similar effect in 44 h and fluconazole could not up to 48 h 
(figures 20.c,d). 
The time dependent killing of C. tropicalis 01 by the test oils and compounds revealed a 
decrease of >llogio in the viable count compared to the control at 6 h by geraniol and 
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eugenol, whereas C. verum and cinnamaldehyde showed such effect in 7-8 h. Oils of C. 
citratus, citral and amphotericin B showed a similar effect by 20 h (figures 21.a,b). 
Eugenol and cinnamaldehyde were most fungicidal against C. neoformans 01 by reducing 
the viable count by >llogioin 6-8 h followed by geraniol and C. verum in 8-10 h. Other 
test oils exhibited similar effect in 18-20 h including amphotericin B (figures 21.c,d). 
The ability to kill fungal strains by most active essential oils and active compounds 
against A. fumigatus MTCC2550 and T. rubrum lOA-9 is given in figure 22. The time-
dependent killing of ^. fumigatus MTCC2550 by essential oils and active compounds 
revealed a difference of > 1 logio in viable counts compared to the control between 6 
and 8 h for cinnamaldehyde (figure 22.b). In contrast, treatment with the oils of C. verum, 
S. aromaticum, C. martini and T. vulgaris (figure 22.a) and eugenol, geraniol and citral 
(figure 22.b) showed a difference of > 1 logio in viable counts compared to the control 
between 8 and 10 h. Fluconazole as a positive control showed no difference of > 1 logio 
up to 10 h. A similar pattern of results was also observed against T. rubrum IOA-9 
(figures 22.c,d). 
4.8. Inhibition of fungal biomass and radial growth in filamentous fungi by essential 
oils 
Essential oils and active compounds exhibiting strong antifungal activity were tested for 
their ability to inhibit production of biomass and radial growth in test fungi. The oils 
tested exerted concentration dependent inhibitory effects on the production of fungal 
biomass (tables 26,27) and mycelial radial growth (tables 28,29) and were highly active 
even at lower concentrations (18 to 40 ng/ml). On the basis of ability to test fungi 
cinnamaldehyde was most inhibitory resulting in 95.30% reduction in the biomass and 
98.11% reduction in the radial growth in T. rubrum lOA-9 at 40 ng/ml. Similarly, 
76.27% reduction in biomass ahd 80.74% in radial growth was recorded against A. 
fumigatus MTCC2550 at 80 ng/ml of cinnamaldehyde. The other test oils exerted 
antifungal activity in the order of eugenol >geraniol =C. verum >citral >iS'. aromaticum> 
C. citratus> C. martini, against both the test fungi Reference drug fluconazole also 
exhibited concentration dependent inhibition in biomass and radial growth of test fungi 
up to 84.89% and 87.08%, respectively at 200 pg/ml (tables 27,29). 
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4.9. Toxic effect of essential oils on fungal hyphae 
The concentration and time dependent toxic effects of oils C. verum and S. aromaticum 
were evaluated against the test fungi and morphological changes if any was observed 
under light microscopy. As shown in figure 23, the treatment with 20 )ig/ml C. verum 
resulted in the formation of chlamydoconidia and also, autolysis of the hyphal cytoplasm 
in 20 h in T. rubrum lOA-9. Formation of chlamydospores is considered as an indicator 
of stress conditions produced in the presence of oils. Several morphological alterations 
such as hyphal shrinkage, autolysis of cytoplasm and necrosis seems to occur in 24 h with 
the treatment of 80 ng/ml S. aromaticum. 
4.10. Effect of essential oils against ungerminated and germinated conidia growth 
It was observed that oils of C. verum, S.aromaticum, cinnamaldehyde and eugenol 
inhibited significantly (P<0.05) both ungerminated and germinated conidia of A. 
fumigatus MTCC2550 and T. rubrum IOA-9 at a concentration range from 5 to 80 |iig/ml 
as depicted in figures 24,25,26,27. Oil of C. verum and its major active constituent 
cinnamaldehyde exhibited edge over S. aromaticum and eugenol in activity against both 
ungerminated and germinated conidia of these fungi at sub-inhibitory concentrations. 
4.11. Effect of essential oils on cellular and hyphal morphology using scanning 
electron microscopy 
To explore the possible mechanism of interacfion of essential oils/compounds with fungal 
cell wall, membrane and cellular content, the strains of C. albicans 04 and A. fumigatus 
MTCC2550 were subjected to scanning electron microscopic studies after treatment with 
sub-inhibitory concentration of cinnamaldehyde and eugenol. The electron micrographs 
for C. albicans 04 obtained from scanning microscopy observations showed important 
morphological damage (figure 28). Untreated cells appeared to be oval in shape and with 
smooth cell surface and polar bud scar (figures 28.a,b). Cells treated with 
cinnamaldehyde at 50 i^g/ml revealed deformed and interconnected cells with shrinkage 
of cell surface, non polar bud scars and lysis of cytoplasmic material (figures 28.c-e). 
Similar observation was also recorded with treatment of eugenol at 200 ng/ml (figures 
28.f-i). 
For, A. fumigatus MTCC2550, as clearly evident from SEM observations, the healthy and 
continuous hyphae are produced in untreated control sample (figures 29.a), whereas 
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treated sample (cinnamaldehyde 40 |ig/ml or eugenol 160 ng/ml) exhibited unusual 
pattern of hyphal growth as well as alterations in cell shapes and sizes such as blistering 
and necrosis of hyphae (figures 29.b-h). Severely collapsed and squashed hyphae were 
evident due to the lack of cytoplasm. 
4.12. Effect of essential oils on ultrastructure of fungal cell using transmission 
electron microscopy 
The effect of sub-inhibitory concentrations of most active compounds (i.e. 
cinnamaldehyde and eugenol) on cell constituents of C albicans 04, A. fumigatiis 
MTCC2550 and T. rubrum IOA-9 was observed by transmission electron microscopy. In 
untreated sample oi Candida cells, organelles such as nuclei, mitochondria and nucleus 
are appeared to be normal (figure 30.a). Treated sample exhibited several changes 
including thickening of cell wall, stretching of cell membrane, expansion of endoplasmic 
reticulum, leakage of cell wall and cell membrane, and abnormal distribution of 
polysaccharides leading to deterioration of cytoplasmic contents (figures 30.b-l). For 
filamentous fungi, in control specimens mycelial cells showed long strands of hyphae 
with smooth cell walls and cell membranes with other cytoplasmic organelles intact 
(figures 31.a, 32.a). In a hyphal specimen treated with cinnamaldehyde or eugenol, the 
ultrastructural changes were indicated as lysis of cell walls and plasma membranes, 
expansion of endoplasmic reticula near the cell membrane and excessive vacuolization 
along with disintegration of cell walls were observed. Other changes like disintegration 
of mitochondria, plasma membranes, and the disorganization of cytoplasmic content due 
to the abnormal distribution of polysaccharides were seen. Disintegration of nuclear as 
well as cytoplasmic contents and leakage of cytosolic content were also observed (figures 
31.b-j,32.b-j). 
4.13. Effect of essential oils on fungal cell wall integrity in the presence of sorbitol 
Cell wall damaging effects of an antimicrobial compound can be reversed in the presence 
of an osmo-protectant compound such as sorbitol. Subsequently MIC of antimicrobial is 
increased several folds in the test medium containing such compounds. Therefore, to 
determine the effect of these agents on fungal cell wall, MIC of C. verum, S. aromaticum, 
cinnamaldehyde, eugenol and fluconazole was evaluated against C. albicans 04 and A. 
fumigatus MTCC2550 in the presence and absence of sorbitol. 
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As presented in table 30, MIC of eugenol and cinnamaldehyde was increased up to two-
folds against C. albicans 04 and there was no increase in MIC of C. verum and S. 
aromaticum upto 7 days. Data presented in table 31 shows that there were two fold 
increase in MIC of C verum, S. aromaticum and eugenol whereas four-fold increase was 
observed for cinnamaldehyde ?^gdmsi A. fumigatus MTCC2550. 
4.14. Effect of essential oils on cell permeability 
Effect on cell permeability in terms of cell leakage can be assessed by measuring 
intracellular component release to the medium from washed cells in buffer. Cellular 
component which absorb light at 260 nm represent one class of leakage components, 
primarily nucleotides of which uracil containing compounds exhibit strongest absorbance. 
The amount of K"^  leaked out to the external environment is also an indicator of 
interference with membrane lipid fluidity or integrity. Therefore, to ascertain the effect of 
these oils onto the cell membrane, the 260 nm absorbing material and K"^  leakage was 
determined. Further, these membrane damaging effects were confirmed by flow 
cytometry. 
4.14.1. Release of cellular material 
Figure 33.a shows that the release of cellular content in C. albicans 04 in the presence of 
test oils is increased in terms of the fungal agent concentration. Eugenol was most 
effective by exhibiting ODaeo of 0.470 at 4X MIC followed by other oils and 
amphotericin B (as a positive control) exhibiting OD260 in the range of 0.403-0.429. The 
treatment with 4X MIC of test agents induced consistent leakage of intracellular content 
with the increase in time. All the test oils and amphotericn B showed significant release 
of 260 nm absorbing material (OD value in the range of 0.450-0.522 at 120 min) with 
eugenol being at edge (figure 33.b). The similar pattern was also observed for A. 
fumigatus MTCC2550 (figures 33.c,d). 
4.14.2. Membrane damage in terms of K* leakage 
At IX MIC, among the test agents, eugenol induced maximum leakage (13.64 n 
moles/mg dry weight of cell) in C. albicans 04 followed by amphotericin B >C. verum >S. 
aromaticum >cinnamaldehyde and further exhibited increase in K"^  leakage with 
increasing concentration (figure 34.a). As evident from figure 34.b, the time dependent 
increase in K+ leakage was also observed for test agents at 4X MIC with the maximum 
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leakage by eugenol (13.90). Similar pattern of concentration and time dependent increase 
in K+ leakage was also recorded for A. fumigatus MTCC2550 (figures 34.c,d)-
4.14.3. Membrane integrity assay by flow cytometry 
Propidium iodide is a nucleic acid biding fluorescent probe commonly employed to 
evaluate the effect of drugs on cell membranes. Cells with sever membrane lesion leading 
to inherent loss of viability will internalize PI, resulting in an increase in red fluorescence. 
The PI penetration in Candida cells treated with various concentrations of test 
compounds and positive control is shown in figures 35,36,37. Our results showed 
eugenol being most effective in damaging the cell membrane of Candida cells in 
treatment of 1 h. At 4X MIC, 50.98% cells were nonviable as indicated by red 
fluorescence in density plots and cell density recorded in histograms by making gate 
(figures 35.a-d, e-h). Eugenol and amphotericn B at this concentration resulted in uptake 
of PI by 40.21 and 30.42% cells, respectively (figures 36.a-d, e-h and 37.a-d, e-h). 
Substantial morphological changes were observed on scattergram of cells upon treatment 
with test agents as shown in figures 35.i-l, 36.i-l, 37.i-l. The production of membrane 
lesion by test agents was increasing with increase in concentration as presented in figure 
38 and the efficacy was at par with the membrane damaging effects shown by 
amphotericin B (figure 39). 
4.15, Ergosterol quantitation in the presence of essential oils 
Table 32 and figure 40 have summarized the effect of test oils and active compounds on 
ergosterol biosynthesis in C albicans 04 compared to positive control fluconazole. A 
decrease in ergosterol biosynthesis with the increasing concentration of test agents was 
observed. Eugenol and cinnamaldehyde were most effective in reducing ergosterol 
biosynthesis exhibiting 59.61% and 58.96%) reduction, respectively compared to 
untreated control at 0.25X MIC. At IX MIC maximum reduction of 97.07% was 
recorded for eugenol followed by cinnamaldehyde > S. aromaticum > C. verum 
>fluconazole. 
4.16. Ergosterol binding assay 
The ergosterol binding assay revealed a two- to four-folds increase in MIC of test agents 
against C. albicans 04 in the presence of 100 ng/ml and 200 ng/ml of ergosterol, 
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respectively (table 33). This effect was similar to as shown by positive control 
amphotericn B. 
4.17. Interaction of essential oils with antifungal drugs against C. albicans, A. 
fumigatus and T. rubrum 
The combinational effects of the oils of C. copticum, C. citratus C. martini, C. verum, S. 
aromaticum, T. vulgaris, and some of their major active compounds like eugenol, 
cinnamaldehyde, citral and geraniol with fluconazole or amphotericin B against C. 
albicans 01, C. albicans 02, C. albicans 09 and C. albicans NRRLY12983 strains are 
given in tables 34,35. Majority of the tested essential oils and active compounds showed 
varying level of interaction with fluconazole or amphotericin B against the test strains. T. 
vulgaris and eugenol showed synergy and C. copticum indifferece with both fluconazole 
and amphotericin B. Oil of S. aromaticum showed synergistic interaction with only 
amphotericin B against all the test strains except C. albicans 01. Citral, cinnamaldehyde 
and oils of C. verum and C citratus exhibited either synergy or no interaction responses 
in combination with amphotericin B. Geraniol displayed a varying level of synergistic 
interaction with both fluconazole and amphotericin B against test strains except C. 
albicans NRJRLY12983. Among all the tested combinations with fluconazole, eugenol (C. 
albicans 02, 09) and citral (C albicans 01) exhibited the highest synergy by reducing the 
MIC of fluconazole and their own by 16- to 32-fold. In combination with amphotericn B, 
cinnamaldehyde exhibited the highest synergy by reducing the MIC of amphotericin B by 
32-fold and its own by 16-fold whereas, eugenol showed reduction of 8- and 16-fold, 
respectively. No combination was found to be antagonistic against the test strains. 
Whereas, interactive effects of these oils in combination with fluconazole against A. 
fumigatus MTCC2550 and T. rubrum IOA-9 are given in table 36. All the tested essential 
oils and active compounds except C. copticum showed significant levels of synergistic 
interaction with fluconazole against T. rubrum IOA-9 (FICI values 0.312, 0.281, 0.257, 
0.250 and 0.156). The oils S. aromaticum, T. vulgaris, eugenol, citral and 
cinnamaldehyde exhibited synergistic interactions with fluconazole against A. fumigatus 
MTCC2550 but no interactions were observed for the oils of C. martini and geraniol with 
fluconazole. The maximum level of synergy was detected between cinnamaldehyde and 
fluconazole against both T. rubrum IOA-9 (0.156) and A. fumigatus MTCC2550 (0.187). 
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Cinnamaldehyde was most effective in combination, showing the strongest synergy with 
fluconazole and reducing the MIC of fluconazole up to 8-fold against both A. fumigatus 
MTCC2550 and T. rubrum IOA-9 and a reduction in its own MIC up to 16- and 32-fold, 
respectively. The highest reduction in MIC (i.e. 128-fold) was recorded for oil of 5. 
aromaticum in combination with fluconazole against T. rubrum IOA-9. No combination 
was found to be antagonistic against the test fungi. 
4.18. Anti-virulence activity of essential oils and antifungal drugs against test fungi 
Six essential oils namely C. copticum, C. citratus C. martini, C. verum, S. aromaticum, T. 
vulgaris and four active compounds viz. eugenol, cinnamaldehyde, citral and geraniol; 
exhibiting promising antifungal activity were assessed for their anti-virulence activity at 
sub-MICs. Antifungal drugs amphotericin B and fluconazole were used as control. Six 
strains of C. albicans (04, 05, 07, 16, MTCC183, SC5314) and one strain C. tropicalis 01 
were selected, being producers of significant amount of virulence factors, for inhibition 
assays. As given in annexure-9, there was no significance {P<0.05) decrease observed in 
log cfu in the test strains of C. albicans samples treated with 0.25X and 0.5X MICs of 
test agents compared to untreated control. 
4,18.1, Effect on GTF, CSH, proteinase and haemolysin production in Candida spp 
Oils C. copticum, C. verum, S. aromaticum, T. vulgaris, eugenol and cinnamaldehyde 
were highly effective at both 0.25X and 0.5X MICs by inhibiting >50% of GTF in strain 
C. albicans 04. The order of GTF in the presence of 0.5X MIC of these oils was C. 
copticum (6.86%) <T. vulgaris =eugenol <cinnamaldehyde < S. aromaticum <C. verum 
(15.60%). Oils of C. citratus and C. martini showed similar reduction only at 0.5X MIC 
(figure 41). Other test oils and fluconazole were least effective at tested sub-MICs in 
hinhibiting GTF. Similar effect of test oils was also recorded against strain C. albicans 
SC5314. 
As evident from table 37, treatment of test strains to sub-MICs of oils influenced the CSH 
in varying capacity. C. copticum at both 0.25X and 0.5X MICs was significantly 
(P<0.05) effective in reducing the CSH in all the test strains with a maximum in C. 
tropicalis 01 (reduction in %CSH from 60.97 to 6.69%) followed by cinnamaldehyde, 
citral and eugenol. Oils T. vulgaris, S. aromaticum, C. verum and C. citratus at tested 
sub-MICs significantly reduced the % CSH in test strains. Geraniol at both the sub-MICs 
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produced significant effect in strain C. albicans 07 (up to 12.90% CSH) and C. albicans 
MTCC183 (up to 19.90% CSH). Oil C. martini was significantly effective only at 0.5X 
MIC in reducing the CSH in test strains except C. albicans 04 and C. tropicalis 01. A 
similar trend of CSH inhibition was recorded with fluconazole and amphotericin B at 
0.5X MIC against test strains. 
Each of test oils at 0.5X MIC reduced the production of proteinase by > 70%) in one or 
other test strains (figures 42, 43, 44). Percent reduction in the proteinase production by C. 
albicans 04 at 0.5X MIC of oils was recorded in the order of T. vulgaris >S. aromaticum 
>C. verum =C. copticum >C. citratus >geraniol >eugenol >citral >C. martini 
>cinnamaldehyde. Similar effect was also observed in C. tropicalis 01 by these oils at 
0.25 X MIC. However, cinnmaldehyde and geraniol were less effective at this 
concentration. Whereas, a maximum reduction of 46.94% was recorded for fluconazole at 
0.5 X MIC against strain C. albicans 09. 
The oils C. coptocium, C. verum, T. vulgaris, cinnamaldehyde and eugenol at 0.5X MIC 
showed haemolysin reduction of >60%) in test strains. Other test oils excluding C. martini 
and citral, at 0.5X MIC produced reduction in the range of 30 - <60%). Similar inhibition 
was exhibited by oils of 5. aromaticum, C. verum, eugenol, cinnamaldehyde and geraniol 
at 0.25 X MIC. The oils C. martini, citral, amphotericin B and fluconazole were 
ineffective at tested sub-MICs (figures 45,46, 47). 
4.18.2. Effect on elastase and keratinase production/activity in filamentous fungi 
More than 50% reduction in elatase production by A. niger IOA-3 was recorded in oils of 
C copticum, C. verum, S. aromaticum, T. vulgaris, cinnamaldehyde and eugenol at 0.5X 
MIC (figure 48.a). A maximum reduction in elastase production (61.84%) and 90.53%) at 
0.25X MIC and 0.5X MIC, respectively) was shown by T. vulgaris. Oils of C. martini 
and geraniol showed >50%) reduction in the keratinase production in T. rubrum IOA-9 
(figure 48.b). Other test oils and fluconazole were less effective in reducing the 
production of proteinases. 
As shown in table 38, cinnamaldehyde showed highest reduction (95.56%)) over untreated 
control in elastase activity followed by C. martini, C. verum, and T. vulgaris. Highest 
inhibition (97.31%)) over untreated control in keratinase activity was recorded for 
geraniol followed by C. martini, and citral. Among the known inhibitors tested, MgS04 
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showed 94.10% and 39.77% inhibition in eiastase and keratinase activities, respectively. 
Similarly, EDTA and PMSF inhibited eiastase activity by 72.63%, 70.06%, and 
keratinase activity by 54.48% and 5.70%, respectively. 
4.19. Anti-biofilm activity of essential oils and antifungal drugs against C. albicans 
The oils which were used to assess their anti-pathogenic activity were also tested for their 
potential to eradicate established biofilms and inhibition of formation of biofilms in C. 
albicans strains. Antifungal drugs amphotericin B and fluconazole were used as reference 
drug. Strains C. albicans 04 and C. albicans SC5314 displayed strong ability to form 
biofim when tested using XTT reduction assay showing OD492 of 1.36±0.66 and 
1.09±0.01, respectively and therefore selected for biofilm inhibition assays. 
4.19.1. Effects of essential oils and antifungal drugs on planktonic and sessile cells 
As evident from table 39, sessile MIC (SlVllC) of amphotericin B and fluconazole were 
Increased to 512- and 1024-folds against above test strains. MIC of oils and compounds 
against planktonic cells was ranged from 90-400 and 45-360 |Jg/m! against C. albicans 
04 and C. albicans SC5314, respectively. SMIC of all the test oils and compounds except 
C. verum were in the range of 200-400 |ag/ml against C. albicans 04 and 100-360 )ag/ml 
against C. albicans SC5314. Eugenol, C. citratus and T. vulgaris showed similar MIC 
against both the planktonic and sessile cells of C albicans 04 and C. albicans SC5314, 
respectively. 
4.19.2. Killing of sessile cells by essential oils and antifungal drugs 
As depicted in figures 49.a,b,c,d more than 80% reduction in viable count of sessile cells 
of both the test strains was exhibited by C. copticum, T. vulgaris, eugenol and geraniol in 
10-12 h. Cinnamaldehyde and citral produced similar effects in 30 h and 48 h, 
respectively against both the strains. Amphotericin B and fluconazole did not show this 
effect up to 48 h. 
4.19.3. Inhibition of biofilm formation by essential oils and antifungal drugs 
As presented in table 40, varying level of attenuation in the biofilm formation by 
planktonic C. albicans cells was observed in the presence of tested (assayed) agents. 
Biofilm formation was inhibited maximally by T. vulgaris at 0.5X MIC followed by C 
citratus >eugenol >C. copticum >cinnamaldehyde in both of the test strains. Other test 
oils/compounds were least effective in inhibiting the biofilm formation. Fluconazole and 
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amphotericin B at 0.5 X MICs led to 48.16 and 67.59% formation of biofilm, respectively 
in C. albicans 04. Similar pattern of inhibition of biofilm formation was also recorded for 
test oils/compounds and drugs against C. albicans SC5314. 
4.19.4. Light microscopy of sessile cells formed in the presence of essential oils 
Concentration dependent inhibition of biofilm formation in C. albicans 04 at sub-MICs 
of eugenol, cinnamaldehyde, C citratus and T. vulgaris was studied using light 
microscopy. Control untreated biofilm of 48 h exhibited dense network of multilayered 
yeast cells and hyphae with extracellular materials (figure 50.a). Treatment with 0.125 X 
MIC of eugenol, seemingly resulted in loss of polysaccharide materials and also 
reduction in the formation of hyphae (figure 50.b). Whereas, scattered aggregation of 
yeast cells was observed at 0.25 X MIC, and loosening of yeast cells and a total 
disruption of biofilm occurred at 0.5 X MIC (figures 50.c,d). Similar effect was also 
observed with the treatment of sub-MICs of cinnamaldehyde, C. citratus and C. copticum 
(Figures 50.e-j). 
4.19.5. Scanning electron microscopy of sessile cells formed in the presence of 
essential oils 
Further, observations with light microscopy were confirmed by SEM analysis. Untreated 
cells resulted in intact biofilm formation with dense matrix and multilayered network of 
yeast cells and hyphae leading to a compact three dimensional structure (figure 51.a). The 
cells treated at 50 and 100 |ag/ml of cinnamaldehyde and eugenol, respectively, exhibited 
loosening of cells and disappearance of matrix. Filamentation was inhibited and amount 
of biofilm formed was also reduced leading to the destruction of three dimensional 
structure (figures 51.b,c). Untreated sessile cells showed smooth cell membrane (figure 
51a. inset) whereas treatment with oils exhibited shrinkage in cell membranes of sessile 
cells (figure 51b. inset I and inset2). Similar effects of C. citratus and T. vulgaris were 
also observed on sessile yeast cells (figure 51.c-e). 
4.19.6. Interactive effect of active compounds and antifungal drugs on established 
biofilms 
The combinational effects of the eugenol and cinnamaldehyde with fluconazole or 
amphotericin B against biofilms of C. albicans 04 and C. albicans SC5314 are given in 
table 41. The test compounds showed varying level of interaction with fluconazole or 
107 
amphotericin B against the biofilms of test strains. Eugene! and cinnamaldehyde were 
synergistic with fluconazole by exhibiting FICl value of 0.25 and 0.312 respectively, 
against the biofilms of C. albicans 04. Among all the tested combinations with 
fluconazole, eugenol exhibited the highest synergy with FlCl value of 0.140 against C. 
albicans SC.5314. Whereas, interaction of test compounds with amphotericin B was 
indifferent against both the strains. 
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Figure 1. Morphological characteristics of Candida spp on Hicrome Candida agar 
media. 
(a) C. albicans, green smooth colonies. 
(b) C tropicalis, blue to purple raised colonies. 
(c) C krusei, large, spreading pink colonies with matt surface. 
(d) C. albicans 01 (i), C albicans 02 (ii), C albicans 03 (iii), C albicans 
04 (iv), C. tropicalis 01 (v), C. albicans 05 (vi), C. ^M5e/ 01 (vii), C. 
glabrata 01 (viii). 
114 
8 i:v.. 0 
<? 
i i' 
o 
e 
B 
(b) 
(P 
(a) 
-O f\ 
^ * 
m.8^ 
0%^^^^ O^o ? &.0 ?^% °^^ c 
vu 
00 ^ 09 
''•V ^ O ; 
s:£L 
'Xm 
(c) (d) 
Figure 2. Microscopic (40 X magnification) characteristics of Candida albicans 04 cells 
grown on commeal agar media. 
(a) yeast cells (i) budding yeast cells (ii) blastospores (iii) germ tubes (iv) 
pseudohyphae (v). 
(b) hyphae (vi). 
(c) chlamydospores (vii). 
(d) typical yeast cells grown on SDA. 
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o 
t - o 
Figure 3. Formation of germ tubes in C. albicans 04 (incubation with serum) observed 
under light microscope (40 X magnification). Arrows indicate production of 
germ tube from yeast cells. 
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Figure 4. Colony morphology of filamentous fungi grown on SDA. 
(a) Aspergillus niger 10A3, black spores. 
(b) Trichophyton rubrum I0A9, pinkish velvety mycelial growth. 
(c) back view of the plate (b), Trichophyton rubrum I0A9, red pigmentation. 
o © " Ov.'tJ.^ u.O 
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Figure 5. Microscopic characteristics of filamentous fiingi grown on SDA, under light 
microscope (40X magnification). 
(a) A. niger I0A3; asexual spores in the larger spherical vesicle produced on 
the conidiophores, presence of chains of dark brown conidia. 
(b) T. rubrum I0A9; thin walled tear shaped macroconidia along the wall of 
hyphae. 
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GTAGGTGAACCTGCGGAAGGATCATTACTGATTTGCTTAATTGCACCACATG 
TGTTTTTCTTTGAAACAAACTTGCTTTGGCGGTGGGCCCAGCCTGCCGCCA 
GAGGTCTAAACTTACAACCAATTTTTTATCAACTTGTCACACCAGATTATTAC 
TAATAGTCAAAACTTTCAACAACGGATCTCTTGGTTCTCGCATCGATGAAGA 
ACGCAGCGAAATGCGATACGTAATATGAATTGCAGATATTCGTGAATCATCG 
AATCTTTGAACGCACATTGCGCCCTCTGGTATTCCGGAGGGCATGCCTGTTT 
GAGCGTCGTTTCTCCCTCAAACCGCTGGGTTTGGTGTTGAGCAATACGACT 
TGGGTTTGCTTGAAAGACGGTAGTGGTAAGGCGGGATCGCTTTGACAATGG 
CTTAGGTCTAACCAAAAACATTGTTTGCGGCGGTAACGTCCACCACGTATAT 
CTTCAAACTTTGACCTCAAATCAGGTAGGACTACCCGCTGAACTTAAGCATA 
TCAATAAGCGGAGGAAA 
Figure 6. 18S rRNA gene sequences of C. albicans 04. 
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Table 4. Detection of extracellular production of virulence factors in the strains 
of Candida spp on solid medium. 
Strains 
C albicans 
C. albicans 01 
C. albicans 02 
C albicans 03 
C. albicans 04 
C. albicans 05 
C. albicans 06 
C albicans 07 
C. albicans 08 
C. albicans 09 
C albicans 10 
C albicans 11 
C albicans 12 
C. albicans 13 
C. albicans 14 
C. albicans 15 
C albicans 16 
C. albicans 17 
C albicans 18 
Ca/Z>/caraNRRLY 12983 
C. fl/^/ca«5MTCC183 
C. albicans SC5314 
Non albicans-Cawrf/fl'a 
C. glabrataOl 
C. glabrata 02 
C.^/flira/aMTCC3019 
C. krusei 0] 
C. tropicalis 01 
C. tropicalis 02 
Activity index (pZ) of viru 
Phospholipase 
0.41±0.03 
0.51±0.04 
0.35±0.03 
0.35±0.04 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
0.52±0.04 
l.OiO.OO 
0.38±0.03 
l.OiO.OO 
0.38±0.02 
l.OiO.OO 
I.OiO.OO 
0.62±0.04 
l.OiO.OO 
0.31±0.03 
0.50±0.04 
Proteinase 
0.50±0.04 
0.78±0.04 
0.55±0.03 
0.80±0.05 
l.OiO.OO 
0.60±0.04 
0.71±0.06 
0.52±0.05 
0.77±0.04 
0.66±0.05 
0.75±0.04 
0.71±0.04 
0.78±0.05 
0.73±0.06 
1 .OiO.OO 
l.OiO.OO 
] .OiO.OO 
1 .OiO.OO 
0.50±0.04 
1 .OiO.OO 
0.58±0.05 
1 .OiO.OO 
I .OiO.OO 
1 .OiO.OO 
0.55±0.04 
0.56±0.04 
0.65±0.05 
lence factors 
Haemolysin 
0.63±0.05 
0.60±0.05 
l.OiO.OO 
1 .OiO.OO 
0.68±0.05 
1 .OiO.OO 
1 .OiO.OO 
l.OiO.OO 
0.83±0.05 
l.OiO.OO 
0.63±0.04 
1 .OiO.OO 
1 .OiO.OO 
1 .OiO.OO 
1 .OiO.OO 
0.65±0.05 
0.64±0.04 
0.68±0.05 
0.73± 0.06 
0.82± 0.06 
0.55± 0.06 
1 .OiO.OO 
l.OiO.OO 
1 .OiO.OO 
0.61±0.04 
0.63± 0.05 
0.66± 0.05 
pZ= (zone of diameter of colony)/ (zone of diameter of colony + zone of 
solubilization or precipitation around the colony) 
pZ=l; indicates no activity 
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(a) (b) (c) 
Figure 7. Detection of extracellular expression of virulence factors in the strains of C 
albicans. 
(a) proteinase production (C. albicans 04). 
(b) phospholipase production (C. albicans 04). 
(c) haemolysin production (C. albicans 02). 
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Figure 8. Distribution of extracellular production of virulence factors among Candida 
spp on solid medium in terms of activity index (pZ). 
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Table 5. Quantitative estimation of virulence factors in the strains of Candida spp in liquid 
medium. 
Strains 
C. albicans 
C. alb 'cans 01 
C. albicans 02 
C. alb 
C. alb 
C.alb 
C. albi 
C. alb 
C. alb 
C. alb I 
C. a lb I 
C. a lb I 
C. alb I 
C. albi 
C. albi 
C. albi 
cans 03 
cans 04 
cans 05 
cans 06 
cans 07 
cans 08 
cans 09 
cans 10 
cans 11 
cans 12 
cans 13 
cans 14 
cans 15 
C. albicans 16 
C. albi 
C. albi 
C. albi 
C. albi 
C. albi 
cans 17 
cans 18 
caraNRRLY 12983 
cans MTCCn3 
cans SC5314 
Non-albicans Candida 
C. glabrata 01 
C. glabrata 02 
C. kruseiQX 
C. tropicalis 01 
C. tropicalis 02 
C glabrataMTCC30\9 
% GTF 
78.33±2.49 
77.66±1.69 
85.66±2.49 
89.33±1.24 
80.33±3.09 
72.33±2.49 
70.66±3.29 
64.00±1.63 
74.66±1.24 
53.66±1.24 
59.33±3.85 
64.33±4.10 
69.33±2.05 
60.33±2.05 
52.33±2.49 
61.33±2.49 
55.33±2.86 
63.66±2.86 
74.66±2.49 
77.00±1.63 
81.43±6.09 
ND 
ND 
ND 
ND 
ND 
ND 
Viru 
% CSH 
41.34±3.75 
ND 
62.11±2.3] 
61.75±2.85 
59.78±4.31 
55.43±3.38 
66.21±2.97 
ND 
55.10±2.75 
ND 
ND 
ND 
25.78±2.98 
33.45±3.71 
44.59±4.97 
24.76±2.38 
40.90±3.36 
53.45±4.97 
25.78±3.17 
35.60±1.76 
63.28±5.18 
65.39±6.1 
ND 
41.22±3.38 
62.99±5.10 
ND 
ND 
ience factors 
Proteinase* 
(ODat280nm) 
1.23±0.I] 
0.45±0.02 
1.35±0.13 
0.42±0.04 
Nil 
0.95±0.04 
0.44±0.03 
1.18±0.14 
0.85±0.06 
1.37±0.22 
0.61±0.05 
1.00±0.09 
1.15±0.10 
I.18±0.I0 
Nil 
Nil 
Nil 
Nil 
1.21±0.10 
1.35±0.12 
1.06±0.09 
0.20±0.05 
Nil 
Nil 
0.98±0.07 
0.57±0.06 
Nil 
% 
Haemolysis 
41.52 
29.10 
ND 
ND 
74.68 
ND 
ND 
ND 
25.84 
ND 
37.33 
ND 
ND 
ND 
ND 
83.18 
81.25 
91.45 
24.32 
24.93 
74.45 
ND 
15.96 
28.95 
60.42 
34.27 
ND 
GTF; germ tube formation, CSH; cell surface hydrophobicity, ND; not detected 
* Proteinase activity was considered as Nil for OD280 < 0.1 
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Table 6. Production of extracellular enzymes as putative virulence factors in 
filamentous fungi. 
Strains 
A.flavus 
NRRL501 
A. fumigatus 
MTCC2550 
A. niger 
I0A3 1 
A. solani 
MTCC210] 
F. oxysporum 
MTCC284 
M. roiaii 
MTCC386 
T. rubrum 
I0A9 
T. rubrum 
MTCC296 
On solid medium 
Lipase 
l.OiO.OO 
l.OiO.OO 
0.70±0.05 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
0.79i0.06 
0.76i0.07 
Phospholipg 
l.OiO.OO 
0.78i0.05 
0.75i0.06 
l.OiO.OO 
l.OiO.OO 
1 .OiO.OO 
0.80i0.07 
0.68i0.04 
Production of virulence factors 
(Activity index 
ise Gelatinase 
l.OiO.OO 
0.73i0.07 
0.79i0.04 
l.OiO.OO 
l.OiO.OO 
l.OiO.OO 
0.68i0.06 
0.65i0.05 
(pZ)) 
Proteinase 
0.68i0.07 
0.73i0.07 
0.35i0.04 
1 .OiO.OO 
l.OiO.OO 
l.OiO.OO 
0.67i0.06 
l.OiO.OO 
In liqui( 
Elastase 
(ODat 
495 nm) 
Nil 
Nil 
0.085i0.006 
Nil 
Nil 
Nil 
Nil 
Nil 
J medium 
Keratinase 
(ODat 
280 nm) 
Nil 
Nil 
Nil 
Nil 
Nil 
Nil 
0.123i0.008 
0.085i0.006 
pZ= (zone of diameter of colony)/ (zone of diameter of colony + zone of solubilization 
or precipitation around the colony) 
pZ=l; indicates no activity 
ND; not detected 
Elastase production was considered as Nil for OD495 < 0.01 
Keratinase production was considered as Nil for OD280 < 0.01 
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Table 7. Biofilm formation in Candida spp. 
Strains 
C. albicans 
C. albicans 01 
C. albicans 02 
C. albicans 03 
C. albicans 04 
C. albicans 05 
C. albicans 06 
C. albicans 07 
C albicans 08 
C. albicans 09 
C. albicans 10 
C. albicans 11 
C. albicans 12 
' C. albicans 13 
C. albicans 14 
C. albicans 15 
C. albicans 16 
C. albicans 17 
C. albicans 18 
C.a/^/c^?7J-NRRLY12983 
C. a/&/cfl«5MTCC183 
C. albicans SC5314 
Non-albicans Candida 
C. glabrata 01 
C. g/a6rafa 02 
C.g/a^ra/flMTCC3019 
C ^M e^z 01 
C tropicalis 01 
C. tropicalis 02 
Visual 
detection 
++ 
-
++ 
+++ 
+++ 
+++ 
++ 
+ 
+++ 
-
+ 
+ 
++ 
++ 
++ 
++ 
++ 
+++ 
+++ 
++ 
+++ 
-
-
-
-
+ 
-
Absorbance 
at 492 nm 
0.49±0.04 
Nil 
0.59±0.02 
1.36±0.66 
l.OiO.08 
1.15±0.10 
0.60±0.03 
0.28±0.04 
1.12±0.09 
Nil 
0.2650.03 
0.35±0.05 
0.67±0.08 
0.62±0.05 
0.55±0.04 
0.58±0.01 
0.780.02 
l.32±0.07 
1.15±0.10 
0.60±0.03 
1.09±0.01 
Nil 
Nil 
Nil 
Nil 
0.14±0.01 
Nil 
(-) no biofilm; (+) weak biofilm; (++) moderate biofilm; 
(+++) strong biofilm 
Biofilm formation was considered as Nil for OD492 < 0.01 
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Figure 9. Visual detection of strains of C. albicans for their biofilm forming ability in 
polystyrene tubes. 
(a) C. albicans SC5314 (+++, strong biofilm) 
(b) C. albicans 04 (+++) 
(c) C. albicans 06 (+++) 
(d) C. albicans 07 (++, moderate) 
(e) C. albicans 10 (-, no biofilm) 
A 1) 
ijj^^K .:'^ ^^  
•=^^' - i ^ ^ • # * fp-
m 
Figure 10. Spectrophotometric detection of biofilm formation in the strains of C. 
albicans using XTT reduction assay in 96 well microtiter plate. 
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Table 10. Minimum inhibitory concentration (MIC) and minimum fungicidal 
concentration (MFC) of antifungal drugs against yeasts. 
Strains 
C. albicans 
C. albicans 01 
C. albicans 02 
C. albicans 03 
C. albicans 04 
C. albicans 05 
C. albicans 06 
C. albicans 07 
C albicans 08 
C. albicans 09 
C albicans 10 
C albicans 11 
C. albicans 12 
C. albicans 13 
C. albicans 14 
C albicans 15 
C. albicans 16 
C. albicans 17 
C. albicans 18 
C.a/Wca«5NRRLY 12983 
C. a/^)/ca«5MTCC183 
C. albicans SC5314 
Non-albicans Candida 
C. glabrataOl 
C. glabrata 02 
C.g/fl6rataMTCC3019 
C. kruseiOl 
C. tropicalis 01 
C. tropicalis 02 
Other yeasts 
C. neoformans 01 
C. neoformans MTCC4424 
AMB 
MIC 
0.5 
0.25 
0.5 
1.0 
32 
64 
64 
1.0 
128 
128 
64 
128 
64 
64 
32 
128 
64 
32 
0.25 
0.25 
0.12 
1.0 
2.0 
0.50 
2.0 
0.12 
1.0 
0.12 
0.5 
MFC 
1.0 
0.5 
1.0 
2.0 
64 
128 
128 
2.0 
256 
256 
128 
256 
128 
128 
128 
256 
128 
64 
0.5 
0.5 
0.25 
1.0 
2.0 
1.0 
4.0 
0.25 
0.25 
0.25 
1.0 
MIC 
64 
256 
256 
128 
2.0 
8.0 
128 
128 
128 
2.0 
32 
16 
32 
8.0 
32 
32 
64 
2.0 
8.0 
16 
0.06 
64 
128 
64 
32 
0.25 
0.5 
0.25 
64 
KTC 
MFC 
256 
512 
512 
512 
4 
32 
256 
256 
256 
4.0 
128 
32 
128 
64 
64 
64 
128 
4 
16 
32 
0.12 
256 
256 
256 
64 
0.50 
0.50 
0.50 
128 
MIC 
64 
128 
128 
128 
128 
32 
4.0 
4.0 
128 
128 
128 
128 
64 
64 
64 
128 
128 
128 
32 
128 
0.03 
128 
64 
128 
128 
32 
16 
64 
128 
ITC 
MFC 
256 
256 
256 
256 
256 
64 
16 
16 
256 
256 
256 
256 
128 
128 
128 
256 
256 
256 
64 
256 
0.06 
256 
256 
256 
256 
64 
64 
128 
256 
1 
MIC 
256 
256 
256 
256 
256 
128 
128 
256 
256 
256 
256 
256 
256 
256 
256 
128 
256 
256 
256 
256 
0.25 
128 
256 
512 
256 
32 
16 
128 
8 
FLC 
MFC 
512 
512 
512 
512 
512 
256 
256 
512 
512 
512 
512 
512 
512 
512 
512 
256 
512 
512 
512 
512 
0.5 
>512 
512 
>512 
>512 
16 
32 
256 
32 
MIC and MFC values are presented in ^g/ml 
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Table 11. Susceptibility beliavior of strains of C. albicans excluding C. albicans SC5314 
in terms of MIC range to antifungal drugs. 
Test agents 
Amphotericin B 
Ketoconazole 
Itraconazole 
Fluconazole 
0.25 
3 
-
-
MIC range (i^ g/ml ) 
Total number of strains 
0.5 1 2 4 8 16 32 
2 2 - - - - 3 
- 3 - 3 2 4 
- - - 2 - - 2 
64 
6 
2 
4 
128 
4 
4 
12 
3 
256 
-
2 
-
17 
MIC50 
64 
32 
128 
256 
MIC90 
128 
256 
256 
256 
indicates no strain 
Table 12. Resistance pattern of yeasts on the basis of MIC of antifungal drugs. 
Resistance pattern Strain designation Total no. (%) 
"AMB, KTC, ITC, FLC C.fl/6/cfl«5 05-07,09-18, 15(51.72) 
C. glabrataO\, 
C. krusei 01 
KTC, ITC, 
KTC, ITC 
ITC, FLC 
FLC 
Susceptible to all drugs 
C. albicans Q\-QA,<di, 
C. glabrata 01 
C.fl/6/coraNRRLY 12983, 
C. albicans U1CC\%2, 
C. glabrata MTCC2Q]9 
C. neoformans MTCC4424 
C. tropicalis 01,02, 
C. neoformans 01 
C. albicans S,C53\A 
9(31.03) 
1(3.44) 
3(10.34) 
1(3.44) 
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Table 15. Resistance pattern of strains of filamentous fungi on the basis 
of MIC of antifungal drugs. 
Resistance pattern Strain designation 
AMB, CLT, FLC, ITC A. solani MTCC 2101 
T. rubrum 10A9 
AMB, FLC, ITC, KTC 
AMB, FLC, ITC, NYT 
AMB, FLC, ITC 
CLT, FLC, ITC, KTC 
CLT, FLC, ITC 
A. fumigatus MTCC 2550 
F. oxysponim MTCC 284 
^../7OTM5NRRL501 
M. rouxii MTCC386 
T. rubrum MTCC296 
A. niger 10A3 
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Figure 11. Chromatogram of Carum copticum (ajowan). 
Table 16. Major chemical constituents of ajowan oil as identified 
by GC-MS. 
Compounds 
a-pinene 
P-pinene 
p-myrcene 
y-terpinene 
p-cymene 
Thymol 
% Amount 
* 
4.59 
12.30 
2.63 
21.61 
33.67 
22.82 
Retention time 
6.89 
8.70 
9.94 
12.47 
13.31 
41.50 
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Figure 12. Chromatogram oi Cymbopogon citratiis (lemongrass). 
Table 17. Major chemical constituents of lemongrass oil as identified 
by GC-MS. 
Compounds 
a-limonene 
a-linalool 
p-citral 
a-terpineol 
a-citral 
trans-geraniol 
% Amount 
2.74 
2.77 
28.87 
1.55 
43.95 
4.0 
Retention time 
11.00 
21.58 
25.97 
26.16 
27.45 
30.24 
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Figure 13. Chromatogram of Cymbopogon martini (paimarosa). 
Table 18. Major chemical constituents of paimarosa oil as identified 
by GC-MS. 
Compounds 
a-terpinene 
trans-ocimene 
P-ocimene 
P-citronellal 
a-linalooi 
Geranyl acetate 
Geraniol 
Neryl acetate 
% Amount 
0.26 
5.44 
3.24 
1.32 
2.96 
26.91 
43.84 
2.07 
Retention time 
9.15 
11.97 
12.48 
19.63 
21.57 
27.96 
30.43 
31.55 
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Figure 14. Chromatogram of Cinnamomum verum (cinnamon). 
Table 19. Major chemical constituents of cinnamon oil as identified by 
GC-MS. 
Compounds 
o-cymene 
Cinnamaldehyde 
Cinnamicaldehyde 
Cinnamic acid 
a-thujene 
% Amount 
5.43 
79.10 
5.81 
8.91 
0.75 
Retention time 
3.94 
9.32 
10.26 
13.13 
19.34 
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Figure 15. Chromatogram of Syzyghm aromaticum (clove). 
Table 20. Major chemical constituents of clove oil as identified 
by GC-MS. 
Compounds 
Eugene 1 
P-caryophyllene 
Iso-caryophyllene 
P" caryophyllene 
a- caryophyllene 
a- caryophyllene 
Caryophyllene oxide 
% Amount 
74.32 
4.92 
5.96 
7.04 
1.28 
4.05 
2.41 
Retention time 
6.28 
7.03 
7.09 
7.14 
7.34 
7.40 
8.61 
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Figure 16. Chromatogram of Thymus vulgaris (thyme). 
Table 21. Major chemical constituents of thyme oil as identified 
by GC-MS. 
Compounds 
a-pinene 
P-pinene 
y-terpinene 
a-cymene 
Thymol 
Carvacroi 
% Amount 
1.09 
0.47 
26.01 
21.22 
44.71 
0.85 
Retention time 
6.85 
8.63 
12.48 
13.23 
41.59 
42.50 
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Figure 17. Chromatogram of Citral. 
. 4^7 J I I Uk,. 
Figure 18. Chromatogram of Geraniol. 
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Figure 19. Antifungal activities of essential oils against test fungi using disc diffusion 
method. 
(a) C. albicans 07; Eucalyptus sp. (i); M piperita (ii); Eugenol (iii); C 
verum (iv). 
(b) C. tropicalis 01; .C. sinensis (i); Eucalyptus sp. (ii); 7. vulgaris (iii); 
Citral (iv). 
(c) r. rubrum IOA-9; S. aromaticum (i); M piperita (ii); C. paradisi (iii); 
M fragrans (iv). 
(d) ^. «/^er I0A3; Eucalyptus sp. (i); C. /iwo« (ii); C. verww (iii); M 
piperita (iv). 
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Figure 20. Time kill curves for essential oils/compounds and antifungal drugs against 
yeasts strains. 
(a) essential oils against C. albicans 01, 
(b) active compounds/drugs against C. albicans 01. 
(c) essential oils against C. albicans 09. 
(d) active compounds/drugs against C. albicans 09. 
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Figure 21. Time kill curves for essential oils/compounds and antifungal drugs against 
yeasts strains. 
(a) essential oils against C tropicalis 01. 
(b) active compounds/drugs against C. tropicalis 01. 
(c) essential oils against C. neoformans 01. 
(d) active compounds/drugs against C. neoformans 01. 
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Figure 22. Time kill curves for essential oils/compounds and antifungal drugs against 
filamentous fungi. 
(a) essential oils against A. fumigatus MTCC2550. 
(b) active compounds/drugs agamst A. fumigatus MTCC2550. 
(c) essential oils against T. rubrum I0A9. 
(d) active compounds/drugs against T. rubrum 10A9. 
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Figure 23. Concentration and time dependent toxicity of essential oils on hyphal 
morphology of T. rubrum IOA-9 (40X, Light microscope aided with 
computer). 
(a) control, 8h 
(b) C verum at 20 Mg/ml, 20h. 
(c) C. verum at 40 ng/ml, 24 h. 
(d) S. aromaticum at 80 |jg/ml, 24 h. 
((1) Autolysis of cytoplasm (2) Chlamydoconidia formation (3) 
Cytoplasmic coagulation and vesiculation (4) Hyphal shrinkage and 
necrosis) 
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Figure 24, Susceptibility of ungerminated and germinated conidia of A. fumigatus 
MTCC2550 against S. aromaticum and C. verum. 
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Figure 25. Susceptibility of ungerminated and germinated conidia of T. ruhrum IOA-9 
against S. aromaticum and C verum. 
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Figure 26. Susceptibility of ungerminated and germinated conidia of A. fumigatus 
MTCC2550 against cinnamaldehyde and eugenol. 
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Figure 27. Susceptibility of ungerminated and germinated conidia of T. rubrum IOA-9 
against cinnamaldehyde and eugenol. 
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Figure 28. Scanning electron micrograph of C. albicans 04 strain. 
(a-b) untreated control 
(c-e) treated with cinnamaldehyde at 50 ^ ig/ml 
(f-i) treated with eugenol at 200 i^ g/ml. 
(a) oval shaped and smooth cell surfaces. 
(b) arrow indicates polar bud scar. 
(c) (i) shrinkage of cell membrane (ii) scar on cell surface indicating 
lysis of cell membrane (iii) lysed and empty cells. 
(d) (i) deformed interconnected cells (ii) with several bud scars 
without preferential position at the polar ends (arrows), (V) 
deposits of lytic material is seen in the form of vesicles. 
(e) (i) interconnected cells with convoluted surfaces, loosened cell 
membrane and receding of cytoplasmic material (ii) lysed bud. 
(f) (i) deformed cells with convoluted and irregular surfaces. 
(g) arrows indicate interconnected cells, (i) lysed cell. 
(h) autolysis of cell (arrows). 
(i) receding of cytoplasmic content from cell membrane and 
disintegration of cellular content (arrow). 
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Figure 29. Scanning electron microscopy of hyphal morphology of A. fumigatus 
MTCC2550 treated with cinnamaldehyde at 40 |ig/ml. 
(a) control, healthy hyphae; 
(b) arrow indicates blistering in hyphae. 
(c) hyphae Avithout cytoplasm. 
(d) necrosis of hyphae. 
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Figure 29 (continue...). Scanning electron microscopy of hyphal morphology of A. 
fumigatus MTCC2550 treated with eugenol at 160 |ag/ml. 
(e) short branched hyphae with a rough and wrinkled surface, swollen tips 
(arrow) on the short branch. 
(f) shrinkage of cytoplasmic materials in hyphae, arrow indicates lateral 
growth of hyphae. 
(g) arrow indicates disruption of hyphal tips. 
(h) collapsed hyphae without cytoplasm. 
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Figure 30. Transmission electron microscopy of C. alhicam 04 treated with 
cinnamaideliyde at 50 ng/ml. 
(a) control untreated Candida ceils with intact cell wall, cell membranes 
and other organelles. 
(b) disorganized protoplasm with receding of cell membrane (1), thickening 
ofcellwall(2). 
(c) excessive vacuolization (v), loosening of cell membrane (3), 
disintegration of cell membrane (4). 
(d) invagination and disintegration of cell membrane (5), deposition of lipid 
globules. 
(e) disintegrated c\topla:-;m and lysis of cell wall and membrane (7). 
(t) cell wall st'-ength is lost and lysis of cellular material (8). 
[% 
(a) (b) 
(c) (d) 
(e) 
157 
Figure 30 (continue....)- Transmission electron microscopy of C. albicans 04 treated 
with eugenol at 200 f.ig/ml. 
(g) thickening of ceil wall (9), loosening of cell membrane (10) 
(h) undulating cell wall (11) 
(i) deposition of lipid globules (12), disintegration of cell membrane (13) 
(j) excessive vacuolization (v), loosening of cell wall and cell membrane 
(14) 
(k) movement of cytoplasmic material to interconnected cell (15) 
(I) disintegrated cytoplasm, rupturing of cell membrane (16), swelling of 
cell wall (17). 
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Figure 31. Transmission electron microscopy of A. fumigalii.s MTCC2550 treated with 
cinnamaldehyde at 40 fig/ml 
(a) Control, intact cell wall, membrane and other organelles. 
(b) expansion of endoplasmic reticulum near cell membrane (1), stripping of 
cell membrane (2). thickening of cell wall (3). 
(c) leakage of cell wall and cell membrane (4). 
(d) autolysis and degradation of cytoplasmic content (5), abnormal 
distribution of polysaccharides (6). 
(e) lack of cytoplasm, folding of nuclear m.embrane, disintegration of 
nuclear material (7). 
(f) leakage of the total cytoplasmic content (8). 
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Figure 31 (continue...). Transmission electron microscopy of ^ . fumigatus MTCC2550 
treated with eugenol at 160 i^g/ml. 
(g) expansion of endoplasmic reticulum near the cell membrane (9), 
thickening of cell wall. 
(h) stripping of plasma membrane (11), disintegration of plasma membrane 
(12), formation of septal wall (13). 
(i) disorganization of nuleus and nucleolar content and folding of nuclear 
envelope (14), destruction of cytoplasmic content (15). 
(j) total loss of cytoplasmic content (16). 
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Figure 32 (continue...). Transmission electron micrograpiis of T. rubrum 10A9 treated 
with eugenol at 40 fig/ml. 
(g) undulation of cell wall (12), expansion of endoplasmic reticulum (13). 
(h) formation of septal wall (14), disintegration of mitochondria (15). 
(i) excessive vacuolization and disintegration of cytoplasmic content (16). 
(j) Loss of cytoplasmic content (17). 
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Table 30. MIC of essential oils and active compounds against C. albicans 04 
in the absence and presence of sorbitol. 
Essential oils/ 
active compounds 
C. verum 
S. aromaticum 
Cinnamaldehyde 
Eugenol 
Control 
Fluconazole 
Congo red 
2 
-sorbitol 
40 
80 
20 
40 
256 
0.25 
days 
MIC( 
+sorbitol 
40 
80 
20 
40 
256 
16 
\iglm\) 
7 
-sorbitol 
40 
80 
40 
40 
256 
0.25 
days 
+sorbitol 
40 
80 
80 
80 
512 
128 
Table 31. MIC of essential oils and active compounds agdimsi A. fumigatus 
MTCC2550 in the absence and presence of sorbitol. 
Essential oils/ 
active compounds 
C. verum 
S. aromaticum 
Cinnamaldehyde 
Eugenol 
Control 
Fluconazole 
Congo red 
5 
-sorbitol 
80 
320 
80 
320 
200 
2 
days 
M1C( 
+sorbitol 
80 
320 
80 
320 
200 
128 
Hg/ml) 
10 
-sorbitol 
80 
320 
80 
320 
200 
2 
days 
+sorbitol 
160 
640 
320 
640 
400 
1024 
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Figure 33. Effect of essential oils, active compounds and antifungal drugs on the release 
of 260 nm absorbing material. 
(a) concentration dependent release in C. albicans 04. 
(b) time dependent release in C. albicans 04. 
(c) concentration dependent release \n A. fumigatus MTCC2550. 
(d) time dependent release in A. fumigatus MTCC2550. 
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Figure 34. Effect of essential oils, active compounds and drugs on the K"^  leakage. 
(a) concentration dependent leakage in C. albicans 04. 
(b) time dependent leakage in C. albicans 04. 
(c) concentration dependent leakage \n A. fumigatus MTCC2550. 
(d) time dependent leakage in A. fumigatus MTCC2550. 
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Figure 35. Effects of treatment with increasing concentration of eugenol on C. albicans 
04 cells in the form of membrane lesion produced and as analysed by flow 
cytometry. Sequence of density plots are given with respective percentages 
of Pl-stained cells in upper left quadrant. 
(a) untreated. 
(b) treated with IX MIC. 
(c) treated with 2X MIC. 
(d) treated with 4X MIC. 
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Figure 35 (continue...). Effects of treatment with increasing concentration of eugenol on 
C. albicans 04 cells in the form of membrane lesion produced and as 
analysed by flow cytometry. Histograms shows non-viable cells marked by 
setting the gate R5. 
(e) untreated. 
(f) treated with IX MIC. 
(g) treated with 2X MIC. 
(h) treated with 4X MIC. 
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Figure 35 (continue...). Effects of treatment with increasing concentration of eugenol on 
C albicans 04 cells in the form of membrane lesion produced and as 
analysed by flow cytometry. Scattergram is showing cell complexity (side 
scatter, SS lin) versus cell size (forward scatter, FS lin), and significant 
morphological alterations. 
(i) untreated. 
(j) treated with IX MIC. 
(k) treated with 2X MIC. 
(1) treated with 4X MIC. 
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Figure 36. Effects of treatment with increasing concentration of cinnamaldehyde on C. 
albicans 04 cells in the form of membrane lesion produced and as analysed 
by flow cytometry. Sequence of density plots are given with respective 
percentages of Pl-stained cells in upper left quadrant. 
(a) untreated. 
(b) treated with IX MIC. 
(c) treated with 2X MIC. 
(d) treated with 4X MIC. 
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Figure 36 (continue...). Effects of treatment with increasing concentration of 
cinnamaldeliyde on C. albicans 04 cells in the form of membrane lesion 
produced and as analysed by flow cytometry. Histograms shows non-viable 
cells marked by setting the gate R5. 
(e) untreated. 
(f) treated with IX MIC. 
(g) treated with 2X MIC. 
(h) treated with 4X MIC. 
173 
192-
128-
64-
; . . - . : • / . 
• ' . • ' • ' . ' : • ^ • • • . ' ' • - • • • 
s' • ' " • • • • . . . v . . . V ; - i . x - ' ' • - ' ' % ' • •••••. •• • • 
256-
192-
01 
64- m 
'••mi 
• '•• : • ' " ' . . . , \ " • " 
C^;:-;.'-!,:.v.r---vvV^-.\ .- • .• ' -
I^ -^'---
128 
FSLin 
64 128 192 
FSLr 
256 
(i) (i) 
256 
192-
64 
192-
^ 1 2 8 -
64-
0-1 
: 
• \ . . ^ - ' ' ' - % v : y ' : • ' • < • • • • •' ^ 
^ g s ••':•••'• 
S4 128 
FSLin 
(k) (I) 
Figure 36 (continue...). Effects of treatment with increasing concentration of 
cinnamaldehyde on C. albicans 04 cells in the form of membrane lesion 
produced and as analysed by flow cytometry. Scattergram is showing cell 
complexity (side scatter, SS lin) versus cell size (forward scatter, FS lin), 
and significant morphological alterations. 
(i) untreated, 
(j) treated with IX MIC. 
(k) treated with 2X MIC. 
(1) treated with 4X MIC. 
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Figure 37. Effects of treatment with increasing concentration of amphotericin B on C. 
albicans 04 cells in the form of membrane lesion produced and as analysed 
by flow cytometry. Sequence of density plots are given with respective 
percentages of Pl-stained cells in upper left quadrant. 
(a) untreated. 
(b) treated with IX MIC. 
(c) treated with 2X MIC. 
(d) treated with 4X MIC. 
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Figure 37 (continue....). Effects of treatment with increasing concentration of 
amphotericin B on C. albicans 04 cells in the form of membrane lesion 
produced and as analysed by flow cytometry. Histograms shows non-viable 
cells marked by setting the gate R5. 
(e) untreated. 
(f) treated with IX MIC. 
(g) treated with 2X MIC. 
(h) treated with 4X MIC. 
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Figure 37 (continue...). Effects of treatment with increasing concentration of 
amphotericin B on C. albicans 04 cells in the form of membrane lesion 
produced and as analysed by flow cytometry. Scattergram is showing cell 
complexity (side scatter, SS lin) versus cell size (forward scatter, FS lin), 
and significant morphological alterations, 
(i) untreated. 
Cj) treated with IX MIC. 
(k) treated with 2X MIC. 
(1) treated with 4X MIC. 
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Figure 38. Histograms showing comparative analysis of viable and non-viable cells in C. 
albicans 04 upon treatment with eugenol and cinnamaldehyde. (red area) 
untreated unstained viable cells, (dark blue area) treatment with eugenol at 
IX MIC, (pink area) cinnamaldehyde at 2X MIC, (yellow area) 
cinnamaldehyde at 4X MIC, (light blue) eugenol at 4X MIC. 
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Figure 39. Histograms showing comparative analysis of viable and non-viable cells in C. 
albicans 04 upon treatment with amphotericin B. (red area) untreated 
unstained viable cells, (green area) treatment with amphotericin B at 2X 
MIC, (dark blue area) amphotericin B at 4X MIC. 
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Figure 40, UV spectrophotemetric sterol profiles of C. albicans 04. 
(i) untreated control (a), 0.25 X MIC C verum (b), 0.5 X MIC C. verum (c) 
1 X MIC C. verum (d) 0.5 X MIC fluconazole (e). 
(ii) untreated control (a), 0.25 X MIC 5. aromatimm (b), 0.5 X MIC S. 
aromaticum (c) 1 X MIC 5'. aromaticum (d) 0.5 X MIC fluconazole (e). 
(iii) untreated control (a), 0.25 X MIC cinnamaldehyde (b), 0.5 X MIC 
cinnamaldehyde (c) 1 X MIC cinnamaldehyde (d) 0.5 X MIC 
fluconazole (e). 
(iv) untreated control (a), 0.25 X MIC eugenol (b), 0.5 X MIC eugenol (c), 1 
X MIC eugenol (d), 0.5 X MIC fluconazole (e). 
179 
Table 32. Ergosterol content of C albicans 04 cells treated with various 
concentrations of essential oils and active compounds. 
Essential oils/ 
active compounds 
C. verum 
S. aromaticum 
Cinnamaldehyde 
Eugenol 
Fluconazole 
(control) 
Mean ergosterol content 
0.25X MIC 
0.0206±0.002 
(32.9) 
0.0223±0.002 
(27.37) 
0.0126±0.001 
(58.96) 
0.0124±0.001 
(59.61) 
0.0257±0.002 
(16.29) 
0.5X MIC 
0.01]6±0.001 
(62.22) 
0.0126±0.001 
(58.96) 
O.OlOliO.OOl 
(67.41) 
0.0073±0.0004 
(76.23) 
0.0197±0.001 
(35.81) 
IX MIC 
O.O055±0.0003 
(82.09) 
0.0037±0.0002 
(87.95) 
0.0022±0.0002 
(92.84) 
0.0009±0.00006 
(97.07) 
0.0118±0.001 
(61.57) Data 
are presented as a percentage of the wet weight of the cell ± SD, followed in 
parentheses by the reduction (%) in the mean cellular ergosterol content compared with 
that of untreated control cell. 
Value for untreated control cell was 0.0307±0.003, considered as 100% ergosterol 
content in an untreated cell. 
Table 33. MIC of essential oils and active compounds against C. albicans 04 
in the absence and presence of ergosterol. 
Essential oils/ 
active compounds 
C. verum 
S. aromaticum 
Cinnamaldehyde 
Eugenol 
Amphotericin B 
(control 
-Ergosterol 
400 
200 
100 
400 
1.0 
MIC (^g/ml) 
+ErgosteroI 
(lOO^g/ml) 
800 
400 
200 
1600 
2.0 
+Ergosterol 
(200 ng/ml) 
1600 
800 
400 
1600 
4.0 
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Figure 41. GTF in the strains of C. albicans in the presence of sub-MICs of essential 
oils, active compounds and drugs. 
(a) C albicans 04. 
(b)C. fl/^zca«5SC5314. . 
184 
Table 37. CSH in the strains of Candida spp. exposed to sub-inhibitory concentrations 
of essential oils, active compounds and drugs. 
Test agents 
(Sub-MICs) 
Percent cell surface hydrophobicity 
C. albicans 
04 
C. albicans 
07 
C. albicans 
MTCC183 
C. albicans 
SC5314 
C. tropicalis 
01 
Untreated control 61.75±3.45' 62.74±4.35' 33.80±3.45" 53 ?8±3 45" 60 97±5 34' 
Essential oils 
C. citratus 
0.25 X MIC 
0.5 X MIC 
C. copticum 
0.25 X MIC 
0.5 X MIC 
C. martini 
0.25 X MIC 
0.5 X MIC 
C. verum 
0.25 X MIC 
0.5 X MIC 
S. aromaticum 
0.25 X MIC 
0.5 X MIC 
T. vulgaris 
0.25 X MIC 
0.5 X MIC 
Active compounds 
Cinnamaldehyde 
0.25 X MIC 
0.5 X MIC 
Citral 
0.25 X MIC 
0.5 X MIC 
Eugenoi 
0.25 X MIC 
0.5 X MIC 
Geranio! 
0.25 X MIC 
0.5 X MIC 
Antifungal drugs 
Amphotericin B 
0.25 X MIC 
0.5 X MIC 
Fluconazole 
0.25 X MIC 
0.5 X MIC 
53.96±4.23'' 
50.83±4.14'' 
22.55*2.24" 
15.00il.67'''' 
60.84*3.56" 
55.01" 
50.94*4.67" 
45.43 "•' 
48.25*4.24" 
40.4i*3.8l"'' 
51.37*4.45" 
43.56*3.31"'' 
28.89*3.67" 
19.26*1.91' 
34.75*4.56" 
21.35*3.12' 
37.50*3.14" 
21.51*3.45' 
66.84*4.67' 
46.21*3.56" 
63.17*4.56' 
58.23*6.78' 
61.68*4.67' 
55.93*3.56' 
17.74*2.23"'' 
21.97*1.91" 
21.16*2.24" 
17.87*1.24"'' 
44.72*4.45"-' 
47.35" 
34.87*3.84" 
22.43' 
20.09*2.34" 
11.65*1.21"' 
33.70*2.34" 
24.91*1.81"'' 
15.26*1.79" 
ll.56v0.82"'' 
15.16*0.91" 
12.34±1..4l"'' 
42.52*4.67" 
24.54*3.67' 
29.50v2.67" 
12.90*2.89' 
58.00*4.67' 
45.11*3.67" 
43.07*3.89" 
32.35*3.56"'' 
31.33*2.23' 
23.67*2.34" 
22.69*1.91" 
12.98*1.47' 
32.59*2.24' 
26.89" 
28.07*3.67" 
31.07"'' 
25.39*2.76" 
21.70*2.34"' 
30.37*2.34' 
17.05*1.23" 
13.62*1.24" 
10.09*0.81"' 
18.90*0.91" 
10.78*0.91' 
9.03*0.045" 
3.03*0.034' 
22.33*3.67" 
19.90*1.89"' 
29.92*2.89' 
26.64*4.78" 
31.74*3.78' 
30.89*3.78' 
28.66*3.14" 
24.12*1.24"'' 
25.34*2.43" 
16.72*1.81' 
52.89*6.34' 
44.56" 
15.67*1.21"'' 
19,09" 
31,90*3.24" 
22,19*1.91' 
40.27*3.81" 
20,18*1.67' 
25.67*2.67" 
31.89*2.45"'' 
30.89*3.45" 
21.56*2.45' 
23.61*1.66" 
15.56*1.91' 
47.68*4.78' 
45.25*2.45" 
55.81*2.78' 
45.89*4.89" 
46.89*3.89' 
40.10*3.89" 
25.55*3.14" 
18.95*1.91' 
17.31*0.82" 
6.69*0.45' 
65.07*5.23' 
57.17' 
38.07*2.34' 
48.07" 
55.39*2.24' 
37.70*3.45" 
43.25*4.16" 
36.39*2.43" 
22.27*3.45' 
26.89*3.56" 
34.56*3.89" 
24.34*2.56' 
32.20*3.20" 
14.56*0.56" 
56.84*4.98' 
51.83*4.78' 
55.45*3.67' 
47.89*3.89" 
51.23*4.78' 
43.92*3.89" 
Within the columns, means values followed by different letters (a, b, c) are significantly different 
according to Duncan's multiple range tests (?<0.05) 
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Figure 42. Effect of sub-inhibitory concentrations of essential oils, active compounds 
and drugs on proteinase production. 
(a) C. albicans 04. 
(b) C. albicans 09. 
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Figure 43. Effect of sub-inhibitory concentrations of essential oils, active compounds 
and drugs on proteinase production. 
(a) C. albicans MTCC183. 
{h)C. albicans SC5314. 
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Figure 44. Effect of sub-inhibitory concentrations of essentia! oils, active compounds 
and drugs on proteinase production in C tropicalis 01. 
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Figure 45. Effect of sub-inhibitory concentrations of essential oils, active compounds 
and drugs on haemolysin production. 
(a) C. albicans 05. 
(b) C. albicans 16. 
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Figure 46. Effect of sub-inhibitory concentrations of essential oils, active compounds 
and drugs on haemolysin production. 
(a) C. albicans MTCCn3. 
(b) C. albicans SC53U. 
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Figure 47. Effect of sub-inhibitory concentrations of essential oils, active compounds 
and drugs on haemolysin production in C. tropicalis 01. 
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Figure 48. Effect of sub-inhibitory concentrations of essential oils, active compounds 
and drugs on proteinase production. 
(a) elastase production in A.fumigatus MTCC2550. 
(b) keratinase production in T. ruhrum I0A9. 
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Table 38. Effect of essential oils and active compounds on elastase and keratinase 
activities in A. niger IOA-3 and T. rubrum [OA-9, respectively. 
Percent reduction in Percent reduction in 
absorbance at 495 nm absorbance at 280 nm 
over untreated control over untreated control 
for elastase activity for keratinase activity 
Test agents 
Essential oils 
C. citratus 
C. copticum 
C. martini 
C. verum 
S. aromaticum 
T. vulgaris 
Active compounds 
Cinnamaldehyde 
Citral 
Eugenol 
Geraniol 
Inhibitors (control) 
EDTA 
MgS04 
PMSF 
56.24 ±1.99 
81.24 ±3.89 
94.56 ±0.84 
93.67 ±1.90 
68.52 ±2.08 
90.75 ±3.45 
96.56 ±1.09 
29.59 ±0.50 
77.95 ± 2.20 
84.54 ±2.63 
72.63 ±1.26 
94.10 ±1.63 
70.06 ±1.61 
13.76±1.01 
24.33 ±1.24 
77.46 ± 1.34 
5.37±2.18 
3.97±1.16 
15.96 ±1.23 
11.90 ±2.22 
57.18±1.74 
9.67 ±1.61 
97.31 ±0.59 
54.48 ±2.20 
39.77 ±1.06 
5.70 ±0.95 
Table 39. Susceptibility of planktonic and sessile C. albicans cells to 
essential oils. 
Test agents 
Essential oils 
C. citratus 
C. copticum 
C. martini 
C. verum 
S. aromaticum 
T. vulgaris 
Active compounds 
Cinnamaldehyde 
Citral 
Eugenol 
Geraniol 
Antifungal drugs 
Amphotericin B 
Fluconazole 
C. albicans 04 
PMIC SMIC 
360 360 
180 360 
90 360 
400 800 
200 400 
360 360 
100 200 
90 360 
400 400 
180 360 
I 16 
256 >1024 
C. albicans SC53\4 
PMIC 
180 
45 
45 
50 
100 
90 
50 
360 
100 
180 
0.12 
0.25 
SMIC 
180 
90 
180 
100 
200 
90 
100 
360 
100 
360 
64 
512 
PMIC; MIC of planktonic cells, SMIC; MIC of sessile or biofilm ceils 
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Figure 49. Time-dependent killing of sessile cells (expressed in terms of log cfu). 
(a) for C. albicans 04 by essential oils. 
(b) for C. albicans 04 by active compounds and drugs. 
(c) for C albicans SC5314 by essential oils. 
(d) for C. albicans SC5314 by active compounds and drugs. 
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Table 40. Effects of essential oils, active compounds and drugs on biofllm 
formation in drug-resistant and -sensitive strains of C. albicans. 
Test agents 
Essential oils 
C. citratus 
C. copticwn 
C. martini 
C. venan 
S. aromaticiim 
T. vulgaris 
Active compounds 
Cinnamaldehyde 
Citral 
Eugenol 
Geraniol 
Antifungal drugs 
Amphotericin B 
Fluconazole 
Biofiim formation* 
C. albicans 04 
0.5 X MIC 
11.46±1.55 
25.32±2.68 
66.24±2.25 
64.14±1.05 
47.6]±1.68 
07.49±0.98 
31.40±2.41 
74.31±2.27 
18.62±2.9I 
69.08±1.48 
67.59±1.69 
48.16±0.97 
0.25 X MIC 
19.48±2.57 
40.08±3.69 
77.07±2.19 
74.56±2.38 
57.I7±2.67 
ll.70±1.91 
63.53±1.75 
84.00±1.99 
28.1i±2.69 
84.70±2.59 
78.34±1.93 
67.61 ±1.39 
C.^//)/cfln.vSC5314 
0.5 X MIC 
17.86±2.21 
28.50±2.4] 
65.41 ±2.04 
65.42±3.01 
42.92±1.93 
I4.72±1.05 
33.23±2.05 
79.45±2.75 
20.65±1.34 
64.34±3.60 
66.90±2.34 
48.63±2.24 
0.25 X MIC 
24.67±2.13 
42.92±2.48 
78.79±2.00 
77.06±1.81 
62.36±2.49 
25.04±2.54 
62.64±1.36 
86.76±2.61 
38.42±2.04 
81.91±2.22 
77.85±2.18 
65.34±3.32 
*Biofilm formation values were calculated as: (mean OD492 treated well)/ 
(mean OD492 control well) XI00. 
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Figure 50. Concentration dependent effect of oils and compounds on the ability of 
pianktonic cells of strain C albicans 04 to form biofilms on catheter discs in 
48 h, under 40X light microscope. 
(a) control untreated cells; mature biofilms exhibiting dense matrix, hyphae 
(i) and embedded yeast cells (ii). 
(b) treatment with eugenol at 50 |ag/ml (0.I25X MIC); extracelluar matrix is 
loosened and formation of hyphae is reduced. 
(c) treated with eugenol at 100 |ag/ml (0.25X MIC); close aggregation of 
yeast cells is only observed. 
(d) treated with eugenol at 200 i^g/ml (0.5X MIC); dispersion of yeast cells 
and blastospores. 
(e) cinnamaldehyde at 25 |ig/ml (0.25X MIC); scattered aggregation of 
yeast cells. 
(f) cinnamaldehyde at 50 |ig/ml (0.5X MIC); dispersion of yeast cells and 
blastospores. 
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Figure 50 (continue...). Concentration dependent effect of oils and compounds on the 
ability of planktonic cells of strain C. albicans 04 to form biofilms on 
catheter discs in 48 h, under 40X light microscope. 
(g) C. citratus at 90 |ig/ml (0.25X MIC); blastospores and aggregation of 
yeast cells. 
(h) C. citratus at 180 ^g/ml (0.5X MIC); dispersion of yeast cells and 
blastospores. 
(i) T. vulgaris at 90 ^g/ml (0.25X MIC); dispersion of yeast ceils and 
blastospores. 
(j) T. vulgaris at 180 ^ g/ml (0.5X MIC); dispersion of yeast cells. 
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Figure 51. Scanning electron micrograph of the 48 h biollhn in C. albicans 04 formed on 
catheter discs in the absence and presence of active compounds. 
(a) biofilm formed in the absence of active compounds, dense network of cells 
and hyphae, white arrow indicates exopolysaccharide material. 
(a. inset) white arrow indicates smooth cell membrane of normal cell. 
(b) biotllm formed in the presence of eugcnol at 100 (ag/ml; no 
exopolysaccharide material, aggregation of cells is observed. 
(b. inset-1) (i) rough cell membrane (ii) bursting of cells (iii) empty cells (iv) 
vesicle formation due to lytic material. 
(b. inset-2) (i) shrinkage in cell membrane (ii) plasmolysis of cell. 
(c) biofilm formed in the presence of cinnamaldehyde at 50 pg/ml; loss of 
biofilm organization. 
(d) biofilm formed in the presence of C. citrahis at 45 |.ig/ml. 
(e) bioflm formed in the presence of T. vulgaris at 45 |.ig/ml. 
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Table 41. FIC and FICl for combination of eugenol and cinnamaldeliyde vvitii 
fluconazole and amphotericin B against C albicans 04 and 
C. albicans SC5314. 
Test combinations 
(Hg/ml) MlCa 
Eugenol with fluconazole 
Eugenol 400 
Fluconazole 1024 
Eugenol with amphotericin B 
Eugenol 400 
Amphotericin B |g 
C. alh 
MICc 
50 
128 
50 
8 
leans 04 
FlCl T 
0.250 S 
0.625 1 
C. albicans SC5314 
MlCa 
200 
512 
200 
64 
MICc FICI T 
25 0.140 S 
8 
12.5 0.562 I 
32 
Cinnamaldehvde with fluconazole 
Cinnamaldehyde 400 100 0.312 S 
Fluconazole JQ24 54 
Cinnamaldehyde with amphotericin B 
Cinnamldehyde 400 100 0.75 1 
Amphotericin B 16 8 
200 
512 
200 
64 
50 
64 
25 
32 
0.375 S 
0.625 I 
MICa; SMIC of one agent alone (|Jg/ml) 
MICc; SMIC of agent in most effective combination (^ ig/ml) 
T; type of interaction, S; synergy; I; indifferent 
201 
Opportunistic fungal infections are the major cause of morbidity in immuno-
compromised individuals such as cancer and HIV patients. The mortality rate of invasive 
fungal infections is high despite of antifungal chemotherapy with amphotericin B, azoles 
and caspofungin (Fridkin 2005). The unprecedented increase in such patients has 
challenged the management of fungal infections. Furthermore, problem of host toxicity 
associated with antifungal drugs and emergence of drug-resistance in primary and 
opportunistic fungal pathogens has impeded the success of antifungal therapy. Therefore, 
new and effective antifungal agents and approaches for treating these infections are 
warranted. To combat above problems various strategies have been made under 
investigation which include combinational therapy, development of new antifungal 
agents with improved efficacy, novel approaches of drug delivery and search of novel 
compounds which can interfere with fungal virulence and biofilm formation both at 
classical and molecular levels of drug targets. 
Natural products derived from medicinal plants have been well known for their 
contribution in developing modem drugs as well as herbal formulation in traditional 
medicine system (Cowan 1999; Braun and Cohen 2010). It is believed and recommended 
by leading scientists that with improved strategy and intelligent design of test assay novel 
bioactivity of natural products may be discovered against various ailments. Essential oils 
from medicinal plants are known for their antifungal activity and uses but these oils and 
their major active compounds have not yet been screened for novel anti-virulence 
potential and its synergy with currently used antifungal drugs against drug-resistant 
strains of fungi. Considering the need of alternative antifungal therapy, a systematic 
investigation on certain plant essential oils known for their ethnomedicinal uses in Indian 
traditional system against fungal infections was made to exploit their antifungal and anti-
virulence activities against drug-resistant strains of yeasts and filamentous fungi. The 
findings of this investigation are discussed below. 
6.1. Occurrence of viruJence factors in Candida spp and filamentous fungi 
In the present study, 26 clinical and 11 reference strains used were isolated/collected, 
identified and confirmed on the basis of standard biochemical, cultural and 
morphological characteristics as Candida albicans, Candida glabrata, Candida krusei, 
Candida tropicalis, Cryptococcus neoformans, Aspergillus flavus, Aspergillus fumigatus, 
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Aspergillus niger, Alternaria solani, Fusarium oxysponim, Miicor rouxii and 
Trichophyton rubrum. Identification of strain C. albicans 04 based on 18S rRNA gene 
sequencing confirmed our biochemical basis of identification. Further, virulence 
attributes namely germ tube formation, cell surface hydrophobicity, proteinase and 
haemolysin were studied for their expression among Candida spp at the phenotypic level 
both qualitatively and quantitatively. In addition, ability to form biofilm by these strains 
was also determined. Filamentous fungi were tested for production of extracellular 
enzymes viz. lipase, phospholipase, gelatinase, elastase and keratinase. 
In this study, varying level of phenotypic expression of these virulence factors was 
observed among test strains of Candida spp and other filamentous fungi. Four strains of 
C. albicans produced all the tested virulence factors i.e. germ tubes, proteinase, 
haemolysin and CSH whereas two strains of non-albicans Candida produced proteinase, 
haemolysin and CSH and others produced either one or two virulence factors. Production 
of these virulence factors in the strains of Candida spp isolated from different sites of 
infection have been reported by several other workers in solid or liquid media (Luo et al. 
2001; Kantarcioglu and Yucel 2002; Kuriyama et al. 2003; Dagdeveren et al. 2005; 
Kumar et al. 2006; Gokce et al. l^Ql; Furlaneto-Maia et al. 2008). Among the 
filamentous fungi, A. niger IOA-3 and T. rubrum IOA-9 exhibited production of several 
virulence factors such as phospholipase, proteinase, gelatinase and keratinase. These 
findings are in agreement with the reports from other workers who have shown 
production of these virulence factors by clinical strains of Aspergillus spp and 
Trichophyton spp (Muhsin et al. 1997; Alp and Arikan 2008). 
Biofilm forming ability was demonstrated by 77% of C. albicans strains from different 
clinical sites as revealed by both visual and spectroscopic methods. This may reflect 
similarities in the ability of strains of C. albicans from different sites of infection to form 
biofilms and aid to the pathogenesis of Candida spp. Formation of biofilms by albicans 
and non-albicans Candida strains isolated from different clinical specimens and their 
relevance to pathogenicity has been reported by several other workers (Shin et al. 2002; 
Gokce et al. 2007; Furlaneto-Maia et al. 2008; Lai et al. 2008; Ferreira et al. 2009). 
Incidence of one or other virulence factors in 50% or more test strains in our study 
highlights the relevance of virulence factors in these isolates to be more pathogenic in 
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nature as reported by various researchers that increased expression of virulence factors is 
attributed to the increased pathogenicity of drug-resistant strains leading to severity of 
disease. Several in vitro studies have reported incidence of these virulence factors in 
clinical isolates of Candida spp including their drug-resistant variants (Sweet et al. 1995; 
Koga-lto et al. 2006; Antony et al. 2007; Ramesh et al 2011; Tay et al. 2011). 
Expression and quantity of virulence factors produced by microorganisms is attributed to 
the specificity of isolates, its association with different clinical conditions, and or 
physiological condition and genetic make up of the strain. For example, blood isolates 
generally produce much higher levels of virulence factors than do isolates from wounds 
and urine (Price et al. 1982; Dagdeveren et al. 2005). Since strains under study were 
isolated from different clinical conditions such as patients of known vaginitis, candidemia 
and urinary tract infections, so variation in amount and expression of virulence factors 
was obvious. 
6.2. Susceptibility of test fungi to antifungal drugs 
The sensitivity behavior of test strains of Candida spp and C. neoformans has revealed a 
cross resistance to azoles namely, fluconazole, itraconazole and ketoconazole showing 
wide range of resistance level (2-512 ng/ml). Our findings are similar with the reports of 
Cross et al. (2000) who have reported cross-resistance between miconazole, clotrimazole, 
and itraconazole and fluconazole in the clinical isolates of C. glabrata and C. albicans. 
The increased cross resistance to azoles is probably due to the frequent use of these drugs 
in medical practice. Several other workers also have reported resistance to azoles in 
Candida spp. and C. neoformans (Krcmery et al. 2002; De Logu et al. 2005; Swinne et a\. 
2005; Hamza et al. 2008; Arechavala et al. 2009). Although some of the strains of this 
study were sensitive to amphotericin B but co-resistance was also clearly displayed. 
Other workers have also reported the development of resistance in C. albicans to 
amphotrericin B (Tseng et al. 2005). Multi drug resistance is a serious issue during 
treatment of opportunistic fungal infections of immunocompromised individuals such as 
transplant recipients and cancer patients undergoing cytotoxic chemotherapy (Thakur et 
al. 2008). Furthermore, similar to yeasts multi-drug resistant human pathogenic fungi 
from different genera of Aspergillus, Trichophyton, Mucor and Fusarium were evident 
from our study. Increasing resistance to azole-drugs amongst various filamentous fungi 
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has become a common problem and has been reported by several other workers (Howard 
et al. 2006; Santos and Hamdan 2007; Snelders et al. 2008; Mortensen et al. 2010; 
Arendrup et al. 2008). 
However, the exact incidence of antifungal resistant strain required more extensive 
sample size and such data are commonly available with clinical observations. The 
purpose of this study was to obtain a set of drug-resistant and virulent strains of human 
pathogenic fungi to be tested for various dimensions of assays. Fluconazole is considered 
to be one of the safest drugs in treating fungal infections but emergence of resistance 
against it has diminished its efficacy in clinical setting. On the other hand newly 
developed echinocandins have shown efficacy against Candida spp but lesser activity to 
Aspergillus spp and poorly active against C. neoformans, in addition, these drugs are 
costlier in use (De Logu et al. 2005; Onyewu and Heitman 2007). 
6.3. Antifungal activity of essential oils against drug-resistant fungi 
Increasing incidence of mycoses in spite of available antifungal drugs triggers interest in 
the development of safe and effective antifungal drugs or alternative antifungal therapy 
from various approaches including medicinal and aromatic plants. Plant essential oils 
have long been used safely and effectively in ethnomedicine in treatment of various 
ailments including fungal infections (Cavaleiro et al. 2006; Park et al. l^Ql; Bajpai et al 
2009) and are expected to be useful in combating current fungal infections (Aqil et al. 
2010). Therefore, considering the problem of drug-resistance in pathogenic fungi, certain 
essential oils and some of their major active compounds were screened for their in vitro 
efficacy against C. albicans and other pathogenic fungi. 
The present study has revealed broad spectrum inhibitory activity from oils of C. 
copticum, C. citratus, C. martini, C. verum, S. aromaticum and T. vulgaris, and major 
active ingredients like cinnamaldehyde, eugenol, geraniol and citral, against multi-drug 
resistant human pathogenic fungi from different genera of Candida, Aspergillus, 
Trichophyton, Mucor and Fusarium both in solid and liquid media. Cinnamaldehyde, 
citral and oil of C. martini exhibited promising anti-candidal activity against multi-drug 
resistant strains of C. albicans with the MIC range of 45 to 200 |ig/ml. 
In general, active compounds namely cinnamaldehyde, citral, eugenol and geraniol, were 
more active than essential oils in their antifungal activities. GC-MS analysis further 
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supported that such active constituents are present in the test essential oils which 
collectively or synergistically interact to impart a more rapid mode of action. In this 
regard, the above-mentioned essential oils and active compounds may act as potential 
antifungal agents against drug-resistant fungi. The antifungal activity of these essential 
oils was reported by several other workers (Park et al. 2007; Bajpai et al 2009; Tyagi 
and Malik 2010a). However, this is probably first attempt to assess the inhibitory activity 
against drug-resistant strains of this group of fungi including C. albicans, Non-albicans 
Candida, Cryptococcus spp, Aspergillus spp, Trichophyton spp and other filamentous 
fungi. The variation in susceptibility to these oils might be due to the variation in the 
structural, physiological and genetic makeup of the different strains of fungi tested as 
well as composition and nature of active compounds present in essential oils tested as 
revealed by GC/GC-MS analysis. 
Further, these oils exerted a concentration dependent effect on growth of filamentous 
fungi in terms of biomass production and mycelial radial growth even at lower 
concentrations (18 to 40 fig/ml). Cinnamaldehyde was found to be most inhibitory 
against T. rubrum and A. fumigatus. Antifungal activities of these oils and compounds are 
also reported by several other workers (Saikia et al. 2001; Wang et al. 2005; Cheng et al. 
2008). In our study, light microscopy revealed the concentration and time dependent 
toxic effects of oils of C verum and S. aromaticum on mycelial and reproductive 
structures of test fungi. Formation of chlamydospores is considered to be the indicator of 
stress conditions produced in the presence of oils and in response hyphal shrinkage and 
autolysis of cytoplasm is achieved. It was also observed that cinnamaldehyde, eugenol, C. 
verum and S. aromaticum inhibited significantly both ungerminated and germinated 
conidia oi A. fumigatus MTCC2550 and T. rubrum IOA-9 at a concentration range from 
5 to 80 }xg/ml. Cinnamaldehyde exhibited edge over tested oils in activity against both 
ungerminated and germinated conidia of these fungi at sub-inhibitory concentrations. Our 
findings are comparable with antifungal drugs such as amphotericin B, itraconazole and 
voriconazole inhibiting both ungerminated and germinated conidia in clinical isolates of 
A. fumigatus as reported by Manavathu etal. (1999). 
Furthermore, to determine that whether the antifungal activities from these oils are cidal 
or static in nature, time kill assays was performed. The data obtained reflected the 
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efficacy of test oils higher than fluconazole in killing C albicans strains exhibiting 
resistance to fluconazole and amphotericin B or susceptible to amphotericin B. The 
potency of cinnamaldehyde in killing the fungi as revealed by time kill assays against A. 
fumigatus MTCC2550 and T. rubrum IOA-9 was found to be higher than fluconazole and 
the other essential oils or active compounds. These findings have indicateed the 
fungicidal activity of essential oils and active compounds over the fungistatic nature of 
fluconazole. Fungistatic nature of fluconazole may be attributed to its lower killing 
potential but these oils even appeared to be more cidal than amphotericin B. 
In spite of well known antifungal properties of these essential oils, less information is 
available on their mechanism of action against the fungi included in this study. Therefore, 
to investigate mechanism of action of these essential oils or active compounds against 
yeasts and filamentous human pathogenic fungi, the strains of C. albicans 04, A. 
fumigatus MTCC2550 and T. rubrum IOA-9 were selected as representative of each 
group and subjected to microscopic observations and other assays. To ascertain the 
surface and ultrastructural changes produced by oils against yeasts and filamentous fungi, 
the cinnamaldehyde and eugenol were selected as test agents as were more inhibitory to 
fungal growth at lower concentrations in our study. The morphological changes produced 
were confirmed by SEM of C. albicans 04, A. fumigatus MTCC2550 treated with sub-
MICs of cinnamaldehyde or eugenol. In the SEM micrograph, the differences between 
treated and untreated Candida cells were clearly visualized. The cell envelope of yeast is 
appeared to be damaged by the oils as evident by shrinkage of cell surfaces, presence of 
non-polar bud scars, and receding of cytoplasm leading to lysis of cells. Increase in buds 
and bud scars implies that drug affect normal division process of yeasts resulting in a 
single cell with multiple attempt to divide but not resulting in increase in viable number 
of cells. The deposition of vesicles on the cell surface is an indicative of broken cells 
releasing cytoplasmic materials upon damage of cell wall and therefore, suggests 
fungicidal nature of oils towards yeast cells. The surface alterations are most probably 
due to the change in cell permeability showing that the first changes are localized at the 
plasmamlema and cell wall before any alteration can be detected in the cell interior (De 
Nollin and Borgers 1974). The indentations of the walls in collapsed cells are indicative 
of permeability changes that provoke osmotic imbalance. The folds in the cell wall giving 
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bulging appearance may be due to the deposition of membranous material between 
plasmalema and cell wall or in the cell wall itself (De Nollin and Borgers 1975). Almost 
similar effects were also observed for thymol and eugenol against Saccharomyces 
cerevisiae as reported by Bennis et al. (2004). Tyagi and Malik (2010a) have shown 
membrane damaging effect of oil of C. citratus against Candida albicans. 
In case of filamentous fungi A. fumigarus MTCC2550, severely collapsed and squashed 
hyphae due to the lack of cytoplasm were evident. Apical growth at the hyphal tip is 
correlated to the highest metabolic activity (Heath 1990) and it has been reported that 
1,3-P-D-gIucan synthase, an fungal cell wall synthesizing enzyme, is located in hyphal tip 
(Beauvais et al. 2001). Therefore, disruption of these sites in filamentous fungi may 
suggest inhibitory activity of oils against cell wall-synthesis similar to micafungin 
(Nishiyama et al. 2005). The disruption of hyphal and lateral branches tips may induce 
extracellular leakage of cellular material leading to collapsed hyphae or autolytic 
destruction of whole hyphae as evident from our study. Similar effects of essential oils on 
the hyphal morphology of the plant pathogenic fungi have also been reported by other 
authors (De Bellerbeck et al. 2001; Soylu et al. 2006; Wang et al. 2010). These changes 
in hyphal morphology may be related to loss of integrity of cell wall and, therefore, it 
could be postulated that essential oils or active compounds are interfering with cell wall 
synthesis. 
Further, to ascertain whether site of action of essential oils against yeasts and filamentous 
fungi is at cell wall, cell membrane or other intracellular structures, strains of C albicans 
04, A. fumigatus MTCC2550 and T. rubrum IOA-9 were subjected to TEM at sub-MICs 
of cinnamaldehyde or eugenol. TEM observations of treated Candida cells showed 
shrinkage of the protoplast, disruption of the cytoplasmic membrane, decomposition of 
inner organelles and even undulant cell wall was observed. Our findings find support 
from the studies of Tyagi and Malik (2010b) who have reported similar effects on cell 
wall and membranous structure oi Candida albicans when exposed to oil of C. citratus. 
Similarly ultrastructural analysis of treated cells of filamentous fungi {Aspergillus 
fumigatus and T. rubrum) highlighted multiple sites of action of oils in fungal cell 
including damages to the cell wall, cell membrane, nucleus, nuclear membrane, 
cytoplasmic contents, mitochondria and other organelles. These observations indicate that 
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mechanisms of action of oils are disruption of overall intracellular endomembranous 
system. An increase in number and expansion of endoplasmic reticula serves to detoxify 
the drugs or pesticides inside the cell (Park et al. 2007) and indicates a stimulation 
response of the cell to oils as evidenced from our findings. Further, accumulation of 
polysaccharide granules is responsible for the rupture of plasmalemma structure 
(Ghahfarokhie/fl/. 2004). 
Therefore, it appears that cell wall and cell membrane integrity, along with other 
membranous structures are the target sites for essential oils or active compounds. This 
effect may be attributed to the lipophilic properties of essential oils or active compounds 
and indicates their ability to penetrate the plasma membrane (Knobloch et al. 1989). Also, 
alterations in the cytoplasm and cell organelles may be responsible for. the change of cell 
architecture causing deterioration of the cell envelope. These findings of ultrastructural 
changes are in agreement with the effects reported in T. rubrum by onion extracts 
(Ghahfarokhi et al. 2004) and in A. niger by oil of Thymus sp (Rasooli et al. 2006). 
Increase in cell wall thickness of yeast or filamentous fungi due to comparable deposits in 
the form of electron dense vesicles and or irregular shaped membranous materials were 
observed in our study. This effect is similar to the fungal cells treated with inhibitors of 
ergosterol synthesis such as azoles and allylamines which are known to damage 
membrane because ergosterol is an essential lipid component of the cell membrane 
(Nishiyama et al. 2005). 
Essential oil components have the ability to alter the cell permeability by entering 
between the fatty acyl chains of membrane lipid bilayers and therefore, disrupt the lipid 
packing (Hammer et al 2004). Due to this the cell membrane properties like 
fluidity/permeability and other functions may get changed (Sikkema et al. 1995). This 
may also affect the regulation and function of the membrane bound enzymes that alter the 
synthesis of many cell wall polysaccharide components (i.e. p-glucan, chitin and mannan) 
and therefore the cell growth and morphogenesis is disturbed (Hammer et al. 2004). 
The findings of electron microscopic studies have highlighted the multiple sites of action 
of oils in fungal cells including damages to the cell walls, cell membranes, other 
membranous structures and cytoplasmic contents; leading to cell death. Further additional 
level of evidence on mechanism of action was assessed by sorbitol assay for detection of 
210 
cell wall as target sites and K"^  leakage for detection of cell membrane damage. Assays 
for UV absorbing material that are released after cell death were also performed. 
A distinctive feature of compounds acting on the fungal cell wall is that the antifungal 
effect can be reversed in a medium containing an osmotic stabilizer such as sorbitol. 
Therefore, MIC of cinnamaldehyde, eugenol, C. verum and S. aromaticum and 
fluconazole (negative control) and congo red (positive control) were evaluated against C. 
albicans 04 and A. fumigatus MTCC2550 in the presence of sorbitol. There was no 
increase in MIC of test agents against C. albicans 04 and A. fumigatus MTCC2550 
except eugenol and cinnamaldehyde exhibiting increase in MIC up to two and four-folds, 
respectively. This marginal increase in MIC is not enough to conclude the cell wall as 
target site by these compounds. Therefore, it may be suggested that primary target of 
these compounds would not be the cell wall synthesis or assembly. However, the 
morphological changes observed in the treated fungi lead to suggest that fungal 
membrane could be the target for them. Therefore, further experiments such as 
absorbance of cytoplasmic content leakage, effect on ergosterol biosynthesis or activity 
were performed to ensure the mode of action of these compounds. 
Effect of these oils on to cell permeability was clearly evident from data obtained in 260 
nm absorbing materials and K^  leakage assays. The data obtained for test oils were at par 
with positive control drug amphotericin B, a membrane disruptive-agent known to affect 
cell permeability and lethal action against fungal cell. The result showed that 
concentration and time dependent increase in release of cytoplasmic content (increase in 
absorbance values at 260 nm compared to untreated control) is accompanied with change 
in K^ concentration in cell membrane (evident from increased extracellular concentration 
in oil/drug treated supernatant) and leads to cell death at higher concentrations of these 
test oils. Similar mechanism of action by palmarosa and tea tree oils has been reported on 
yeasts (Prashar et al. 2003; Hammer et al. 2004) and filamentous fungi (Wang et al. 
2010). In our study delayed (30 min after exposure to agent) release of 260 nm absorbing 
material from fungal cell was observed that may be due to the time required to induce the 
membrane bound cell wall autolytic enzymes leading to lysis (Gilbert 1984). While the 
activation of autolytic enzymes may have been responsible for this effect, the lysis may 
also have been due to the weakening of the cell wall and the subsequent rupture of the 
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cytoplasmic membrane due to osmotic pressure or a specific action on the cytoplasmic 
membrane. However, in our study substantial leakage of K"^  from treated cell has 
indicated that cytoplasmic membrane is targeted by test oils and its fluidity and 
permeability is changed leading to leakage of cytoplasmic material. Loss of significant 
amount of 260 nm absorbing material suggests that nucleic acids were lost through 
damaged cytoplasmic membrane. Marked leakage of cytoplasmic material is considered 
as indicative of gross and irreversible damage to the cytoplasmic membrane (Hugo and 
Longworth 1964). 
Therefore, to further confirm membrane damage or lesion the flow cytometry of treated 
fungal cells were performed using PI as fluorescent marker. In a dose dependent manner 
eugenol at 4X MIC resulted in 50.90% dead cells, with an edge over cinnamaldehyde 
(40.21%) and amphotericin B (30.42%i), an ergosterol-binding fungicidal antifungal agent. 
Our findings are in accordance with the reports on membrane damaging action by oils of 
Thymus vulgaris, Syzygium aromaticum, eugenol, thymol and carvacrol against Candida 
albicans, Aspergillus spp and dermatophytes (Pinto et al. 2006; Pinto et al. 2009; Ahmad 
et al. 2011). Permeation to PI, particularly following short incubation periods as was 
shown in our study, indicates that the mechanism of action of the eugenol and 
cinnamaldehyde against Candida cells involves a primary lesion of the cell membrane 
with substantial morphological changes leading to cell death. 
Since the membrane damaging effects of antfungal agent might be resulted from different 
mechanisms of activity involving direct binding to ergosterol (amphotericn B) or 
indirectly inhibiting the ergosterol biosynthesis (fluconazole). Therefore, additional 
experiments for differentiating these kinds of mechanism, ergosterol quantitation and 
ergosterol binding assays were performed for Candida cells in the presence of test oils. 
Our studies revealed a dose dependent decrease in the synthesis of ergosterol content at 
sub-MICs of C. verum, S. aromaticum, cinnamaldehyde and eugenol, and the effect was 
far greater than fluconazole. These oils at MICs blocked the ergosterol synthesis almost 
completely in the order of eugenol >cinnamaldehyde >5'. aromaticum > C. verum. The 
similar dose dependent effect on ergosterol biosynthesis in Candida albicans by oils of 
Coriaria nepalensis, Thymus vulgaris, Syzygium aromaticum, eugenol, thymol and 
carvacrol has been reported by other workers (Pinto et al. 2006; Pinto et al. 2009, Ahmad 
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et al. 2010; Ahmad et al. 2011). The effect on membrane integrity, thus, appears to 
originate from the inhibition of ergosterol biosynthesis in a manner similar to fluconazole 
or other ergosterol synthesis inhibitors. However, when these oils were tested for their 
ability to bind ergosterol resulted in increase in MIC against Candida albicans cells in the 
presence of increasing concentration of ergosterol in a manner similar to amphotericin B. 
These observations together led to make tentative suggestion that these oils viz. C. verum, 
S. aromaticum, cinnamaldehyde and eugenol primarily exert membrane damaging effect 
that may be attributed to their ability to inhibit ergosterol biosynthesis and simultaneously 
interacting with membrane by binding to ergosterol. This is to be mentioned here that a 
whole line of current antifungals such as amphotericin B, azoles, allylamines and other 
target the ergosterol biosynthesis pathway or its end product, which is unique to fungi. 
Ergosterol is an important target because it maintains membrane fluidity, asymmetry and 
integrity and therefore various cell functions (Rodriguez et al. 1985). In this regard, these 
oils with potential antifungal activity are supposed to be effective antifungals to be 
exploited in drug. development. Ergosterol also contributes to proper functioning of 
membrane bound enzymes (Lupetti et al. 2002). That may involve interference with the 
cell wall synthesizing enzymes and this may pertained to partial or secondary action of 
these oils affecting cell walls as observed under electron microscopic studies. 
In light of the present findings, it could be proposed that antifungal action of oils of C. 
verum, S. aromaticum, cinnamaldehyde and eugenol against yeasts in particular C 
albicans and filamentous fungi in particular A. fumigatus, takes place via two step 
process. The first step involves the passive entry of oils and its components being 
ampiphillic in nature into plasma membrane in order to initiate membrane disruption by 
altering fluidity and integrity. The second stage is the accumulation of oils/components in 
the plasma membrane resulting in the inhibition of cell growth due to increased bilayer 
disorder, leakage of ions and cytoplasmic materials resulting in disorganized cytoplasm. 
These effects disturb the osmotic balance of cell leading to membrane associated proteins 
inefficient to perform cellular functions and eventually leading to cell death. Therefore, 
the excellence of these oils/compounds exhibiting multiple sites of actions demands more 
insight studies into all of the possible mechanisms of these compounds. 
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6.4. Antifungal activity oi essential oils in combination with antifungal drugs against 
drug-resistant fungi 
Development of new and ideal antifungal agents is remained a challenge for researchers 
and has encouraged the search for alternative strategies to combat Candida infections 
including combinational approach of two or more antifungal agents. Considering this 
view, the essential oils viz. C. copticum, C. citratus, C. martini, C. verum, S. aromaticum, 
T. vulgaris, cinnamaldehyde, citral, eugenol and geraniol exhibiting promising antifungal 
activity alone against Candida spp, Aspergillus spp and Trichophyton rubrum were tested 
in combination with antifungal drugs viz. amphotericin B and fluconazole to explore 
more effective approach. Combination of antifungal agents has advantages over 
monotherapy because it can exhibit improved efficacy due to the increased rate of killing, 
a broader spectrum of action covering multiple infections by different pathogens, a 
reduced duration of therapy resulting in the decreased likelihood of developing resistance 
and minimization of the dose-related toxicity of antifungal drugs (Vazquez 2003; Vitale 
et al. 2005). Combination therapy with available antifungal drugs has been recommended 
and used in treatment for various mycoses (Cuenca-Estrella 2004; Baddley and Pappas 
2007; Segal and Steinbach 2007; Wirk and Wingard 2008); however, combination 
therapy with plant products is less explored. In spite of their diverse activity, essential 
oils or active compounds in combination with antifungal drugs have been less frequently 
investigated. Since natural products are cheaper and considered safer, they could be better 
explored for their synergistic interaction with drugs of choice against Candida and other 
mold infections potentially resulting in more cost effective and safer formulations. 
Some in v/tro studies have revealed synergistic interactions for antifungal activity 
including latex from Euphorbia characias with ketoconazole (Giordani et al. 2001), oils 
ofAlium and Pelargonium graveolens with ketoconazole against Trichophyton spp (Shin 
and Lim 2004; Shin and Pyun 2006), Agastache rugosa oil with ketoconazole against B. 
capitatus (Shin and Kang 2003), and santolina oil with clotrimazole, allicin with azoles, 
oils of Thymus vulgaris and Myrtus communis with amphotericin B against Candida 
albicans (Suresh et al. 1997; Giordani et al. 2004; Khodavandi et al. 2010; Mahboubi 
and Bidgoli 2010); but little information is available against drug-resistant fungi. In this 
perspective, the current findings highlight the synergistic interaction of certain essential 
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oils or active compounds with amphotericn B/fluconazole against tfie drug-resistant 
strains of C albicans, A. fumigatus and T. riibrum. Promising results are coming in the 
form of potentiation of these drugs by their partner drugs in combination, preferably, by 
combining agents with different antifungal mechanisms. 
In the present study, eugenol, citral and T. vulgaris being promising anti-candidal agent 
alone, also exhibited synergistic interaction with both fluconazole and amphotericin B. 
Although, oil of C. martini was an effective anti-candidal agent alone, but in combination 
was indifferent with both fluconazole and amphotericin B. Geraniol exhibited moderate 
anti-candidal activity alone, and also showed a significant level of synergy with both 
fluconazole and amphotericin B. Also, a relatively higher limit of tolerance (greater MIC) 
to amphotericin B and fluconazole as observed in test strains was reduced substantially 
by 16- to 32-fold and, thereby indicated effectiveness of these combinational approaches. 
All test combinations showed synergistic interactions against the test strains of 
filamentous fungi except the oils of C martini and geraniol against A. fumigatus. 
Differences occurring with the same combination may be because the geraniol and 
geraniol acetate shared more than 50% of the C. martini oil. It is possible that the 
behavior of C martini oil is greatly affected by geraniol and that C. martini oil and its 
major ingredients share the same mechanistic differences in the interaction results. 
Cinnamaldehyde was most effective in the combination showing strongest synergy with 
fluconazole against both A. fumigatus and T. rubrum. Cinnamaldehyde also reduced the 
MIC of fluconazole up to eight-fold and its MIC decreased up to 16- and 32-fold. 
Treatment of fungal infections caused by the drug-resistant fungi may require higher 
treatment doses. If fluconazole is used in higher doses in monotherapy it can lead to 
adverse side effects such as hepatotoxicity (Groll et al. 1998). With this in consideration, 
our data suggests that dose-related toxicity associated with amphotericin B and drug 
resistance against fluconazole can be overcome in combinations with essential oils or 
active compounds. As revealed in this study, the interactive responses of oils and active 
compounds did not appear to be affected by the susceptibility behavior of the strains to 
amphotericin B or fluconazole rather variation in a combinational effect may pertain to 
the nature of oils, their constitutional compounds and their concentrations. However, this 
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study is based on in vitro observations and thus required careful investigation under in 
vivo system of diseased model to develop effective combination. 
The synergistic interactions of essential oils or active compounds with 
fluconazole/amphotericin B may be related to the simultaneous inhibition of different 
target sites by test agents and drugs. Fluconazole inhibits fungal cytochrome P450 
dependent enzyme lanosterol 14-a-demethylase and thereby blocks ergosterol 
biosynthesis, and also inhibits P450 dependent enzymes involved in fungal respiration. 
Amphotericin B binds to ergosterol in the cell membrane leading to perforation and 
leakage of cytosol and hence cell death (Vazquez 2003; Onyewu and Heitman 2007). The 
synergistic combination of these drugs with oils may be explained mechanistically that 
oils exerting effects in ways other than available antifungal drugs, mainly on cell wall, 
plasma membrane and other membrane structures of Candida and other filamentous 
fungal cells as evidenced from our study; aids these drugs in their mode of action. Also, it 
could be possible that fungicidal action of essential oils or active compounds lower the 
burden for these drugs to act upon. Since fluconazole is a hydrophilic azole, it is less 
effectively absorbed compared to lipophilic azoles like ketoconazole, clotrimazole and 
itraconazole by cytosolic components of fungal cells (Scheven and Schwegler 1995). The 
oils damaging the cell membrane may facilitate its improved entry to the cell leading to 
more effect on the ergosterol biosynthesis inhibition and adding to the effect of cell 
membrane destruction. Regarding amphotericin B, its binding to ergosterol in the cell 
membrane may be aided by alteration in membrane permeability or fluidity by test oils 
and may lead to enhanced effect of cell membrane damage. The exact mechanism for 
disruption of cell membrane or cell wall synthesis by oils is not understood but multiple 
target sites by such kind of antifungal agents are added advantages in the combination 
therapy. Furthermore, efficient fungicidal activity of oils against azole- and amphotericin 
B-resistant strains suggests that these oils are effective against strategy or adaptive 
mechanisms of resistance exhibited by test fungi. 
6.5. Inhibition of virulence factors production/activity in drug-resistant fungi by 
essential oils 
Another approach to deal with drug resistance in fungi is the development of an agent 
that can target essential virulence factors whose absence or inhibition, although not lethal 
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for fungi may result in loss of virulence of the organism. Therefore, compounds 
influencing the release of virulence factors may be useful in combating fungal diseases 
caused by drug-resistant strains. In the present study, oils C. cupticum, C. veriim, C. 
citratus, C. martini, S. aromaticum, T. vulgaris, eugenol, cinnamaldehyde, citrai and 
geraniol exhibiting significant antifungal activity were assessed for their ability at sub-
MICs (0.5X and 0.25X MIC) to reduce the production of virulence factors namely germ 
tube formation, cell surface hydrophobicity, proteinase and haemolysin in drug resistant 
strains of C albicans, and keratinase and elastase production/activity in the drug-resistant 
strains oiAspergillus spp and Trichophyton spp. 
Test oils especially C. verum, C. copticum, S. aromaticum, T. vulgaris, eugenol and 
cinnamaldehyde significantly inhibited the ability of GTF. This is probably the first 
report on the anti-GTF activity by these oils in pathogenic strains of C. albicans. 
However, oils of Tea tree and certain other plants have been reported to inhibit GTF by 
some other workers (Hammer et al. 2000; Pozzati et al. 2010). Anti-GTF activity by oils 
is a promising anti-virulent property because germ tubes have been shown to contribute 
in increased adherence and invasiveness of Candida cells in models of skin, mucosal and 
disseminated candidiasis (Wellmer and Bernhardt 1997). 
It is considered that hydrophobic interactions play an important role in the adherence of 
opportunistic pathogen yeasts to eukaryotic cells and is an important event in the 
initiation of the pathogenic process (Hazen 1989). Considering this the above mentioned 
oils were tested for their effect on hydrophobicity of Candida spp. Except C. martini, all 
other test oils significantly (PSO.OS) reduced the CSH at both 0.5X and 0.25X MIC in 
one or other strains of Candida spp tested. Similar to our findings, concentration 
dependent inhibition of CSH in C. albicans by tannins from Stryphnodendron 
adstringens has been reported by Ishida et al. (2006). Hydrophobic cells are more 
adherent and resistant to phagocytosis and, therefore more virulent than hydrophilic cells. 
In this regard, lowering of CSH oi Candida cells by test oils suggests their importance in 
arresting the candidal colonization during pathogenesis. 
Production of proteinase is a highly regulated process and transcriptionally co-regulated 
with other virulence attributes in C. albicans. Our findings have revealed a strong 
inhibition of proteinase production in Candida spp by at least six essential oils (C. verum. 
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C. copticum, S. aromaticum, T. vulgaris, cinnamaldehyde and eugenol) at sub-MICs. 
Similar findings have also been reported by Hofling et ah (2011), who have reported 
inhibition of proteinases in C. albicans by six other plant extracts. Proteinase activity 
helps in vivo in obtaining nutrients, adherence, invasiveness, dimorphism, phenotypic 
switching, biofilm formation and degradation of immune components such as antibodies, 
complements and cytokines (De Bernardis and Sullivan 2001; Kuriyama et al. 2003; 
Khan et al. 2010). Therefore, test oils exhibiting strong anti-proteinase activity could be 
considered as important anti-pathogenic agents. 
Moreover, these test oils also exhibited inhibition of haemolysin production at varying 
level. To the best of our knowledge, this is the first report on inhibition of haemolysin 
production in Candida spp by test essential oils particularly C. verum, S. aromaticum, 
cinnamaldehyde, eugenol and geraniol. The role of haemolysin is to obtain iron as a 
nutrient from haemoglobin during disseminated growth of candidal infections; adherence 
is also shown to be reduced in iron limiting environment (Almeida et al. 2009). Therefore, 
exhibition of anti-haemolysin activity in test oils further may aid to their anti-pathogenic 
efficacy against Candida strains. 
These drug targets have been attempted by many researchers to obtain effective anti-
pathogenic drugs against fungal infections as reviewed by Gauwerky et al. (2009). In 
general, test oils or compounds inhibited different virulence factors in one or other strains 
in both C. albicans and non-albicans Candida in the order of efficacy of proteinase >CSH 
>GT >haemolysin. Oils C. copticum, C. verum, S. aromaticum, T. vulgaris, eugenol and 
cinnamaldehyde were highly effective in reducing all the tested virulence factors at 0.5X 
and 0.25X MICs. Other oils could effectively inhibit one or two virulence factors at 0.5X 
MIC. Therefore, oils exhibiting broad spectrum anti-virulent activity may be potential 
candidates as anti-pathogenic drugs. It is to be considered that not all the virulence 
factors are expressed in infections or necessarily in a particular stage of infection (Naglik 
et al. 2003), the inhibition of even single virulence factor by test agents is of practical 
value. Eugenol constitutes 74.32% of oil of S. aromaticum and cinnamaldehyde shares 
79.10% of C. verum as major active ingredients as evident from our study. Activity of 
these ingredients being at par with their respective oils is an indicative of that mechanistic 
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role of these oils is attributed to their major active ingredients and other minor 
compounds are of less importance. 
Essential oils interrupt cell walls, cell membranes, nuclear and mitochondrial membranes 
and respiration in fungal cells as evident from our study together with reports from other 
workers (Inouye et al. 1998; Ishida et at. 2006). It has been suggested that where 
membrane integrity is adversely affected, membrane associated functions may also be 
compromised (Sikkema et al. 1995). Membrane associated enzymes such as chitin, 
mannan, 1,3-P-D-glucan synthase and adenosine triphosphatase (ATPase) are involved in 
GTF (Odds 1998). Therefore, loss of these enzymes together with lack of energy 
production may prevent the morphological transition from blastoconidia to hyphae, a 
form that is more adherent and invasive. In addition, mannoprotein acting as principle 
adhesion protein is associated with cell wall (Hazen 1989). The haemolytic factors 
produced by C. albicans are also believed to be mannoproteins (Watanabe et al. 1999). 
Interference with the production of this protein upon damage of cell wall or cell 
membrane may result in reduced cell adherence and low haemolytic activity. Essential 
oils being hydrophobic in nature will aggregate more hydrophobic cells and severe action 
of oils onto cell walls and membranes of Candida cells might be achieved. This could 
result in the damage of hydrophobic interaction bonds and, therefore lowering of cell wall 
associated CSH. These oils except C. martini at sub-MlCs effectively reduced the 
production of virulence factors in C. albicans SC5314 a well known strain to study 
virulence. 
To explore broad spectrum anti-virulence activity against filamentous fungi these oils 
were assessed for their inhibition of elastase and keratinase production or activities in A. 
fumigatus and T. rubrum. Oils of C copticum, C. verum, T. vulgaris and cinnamaldehyde 
were significantly effective against production of elastase at 0.5X MIC. All the test oils 
except C. citratus and citral significantly reduced the elastase activity whereas only C. 
martini and geraniol were effective against keratinase production and activity. Production 
of elastases and keratinases are reported to aid in the pathogenesis o^Aspergillus sp. and 
Trichpohyton sp. (Okumura et al. 2007; Vermout et al. 2008). Since proteinases 
contribute to fungal virulence by destroying host tissues and digesting immunologically 
important proteins such as antibodies and complement factors (Santos et al. 2007), the 
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inhibition of these enzyme production or activities may reduce the pathogenesis of 
filamentous fungi. Therefore, ability to inhibit proteinase production/activity in 
filamentous fungi is added to the effectiveness of these oils as an anti-pathogenic 
candidate against wide range of fungal infections. 
At higher concentrations these oils are cidal for candidal growth but at lower sub-lethal 
concentrations these lead to attenuation of virulence in Candida cells and may augment 
its susceptibility to immune cells, antibodies and natural killer cells. Moreover, at the 
tested sub-MICs of oils viability of Candida cells was non-significantly affected 
compared to untreated cells and, indicates that reduction in the production of virulence 
factors by oils is not due to the inhibition of growth rather interference with their 
synthesis. Therefore, mode of action of these oils towards fungal cells highlights their 
ability to arrest both the fungal growth at higher concentrations and inhibition of 
virulence factors at lower concentrations. Further, investigations are needed to know the 
exact mechanism of inhibition of virulence factors production. Inhibition of one or more 
virulence factors in fungal cells by oils at lower concentrations would result in no 
survival pressure of killing in cells as exerted by conventional antifungal drugs. Since 
most of the virulence traits are not essential for fungal growth, the chances of developing 
resistance are minimized. This approach might be more effective in immunosuppressed 
patients, where drug-resistant strains lead to relapses of infection due to their virulence 
potential and result in high mortality rate accounting for nosocomial fangaemia (Perfect 
and Cox 1999; Krcmery and Barnesz 2002). 
6.6. Anti-biofilm activity of essential oils against drug-resistant strains of C. albicans 
Extending the view of virulence in fungi, the formation of biofilms is considered as 
important aspect of microbial pathogenesis. The majority of manifestations of candidiasis 
are associated in one way or another with the formation of Candida biofilms on the 
surfaces of inert or biological materials (Crump and Collignon 2000). Sessile (biofilm) 
cells display unique phenotypic traits in comparison with pjanktonic cells. The most 
notable of these is that sessile cells are notoriously resistant to antimicrobial agents and 
withstand host immune defenses (Douglas 2003). This is the main reason why biofilm-
associated infections are frequently refractory to conventional antibiotic therapy. 
Therefore, essential oils/active compounds namely C. copticum, C. citratus, C. martini, C. 
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verum, S. awmaticum, T. vulgaris, cinnamaldehyde, citral, eugenol and geraniol 
exhibiting potential inhibition of growth and virulence in test fungi, were also tested for 
their anti-biofim activity against C. albicans strains. 
In our study, antifungal susceptibility studies of the test strains have demonstrated a rise 
from the planktonic MICs to corresponding sessile MlCs, a characteristic of C. albicans 
biofilms first described by Hawser and Douglas (1995). The drug susceptibility of these 
strains under biofilm conditions exhibited several folds increase in MICs. Sessile MIC 
(SMIC) of amphotericin B was raised up to 16- and 512- folds in C. albicans 04 and C. 
albicans SC5314, respectively. Similarly, SMIC of fluconazole was increased to 8- and 
1024- folds, respectively. Increased resistance to fluconazole and amphotericin B 
Candida biofilms has been reported by other workers as well and antifungal drugs have 
been reported to exhibit 30 to 2000 times higher MIC against sessile cells compared to 
planktonic cells (Hawser and Douglas 1995; Seneviratne et al. 2008). Increases in MIC 
of test oils/compounds against sessile cells compared to their planktonic counterparts 
were only 2- folds higher for C. copticum, C. verum, S. aromaticum, cinnamaldehyde and 
geraniol and 4- folds for C. martini and citral. Remarkably, C. citratus, T. vulgaris, and 
eugenol showed no increase in SMIC compared to planktonic MIC against test strains. 
Furthermore, efficacy of test compounds was evaluated in terms of the time-dependent 
killing of established C. albicans biofilms. Data obtained have showed highest cidal 
activity from C. citratus, geraniol and eugenol compared to other oils and antifungal 
drugs tested. 
It was interesting to observe the ability of test oils to destroy preformed biofilms of C. 
albicans. This prompted us to evaluate the effect of these compounds at sub-MICs to 
inhibit the formation of biofilms when the oils/drugs were added to the medium at the 
same time as the cells. Biofilm formation is considered to be an important virulence 
attributes for establishing and maintaining candidiasis, if an agent is added at the 
beginning of the experiment, the agent might act before the biofilm formed and inhibit 
development of biofilm; it could be of greater interest in combating recalcitrant infections 
of Candida biofilms. Our data revealed varying level of attenuation of biofilm formation 
by planktonic Candida cells in the presence of oils and drugs in a dose dependent manner. 
Among the tested agents, T. vulgaris showed most inhibitory effect on biofilm formation 
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at 0.5 X and 0.25 X MIC followed by C. citratits, eugenol, C. copticum, cinnamaldehyde. 
Other test oils and antifungal drugs were less effective in preventing the formation of 
biofilms. 
These findings of concentration dependent inhibition of formation of biofilms were 
visually confirmed by light microscopy and scanning electron microscopy of C. albicans 
04. Under light microscopy, untreated cells resulted in intact biofilm formation in 48 h 
whereas treated cells exhibited disorganization of biofilm stages with the increasing 
concentration of oils at sub-MICs. Ability to form hyphal forms plays a pivotal role in the 
development of the spatially organized architecture of mature C. albicans biofilms 
(Ramage et al. 2005). Inhibition of filamentation results in atypical biofilm architecture 
consisting of densely packed yeast cells that are easily detached from the substratum as 
shown in our observations. Therefore, it is speculated that anti-pathogenic (especially 
inhibition of dimorphic transition) activity of oils/phytocompounds of plant origin against 
planktonic cells might prevent the initiation and development of different stages of 
biofilms. Our findings have strengthen the exploitation of anti-biofilm properties from 
plant products including essential oils of Cymbopogon citratus, and active compounds 
like thymol, eugenol and terpenoids against Candida spp as recently reported by several 
other workers (He et al. 2007; Agarwal et al. 2008; Braga et al. 2008; Dalleau et al. 
2008; Sangeetha et al. 2009; Sandasi et al. 2011; Taweechaisupapong et al. 2011). 
In our study, SEM observations have clearly indicated the interference of eugenol and 
cinnamaldehyde with cell membrane integrity in Candida cells as evidenced by shrinkage 
of cell surface in planktonic cells. Other workers have also shown that compounds from 
essential oils affect cell membrane integrity of the yeast cells (Bennis et al. 2004; Tyagi 
and Malik 2010a). The similar mode of action was also observed against sessile cells of C. 
albicans as evidenced from our study. These observations lead to suggest that these 
compounds target cell membranes in both the planktonic (higher sterol content) and 
sessile (lower sterol content) cells of C. albicans and their mode of action remain 
unaffected with the phenotypic variation in terms of ergosterol content exhibited by 
planktonic and sessile cells. 
Mature biofilms are notoriously difficult to eradicate and represent a source of infection 
that is recalcitrant to antifungals. This is puzzling because planktonic populations of the 
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same strain can be susceptible to a wider range of antifungals. Sessile ceils exhibit drastic 
phenotypic changes compared to their planl<tonic counterparts resulting from a decreased 
growth rate or nutrient limitation, therefore, modes of action of conventional antifungal 
drugs have been restricted or ineffective in biofilms. 
The most commonly used antifungals such as amphotericin B and fluconazole directly or 
indirectly target the ergosterol in planktonic Candida cells. Azoles act by inhibiting 
ergosterol biosynthesis, and amphotericin B binds to ergosterol. Decreased ergosterol 
content (Mukherjee et al. 2003a) and a diminished level of ergosterol biosynthetic gene 
expression (Garcia-Sanchez et al. 2004) have been reported in mature Candida biofilms. 
Since sterol metabolism is the primary cellular process affected by the most widely 
employed antifungal drugs, the diminished levels of ergosterol present in sessile C. 
albicans may reflect a physiological state more conducive to resistance in these cells. 
These all mechanisms of drug resistance are supposed to be overcome by 
phytocompounds exhibiting mode of action other than that of conventional antifungal 
drugs. This mode of action of these classes of compounds towards sessile cells could be 
compared to that of chlorhexidine, a membrane-active antiseptic that is very effective 
against bacteria that lack sterols (LaFleur et al. 2006). 
Furthermore, the hydrophobic nature of such compounds may result in increased uptake 
of oils through charged polysaccharides of extracellular matrix making more cells in 
contact to compounds and exerting greater membrane permeation into Candida cells. 
Moreover, as per literature reports, one of the predominant reasons for drug-resistance of 
the C albicans biofilms appears to be the restricted penetration of drugs inside the 
exopolymeric matrix, which can bind or restrict the diffusion of antifungals (Douglas 
2003; Ramage et al. 2005). But the volatile nature of essential oils or its constituents can 
overcome this barrier by exerting more penetration inside the exo-polysaccharide matrix 
and therefore, may act as better antifungal against preformed biofilms. This may result in 
an increased spectrum of action of these compounds on sessile cells including persister 
cells leading to a retarded or disorganized development of biofilms. However, further 
work is needed to explore the exact mechanism of oils for overcoming the drug-resistant 
phenotype of biofilm cells. 
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It is to be considered tliat combination therapy overcomes the problem of drug-resistance 
and toxicity associated with the conventional antifungal drugs (fluconazole and 
amphotericin B) when used alone. Therefore, an attempt was made to determine whether 
synergism of fluconazole or amphotericin B and phytocompounds from essential oils in 
combinations could be extended to C. albicans biofilms. The compounds exhibiting 
strong anti-biofilm activity viz. eugenol and cinnamaldehyde were tested for their 
interaction with amphotericin B or fluconazole to examine possible synergy with drugs 
against established biofilms of C. albicans. Eugenol being a potential anti-biofilm agent 
against preformed biofilms and formation of biofilms alone, also exhibited synergistic 
interaction with fluconazole against biofilms formed by test strains. However, 
combination with amphotericn B was indifferent. Similar interaction result was also 
obtained for cinnamaldehyde. SMIC of fluconazole was reduced substantially by 32-fold 
and, thereby indicated effectiveness of these combinational approaches. This could be 
explained that when phytocompounds exhibiting cidal activity against biofilm cells are 
combined with fluconazole, the fungistatic nature of this drug is converted to fungicidal. 
In overall, combination approach may result in cell death and better activity in 
combination is achieved against Candida biofilms. 
6,7. Conclusion 
I. The findings of our in vitro study have highlighted the occurrence of multi-drug 
resistance among the strains of Candida spp, Aspergilus spp and Trichophyton 
spp from different diseased conditions. 
II. In addition, these strains exhibited production of various virulence factors namely 
germ tube formation, cell surface hydrophobocity, proteinases, phospholipases, 
haemolysins and biofilm formation in Candida spp and production of lipases, 
gelatinases, keratinases and elastases in filamentous fungi. This has indicated a 
possible role of various virulence factors in the pathogenicity of fungi to cause 
fungal infections. 
III. A fair number of common essential oils used in this study especially C. copticum, 
C. citratus, C. martini, C. verum, S. aromaticum, T. vulgaris and some of their 
major active compounds such as cinnamaldehyde, citral, eugenol and geraniol 
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demonstrated strong antifungal activity against drug-resistant strains of Candida 
spp, Aspergillus spp, T. rubrum and other tllamentous fungi. 
IV. The mechanism of action of some of these oils primarily appeared to be the 
damage of cytoplasmic membranes by inhibiting ergosterol biosynthesis and or 
binding to ergosterol in the membrane and thereby altering the membrane fluidity 
and integrity. In a consequence they may damage cell wall as a secondary effect 
as observed under electron microscopy studies. 
V. An alternative combinational approach to antifungal agents, these oils exhibited 
synergistic interaction in a varying capacity when tested in combination with 
amphotericin B/fluconazole against drug-resistant strains of Candida spp, A. 
fumigatus and T. rubrum. This has indicated their possible effective exploitation 
in combination approach to combat mycoses caused by these drug-resistant fungi. 
VI. These oils at sub-MlCs also showed varying level of anti-virulence potential by 
inhibiting production of germ tubes, cell surface hydrophobicity, proteinase and 
haemolysin in Candida spp and inhibition of elastase and keratinase 
productions/activity in the strains oiAspergillus sp and Trichophyton sp. This is 
an indicative of their possible role in reducing the virulence of pathogenic fungi. 
VII. Varying level of anti-biofilm activity of these oils against preformed biofllms or 
formation of biofilms alone and or in combination with fluconazole in C. albicans 
further indicated their potential role in inhibition of biofilm on medical implants 
in the host tissue. This also justify their effective use in combating the problems 
of drug-resistance associated with the biofilm mode of growth. 
6.8. Future direction 
The broad spectrum antifungal and anti-pathogenic activities of these test oils/compounds 
need to be evaluated in vivo alone and in combination with antifungal drugs to uncover 
their therapeutic potential against fungal infections caused by strains of Candida spp, 
Aspergillus spp and Trichophyton spp. Biochemical and molecular mechanism of anti-
virulence activity of these oils need to be explored and also to check loss of virulence in 
animal model. 
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Annexure-l. Physico-chemical properties of essentia! oils. 
Parameters 
Essential oils and 
active compounds 
Essential oils 
Colour 
Refractive Optical Specific 
index rotation gravity 
Carum copticum Pale yellow 1.5 +05.25 0.90 
Cinnamomum verum Reddish brown 1.53 -01.20 1.03 
Cymbopogon citratus Yellow 1.49 -01.51 0.96 
Cymbopogon martini Pale yellow 1.47 +00.82 0.88 
Syzygium aromaticum Pale yellow 1.53 -01.53 1.04 
Thymus vulgaris Golden yellow 1.50 +05.16 0.90 
Solubility 
in 90% 
alcohol 
Soluble 
-do-
-do-
-do-
-do-
-do-
Active compounds 
Cinnamaldehyde 
Citral 
Eugenol 
Geraniol 
Pale yellow 
Pale yellow 
Pale yellow 
Colourless 
1.54 
1.49 
1.54 
1.48 
-01.15 
+00.46 
-01.51 
+00.40 
1.05 
0.89 
1.06 
0.88 
-do-
-do-
-do-
-do-
All the values were determined at 27 °C except colour at room temperature 
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Annexure-5. Release of cellular material absorbing at 260 nm from C. albicans 04 cells 
upon treatment with oils and drugs. 
Test agents 
C. verum 
S. aromaticum 
Cinnamaldehyde 
Eugenol 
Amphotericin B 
(Control) 
IXMIC 
0.1200 
±0.009 
0.1300 
±0.010 
0.1250 
±0.010 
0.1190 
±0.009 
0.1000 
±0.010 
Concentrations 
2XMIC 
0.2190 
±0.016 
0.2440 
±0.020 
0.2230 
±0.020 
0.2720 
±0.023 
0.2300 
±0.017 
4XMIC 
0.4030 
±0.034 
0.4140 
±0.045 
0.4290 
±0.039 
0.4700 
±0.040 
0.4030 
±0.037 
30 
0.0450 
±0.004 
0.0650 
±0.005 
0.0720 
±0.005 
0.0790 
±0.008 
0.0580 
±0.005 
Time 
60 
0.1270 
±0.012 
0.1380 
±0.013 
0.1270 
±0.013 
0.1350 
±0.012 
0.1070 
±0.0122 
(min) 
90 
0.3120 
±0.023 
0.3240 
±0.034 
0.3110 
±0.023 
0.3390 
±0.034 
0.3030 
±0.022 
120 
0.4950 
±0.035 
0.4750 
±0.032 
0.5060 
±0.045 
0.5220 
±0.045 
0.4500 
±0.033 
Values are given in absorbance at 260 nm 
Annexure-6. Release of cellular material absorbing at 260 nm from A.fumigatus 
MTCC2550 cells upon treatment with oils and drugs. 
Test agents 
C. verum 
S. aromaticum 
Cinnamaldehyde 
Eugenol 
Amphotericin B 
(Control) 
IXMIC 
0.0850 
±0.005 
0.0820 
±0.005 
0.0900 
±0.008 
0.0950 
±0.006 
0.0800 
±0.004 
Concentrations 
2XMIC 
0.1820 
±0.014 
0.1750 
±0.020 
0.1950 
±0.0156 
0.2100 
±0.013 
0.1520 
±0.015 
4XM1C 
0.3550 
±0.027 
0.3250 
±0.025 
0.3750 
±0.034 
0.3950 
±0.036 
0.3010 
±0.030 
30 
0.0450 
±0.003 
0.0520 
±0.006 
0.0550 
±0.004 
0.0410 
±0.003 
0.0350 
±0.007 
Time (min) 
60 
0.0910 
±0.006 
0.0820 
±0.007 
0.1020 
±0.008 
0.1050 
±0.006 
0.0900 
±0.008 
90 
0.1800 
±0.023 
0.1600 
±0.012 
0.2020 
±0.023 
0.2100 
±0.013 
0.1710 
±0.015 
120 
0.3500 
±0.034 
0.3500 
±0.023 
0.3900 
±0.034 
0.4100 
±0.034 
0.3950 
±0.028 
Values are given in absorbance at 260 nm 
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Annexure-7. Extracellular leakage of K^  content from C. albicans 04 cells upon 
treatment with oils and drugs. 
Test agents 
C. verum 
S. aromaticum 
Cinnamaldehyde 
Eugenol 
Amphotericin B 
(Control) 
IX MIC 
12.32 
±0.90 
9.24 
±0.70 
7.04 
±0.70 
13.64 
±1.34 
13.20 
±1.65 
Concentrations 
2XMIC 
13.64 
±0.80 
10.56 
±0.70 
9.68 
±0.60 
15.84 
±1.21 
16.28 
±1.23 
4XM1C 
15.40 
±1.21 
11.88 
±1.23 
11.88 
±0.09 
18.48 
±1.44 
18.04 
±1.45 
30 
3.08 
±0.34 
3.52 
±0.10 
2.64 
±0.12 
3.52 
±0.30 
3.96 
±0.20 
Time 
60 
4.84 
±0.34 
5.28 
±0.45 
4.40 
±0.23 
6.16 
±0.60 
6.60 
±0.45 
(min) 
120 
9.24 
±0.56 
7.92 
±0.56 
6.16 
±0.45 
9.24 
±0.80 
10.12 
±0.78 
240 
12.50 
±0.93 
9.68 
±0.86 
7.48 
±0.78 
13.90 
±0.98 
13.08 
±0.98 
Values are given in n moles/mg dry weight of cell 
Annexure-8. Extracellular leakage of K^  content from A. fumigatus MTCC2550 cells 
upon treatment with oils and drugs. 
Test agents 
C. verum 
S. aromaticum 
Cinnamaldehyde 
Eugenol 
Amphotericin B 
(Control) 
IX MIC 
11.00 
±1.23 
10.12 
±1.06 
8.80 
±0.98 
14.96 
±1.45 
12.76 
±1.23 
Concentrations 
2XMIC 
14.52 
±1.45 
12.76 
±1.23 
11.44 
±1.23 
18.04 
±1.56 
16.28 
±1.08 
4XMIC 
16.28 
±1.45 
14.96 
±1.34 
14.52 
±1.56 
21.56 
±1.81 
19.36 
±1.45 
30 
4.40 
±0.30 
3.52 
±0.10 
3.96 
±0.20 
4.84 
±0.40 
3.52 
±0.10 
Time 
60 
7.48 
±0.70 
6.16 
±0.50 
6.60 
±0.70 
9.68 
±0.70 
6.16 
±0.40 
; (min) 
120 
8.36 
±0.40 
8.36 
±0.60 
7.92 
±0.70 
12.76 
±0.90 
9.24 
±0.70 
240 
11.56 
±0.90 
10.98 
±0.90 
9.24 
±0.70 
14.52 
±1.21 
12.96 
±0.90 
Values are given in n moles/mg dry weight of cell 
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Annexure-9. Viability assays of strains of Candida spp. exposed to sub-inhibitory 
concentrations of essential oils, active compounds and drugs. 
Test agents 
(sub-MICs) 
Untreated control 
Essential oils 
CA04 
8.I4±0.02 
CA05 
8.04^0.01 
Cell viability assay (log CFU/m! at 10' dilution) 
CA07 CA09 CA 16 MTCC 
8.12±0.03 8.25±0.01 8.02±0.04 8.19±0.01 
CASC 
8.45±0.03 
CTOl 
8.07±0.04 
C. citratus 
0.25 X MIC 
0.5 X MIC 
C. copticum 
0.25 X MIC 
0.5 X MIC 
C. martini 
0.25 X MIC 
0.5 X MIC 
C. vcrum 
0.25 X MIC 
0.5 X MIC 
S. aromaticum 
0.25 X MIC 
0.5 X MIC 
T. vulgaris 
0.25 X MIC 
0.5 X MIC 
Active compounds 
Cinnamaldehyde 
0.25 X MIC 
0.5 X MIC 
Citral 
0.25 X MIC 
0.5 X MIC 
Eugenol 
0.25 X MIC 
0.5 X MIC 
Geraniol 
0.25 X MIC 
0.5 X MIC 
Antifungal drugs 
Amphotericin B 
0.25 X MIC 
0.5 X MIC 
Fluconazole 
0.25 X MIC 
0.5 X MIC 
7.12±0.04 
6.18±0.08 
7.16±0.04 
6.10±0.03 
7.41±0.05 
6.10±0.04 
7.12±0.03 
6.39±0.02 
7.12±0.02 
6.19±0.03 
7.09±0.03 
6.43±0.06 
7.42±0.02 
6.19±0.04 
7.44±0.03 
6.25±0.03 
7.62±0.04 
6.23±0.04 
7.57±0.03 
6.23±0.02 
7.46±0.02 
6.59±0.05 
7.56±0.04 
6.99±0.04 
7.09±0.0I 
6.19±0.04 
7.29±0.07 
6.39±0.05 
7.39±0.04 
6.15±0.03 
7.19±0.03 
6.23±0.04 
7.11 ±0.07 
6.12±0,04 
7,24±0.06 
6.41 ±0.05 
7.63±0.04 
6.14±0.05 
7.41 ±0.06 
6.13±0.04 
7.51 ±0.06 
6.11 ±0.01 
7.49±0.04 
6.29±0.04 
7.25±0.03 
6.44±0.02 
7.45±0.05 
6.90±0.05 
7.54±0.04 
6.36±0.01 
7.34±0.03 
6.46±0.04 
7.35±0.04 
6.39±0.02 
7.34±0.02 
6.29±0.04 
7.27±0.06 
6.17±0.04 
7.14±0.05 
6.39±0.07 
7.51 ±0.06 
6.25±0.05 
7.43±0.02 
6.89±0.05 
7.47±0.08 
6.17±0.03 
7.57±0.05 
6.31±0.02 
7.39±0.04 
6.30±0.05 
7.59±0.02 
7.10±0.04 
7.36±0.03 
6.14±0.03 
7.26±0.04 
6.24±0.02 
7.34±0.05 
6.18±0.01 
7.39±0.04 
6.13±0.06 
7.05±0.05 
6.21 ±0.06 
7,19±0.05, 
6.19±0.04 
7.41 ±0.04 
6.21 ±0.07 
7.45±0.04 
7.12±0.03 
7.35±0.05 
6.18±0.03 
7.60±0.03 
6.18±0.05 
7.51 ±0.04 
6.2±0.02 
7.47±0.03 
6.96±0.03 
7.50±0.01 
6.30±0.05 
7.40±0.06 
6.35±0.03 
7.59±0.02 
6.29±0.04 
7.45±0.05 
6.19±0.01 
7.11 ±0.03 
6.29±0.04 
7.37±0.04 
6.27±0.06 
7.50±0.05 
6.15±0.02 
7.52±0.04 
6.31 ±0.04 
7.31±0.04 
6.19±0.02 
7.45±0.02 
6.09±0.04 
7.49±0.05 
6.11 ±0.05 
7.55±0.06 
7.11 ±0.02 
7.32±0.05 
6.24±0.05 
7.38±0.05 
6.44±0.04 
7.52±0.03 
6.23±0.04 
7.19±0.06 
6.22±0.04 
7.19±0.04 
6.11 ±0.03 
7.32±0.05 
6.44±0.07 
7.32±0.07 
6.18±0.04 
7.49±0.02 
6.I6±0.06 
7.43±0.02 
6.21 ±0.03 
7.66±0.04 
6.19±0.03 
7.45±0.04 
6.99±0.06 
7.45±0.05 
6.99±0.03 
7.70±0.03 
7.10±0.02 
7.60±0.02 
7.17±0.01 
7.88±0.02 
7.16±0.03 
7.75±0.03 
7.11 ±0.05 
7.91 ±0.04 
7.09±0.02 
7.71±0.04 
7.02±0.04 
7.79±0.04 
7.05±0.03 
7.82±0.02 
7.29±0.03 
7.95±0.03 
7.07±0.03 
7.86±0.02 
7.09±0.03 
7.55±0.04 
7.19±0.04 
7.85±0.04 
7.29±0.06 
7.51 ±0.06 
6.98±0.03 
7.41 ±0.04 
6.98±0.05 
7.5I±0.03 
6.90±0.04 
7.62±0.05 
6.89±0.02 
7.82±0.04 
6.99±0.02 
7.52±0.02 
6.71±0.06 
7.52±0.02 
6.89±0.01 
7.61 ±0.03 
6.96±0.05 
7.62±0.03 
6.83±0.05 
7.59±0.04 
7.01 ±0.04 
7.45±0.03 
6.69±0.03 
7.56±0.08 
6.89±0.07 
Within the columns, untreated means followed by treated means are non-significantly different according to 
Duncan's multiple range tests {P<0.05) 
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Annexure-10. Effects of sub-inhibitory concentrations of essential oils, active 
compounds and drugs on proteinase production in Candida spp. 
Test agents 
(Sub-MICs) 
Essential oils 
C. citratus 
0.25X MIC 
0.5X MIC 
C. copticum 
0.25X MIC 
0.5X MIC 
C. martini 
0.25X MIC 
0.5X MIC 
C. verum 
0.25X MIC 
0.5X MIC 
S. aromaticum 
0.25XMIC 
0.5X MIC 
T. vulgaris 
0.25X MIC 
0.5X MIC 
Active compounds 
Cinnamaldehyde 
0.25X MIC 
0.5X MIC 
Citral 
0.25X MIC 
0.5X MIC 
Eugenol 
0.25X MIC 
0.5X MIC 
Geraniol 
0.25X MIC 
0.5XMIC 
Antifungal drugs 
Amphotrericin B 
0.25X MIC 
0.5X MIC 
Fluconazole 
0.25X MIC 
0.5X MIC 
C albicans 
04 
89.23±3.45 
94.20±3.45 
89.23±4.56 
94.80±3.56 
75.45±2.45 
87.65±4.56 
88.85±2.34 
94.87±5.67 
87.80±4.56 
95.03±3.56 
92.54±5.67 
96.00±2.34 
58.58±3.45 
78.68±5.90 
69.27±2.34 
88.85±4.54 
80.79±4.56 
90.96±6.24 
87.72±3.56 
93.07±5.67 
36.58±2.34 
5!.64±3.56 
14.17±1.24 
34.86±2.34 
Percent reduction over untreated control 
in terms of absorbance at 280 nm 
C. albicans 
09 
26.76±1.8I 
45.74±2.34 
80.74±3.45 
84.59±5.67 
51.59±2.34 
62.76±3.45 
29.38±1.45 
43.51±2.45 
35.30±2.34 
49.74±3.67 
86.31±5.67 
91.45±5.67 
28.07±1.34 
41.43±3.45 
41.97±2.34 
59.29±4.45 
30.68±1.34 
39.66±2.34 
70.50±4.56 
80.93±5.67 
32.25±2.34 
57.53±3.45 
19.I1±1.8I 
46.94±1.34 
C. albicans 
MTCC183 
86.18±3.45 
93.02±3.45 
88.50±2.34 
90.91±5.78 
86.07±2.34 
88.73±4.89 
58.3I±4.56 
75.92±3.67 
50.56±3.45 
61.67±4.56 
71.99±3.67 
80.55±5.67 
59.95±5.67 
73.80±3.45 
66.96±2.34 
74.78±5.60 
53.90±2.34 
73.67±3.56 
72.96±4.56 
77.35±5.70 
32.45±1.34 
47.80±4.78 
I2.12±2.34 
35.14±2.34 
C albicans 
SC5314 
54.55±2.34 
71.23±5.67 
70.48±4.56 
82.45±4.56 
41.14±2.34 
6I.23±3.45 
62.47±4.44 
76.57±3.45 
61.61 ±4.67 
72.73±4.67 
65.78±5.67 
74.83±4.56 
63.56±3.44 
70.76±4.78 
44.38±2.34 
59.34±3.45 
66.32±4.56 
73.85±5.89 
53.31±3.45 
70.90±3.45 
48.90±4.56 
65.56±3.45 
40.10±2.34 
62.75±2.34 
C. tropicalis 
01 
46.80±1.24 
65.73±4.56 
63.67±2.34 
82.50±3.45 
54.28±2.34 
65.94±4.56 
80.04±4.56 
83.94±3.45 
70.31 ±3.45 
87.43±4.56 
75.05±4.56 
87.34±2.34 
64.92±3.45 
82.81±4.56 
49.08±3.45 
62.80±2.34 
76.08±4.56 
87.80±3.45 
59.13±2.34 
71.89±4.56 
36.41±1.23 
51.45±2.34 
41.00±2.34 
56.41±2.45 
Absorbance at 280 nm for untreated controls were 0.442±0.009 (C. albicans 04), 0.865±0.003 
(C albicans 09), 1.267±0.006 (C albicans MTCC183), 1.032±0.043 (C. albicans SC5314), 
1.010±0.007 (C tropicalis 01) 
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Annexure-11. Effects of sub-inhibitory concentrations of essential oils, active 
compounds and drugs on haemolysin production in Candida spp. 
Test agents 
(Sub-MICs) 
Essential oils 
C. citratus 
0.25X MIC 
0.5X MIC 
C. copticum 
0.25X MIC 
0.5X MIC 
C. martini 
0.25X MIC 
0.5X MIC 
C. verum 
0.25X MIC 
0.5X MIC 
5. aromaticum 
0.25X MIC 
0.5X MIC 
T. vulgaris 
0.25X MIC 
0.5X MIC 
Active compounds 
Cinnamaldehyde 
0.25X MIC 
0.5X MIC 
Citral 
0.25X MIC 
0.5X MIC 
Eugenol 
0.25X MIC 
0.5X MIC 
Geraniol 
0.25X MIC 
0.5X MIC 
Antifungal drugs 
Amphotrericin B 
0.25X MIC 
0.5X MIC 
Fluconazole 
0.25X MIC 
0.5X MIC 
C. albicans 
05 
19.63±1.23 
42.55±3.45 
53.90±3.45 
64.13±4.56 
4.66±0.98 
5,89±0.98 
62.44±3.45 
78.55±3.45 
47.88±2.34 
53.76±2.34 
55.41 ±3.45 
71.05±4.56 
55.45±3.89 
67.I8±4.56 
4.54±0.98 
9.28±0.98 
55.47±3.45 
60.32±5.67 
44.28±2.42 
47.69±3.45 
24.56±1.23 
34.62±2.34 
4.62±0.98 
5.05±0.98 
Percent reduction over untreated control 
C. albicans 
16 
30.93±2.34 
57.79±3.45 
74.70±4.56 
87.83±5.67 
3.45±0.90 
6.89±0.98 
35.67±2.34 
53.38±3.45 
56.70±2.34 
62.38±4.56 
79.47±3.45 
79.47±4.56 
53.58±2.34 
85.20±5.67 
2.31±0.90 
8.31±0.98 
40.27±2.34 
71.10±3.45 
49.10±2.34 
58.17±2.34 
27.89±1.23 
40.89£3.45 
6.83±0.96 
8.19±0.98 
C. albicans 
MTCC183 
15.26±1.81 
16.02±2.34 
56.89±2.34 
77.56±3.33 
11.29±1.23 
16.02±1.23 
54.89±3.45 
62.95±3.45 
29.03±2.34 
47.79±2.34 
48.1i±3.45 
63.16±3.45 
49.30±3.45 
77.52±4.56 
2.20±0.98 
15.53±1.21 
33.27±2.34 
47.25±2.34 
37.25±2.34 
50.10±2.34 
25.37±2.34 
43.65±2.34 
8.96±0.98 
I5.96±1.23 
C. albicans 
SC53I4 
19.84±1.23 
47.86±3.45 
56.89±3.45 
65.78±3.45 
13.45±].23 
19.80±1.23 
32.34±3.45 
38.90±3.45 
45.38±3.45 
54.56±4.56 
50.89±4.56 
59.80±3.45 
54.07±2.34 
59.62±4.56 
17.84±1.23 
15.99±1.23 
54.07±3.45 
59.62±3.45 
16.78±l.23 
24.56±l.23 
25.46±3.45 
43.34±3.45 
24.96±2.34 
47.32±4.56 
C. tropicalis 
01 
28.65±1.23 
33.53±2.34 
58.90±3.67 
70.89±4.56 
25.63±2.90 
34.07±2.34 
47.75±2.34 
63.I3±5.67 
34.53±3.45 
40.64±2.34 
50.46±4.56 
67.10±3.45 
58.62±2.98 
78.90±4.56 
14.48±1.81 
21.99±1.23 
58.62±2.34 
78.90±3.45 
14.48±1.89 
26.13±2.34 
35.37±2.34 
50.65±3.45 
34.45±3.45 
49.36±2.66 
% haemolysin production in untreated controls were 74.68±3.45 (C albicans 05), 83.18±5.67 
(C albicans 16), 24.93±2.67 (C albicans MTCC183), 74.45±4.56 (C albicans SC5314), 
60.42i:3.45 (C. tropicalis 01) 
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Annexure-12. Proteinase production in tlie strains of A. niger I0A3 and T. rubrum 
I0A9 exposed to sub-MlCs of essential oils, active compounds and 
drugs. 
Test agents 
(Sub-MICs) 
Essential oils 
C. citratus 
0.25 X MIC 
0.5 X MIC 
C. copticum 
0.25 X MIC 
0.5 X MIC 
C. martini 
0.25 X MIC 
0.5 X MIC 
C. verum 
0.25 X MIC 
0.5 X MIC 
S. aromaticum 
0.25 X MIC 
0.5 X MIC 
T. vulgaris 
0.25 X MIC 
0.5 X MIC 
Active compounds 
Cinnamaldehyde 
0.25 X MIC 
0.5 X MIC 
Citral 
0.25 X MIC 
0.5 X MIC 
Eugenol 
0.25 X MIC 
0.5 X MIC 
Geraniol 
0.25 X MIC 
0.5 X MIC 
Antifungal drugs 
Fluconazole 
0.25 X MIC 
0.5 X MIC 
Percent reduction in the Percent reduction in the 
absorbance at 495 nm over absorbance at 280 nm over 
untreated control for eiastase untreated control for 
production keralinase production 
A. niger lOA 3 
12.45 
33.27 
53.45 
81.56 
18.30 
35.64 
49.51 
72.23 
27.36 
62.02 
61.84 
90.53 
39.49 
71.29 
13.25 
26.89 
31.59 
55.29 
16.37 
31.02 
11.54 
37.61 
T. rubrum lOA 9 
22,93 
33.11 
15.59 
29.77 
33.69 
59.62 
18.43 
19.68 
9.591 
6.505 
8.924 
14.59 
6.75 
25.18 
26.59 
45.44 
8.17 
10.00 
30.60 
65.28 
39.11 
31.77 
Absorbance 495 nm for untreated control; 0.399 ± 0.080 
Absorbance 280 nm for untreated control; 0.173 ±0.017 
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Opportunistic fungal infections are the major cause of morbidity in immuno-compromised 
individuals such as cancer and HIV patients. The mortality rate of invasive fungal infections is 
high despite of antifungal chemotherapy with amphotericin B, azoles and caspofungin. The 
unprecedented increase in such patients has challenged the management of fungal infections. 
Furthermore, problem of host toxicity associated with antifungal drugs and emergence of drug-
resistance in primary and opportunistic fungal pathogens has impeded the success of antifungal 
therapy. Therefore, new and effective antifungal agent and approaches for treating these 
infections are warranted. To combat above problems various strategies have been made under 
investigation which include combinational therapy, development of new antifungal agents with 
improved efficacy, novel approaches of drug delivery and search of novel compounds which can 
interfere with fungal virulence and biofilm formation. Such anti-virulence compounds might be 
useful alone or in combination with currently available antifungal drugs. 
Natural products derived from medicinal plants are widely known for their contribution in 
developing modern drug as well as herbal formulation in traditional medicine system. Essential 
oils from medicinal plants are known for their ethnomedicinal uses in Indian traditional system 
against fungal infections. These essential oils have not yet been evaluated for their novel 
antifungal and their mode of action against drug-resistant fungi. Therefore, considering the 
problem of antifungal therapy, a systematic investigation on certain plant essential oils was made 
with the following aims and objectives (i) to characterize strains of Candida spp and filamentous 
fungi for their typical characteristics including production of virulence factors, susceptibility to 
antifungal drugs and formation of biofilms (ii) to evaluate antifungal properties of certain 
essential oils and some of their active ingredients against drug-resistant fungal pathogens (iii) to 
examine the mode of antifungal action of essential oils (iv) to evaluate synergistic interaction 
between essential oils and antifungal drugs against drug-resistant fungal strains (v) to study the 
effect of potential antifungal essential oils on the production of certain virulence factors including 
extracellular enzyme activity in test fungi (vi) to determine the anti-biofilm activity of certain 
essential oils alone and in combination with antifungal drugs against C. a/fa/cans. The findings of 
this investigation are summarized as below. 
Isolation, characterization and Occurrence of virulence factors in test fungi 
In the present study, 26 clinical and 11 reference strains used were isolated/collected, identified 
and confirmed on the basis of standard biochemical, cultural and morphological characteristics 
as Candida albicans (21), non-albicans Candida (6), Cryptococcus neoformans (02), and eight strains 
of filamentous fungi viz. Aspergillus spp (03), Trichophyton rubrum (02), Alternaria solani (01), 
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Fusarium oxysporum (01), Mucor rouxii (01). Identification of strain C albicans 04 based on I8S 
rRNA gene sequencing confirmed our biochemical basis of identification. 
Virulence factors namely germ tube formation, cell surface hydrophobicity, and production of 
extracellular enzymes viz. phospholipase, proteinase and haemolysin were studied for their 
expression among Candida spp at the phenotypic level both qualitatively and quantitatively. In 
addition, ability to form biofilm by these strains was also determined. Filamentous fungi were 
tested for production of extracellular enzymes namely lipase, phospholipase, gelatinase, elastase 
and keratinase. Out of 21 strains of Candida albicans tested for extracellular production of 
phospholipase, proteinase and haemolysin on solid medium, a maximum number of strains (15) 
were positive for proteinase production followed by production of haemolysin ( I I ) and 
phospholipase (7). Among 6 strains of non-albicans Candida (NAC) production of phospholipase, 
proteinase and haemolysin was recorded in 3 different strains. All the test strains of C. albicans 
produced germ tubes in the range of 52.33% to 89.33%. However, 76% of test strains were 
positive for CSH (24.76% to 66.21% CSH). Production of proteinase was recorded in 75% of the 
test strains of C albicans. Haemolysin production was recorded in 52% of the C albicans strains. 
Among the NACs, three strains out of 6 were hydrophobic with % CSH ranging from 41.22 to 
65.39. Biofilm forming ability was demonstrated by 77% of C albicans strains. 
Among the filamentous fungi, Aspergillus niger IOA-3 and Trichophyton rubrum IOA-9 exhibited 
production of several virulence faaors such as phospholipase, proteinase, gelatinase and 
keratinase. When the production of elastase and keratinase was evaluated in liquid medium, only 
A. niger IOA3 could produce elastase (OD495 of 0.085) and keratinase was produced by T. 
rubrum IOA9 and T. rubrum MTCC296. 
Susceptibility of test fungi to antifungal drugs 
The sensitivity behavior of test fungi was determined using disc diffusion and macrobroth 
dilution method as per guidelines of Clinical and Laboratory Standards Institute (CLSI). Data 
obtained for strains of Candida spp and C neoformans has revealed a cross resistance in azoles 
namely, fluconazole, itraconazole and ketoconazole showing wide range of resistance level (2-
512 Mg/ml). Although some of the strains of this study were sensitive to amphotericin B but co-
resistance was also clearly displayed. Furthermore, similar to yeasts drug-resistance in human 
pathogenic molds from different genera of Aspergillus, Trichophyton, and other filamentous fungi 
were evident from our study. 
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Antifungal activity of essential oils against drug-resistant fungi 
The present study has revealed broad spectrum inhibitory activity from oils of C. copticum, C. 
citratus, C. martini, C. verum, S. aromaticum and T. vulgaris, and major active ingredients like 
cinnamaidehyde, eugenoi, geraniol and cttral, against drug-resistant human pathogenic fungi from 
different genera of Car)dida, Aspergillus, Trichophyton, Mucor and Fusarium both in solid and liquid 
media. Out of the 23 tested essential oils and active compounds, cinnamaidehyde and oil of C. 
martini were highly active against all the test strains of yeasts followed by others in the order of 
citral >eugenol >C. verum >C citratus >S. aromaticum =C. copticum =geraniol >T. vulgaris, 
exhibiting zone of inhibition >20 mm against majority of strains. Oils of Eucalyptus sp, M. 
piperita, C. sinensis, C. paradisi and C. limon were least active against majority of the strains 
exhibiting zone of inhibition < I6 mm. Oils of A. graveolens, F. vulgare, P. crispum, R. officinalis, S. 
album, Z .mays, M. fragrans and Z officinale were found inactive at tested concentrations. 
Further, a total of ten essential oils and active compounds exhibiting the highest activity against 
the test yeasts strains by disc diffusion method were assessed for their potency of inhibitory 
activity in terms of MIC using broth macrodilution method. Test oils were highly active in the 
order of C martini (MIC50, 90 Mg/ml) >cinnamaldehyde >citral =C citratus =C copticum >eugenol 
=S. aromaticum =C. verum >T. vulgaris =geraniol. 
Essential oils, namely C. copticum, C. verum, S. aromaticum, C martini, and T. vulgaris exhibited 
strong and broad spectrum activity against all the strains of filamentous fungi with a zone of 
inhibition ranging from 11.00 mm to 38.66 mm. Oils of C. copticum, C. verum, S. aromaticum, C. 
martini and T. vulgaris exhibited strong inhibitory activity against the test strains (MIC range, 72-
288 pg/mland MFC range, 144-576 Mg/ml). Active compounds namely cinnamaidehyde, eugenoi 
and geraniol, showed activity higher than essential oils with MlCs ranging from 40 to 160 |Jg/ml. 
In general, active compounds namely cinnamaidehyde, citral, eugenoi and geraniol, were more 
active than essential oils in their antifungal activities. GC-MS analysis further supports that such 
active constituents are present in these essential oils which collectively or synergistically interact 
to impart a more rapid mode of action. 
Further, these oils exerted a concentration dependent effect on grov/th of filamentous fungi in 
terms of biomass production and mycelial radial growth even at lower concentrations (IS to 40 
Mg/ml). Cinnamaidehyde was found to be most inhibitory against T. rubrum and A fumigatus. In 
our study, light microscopy revealed the concentration and time dependent toxic effects of oils 
of Cinnamomum verum and S/zyg;um aromaticum on mycelial and reproductive structures of test 
fungi. It was also observed that cinnamaidehyde, eugenoi, C. verum and S. aromaticum inhibited 
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significantly (p=0.05) both ungerminated and germinated conidia of A. fumigatus MTCC2550 and 
T. rubrum IOA-9 at a concentration range from 5 to 80 |Jg/ml. Cinnamaldehyde exhibited edge 
over tested oils in activity against both ungerminated and germinated conidia of these fungi at 
sub-inhibitory concentrations. 
The data obtained from time-kill assays reflected the efficacy of test oils higher than fluconazole 
in killing of different C albicans strains exhibiting resistance to fluconazole and amphotericin B or 
susceptible to amphotericin B. The potency of cinnamaldehyde in killing A fumigatus MTCC2550 
and T. rubrum IOA-9 was found to be higher than fluconazole and the other essential oils or 
active compounds as revealed by time kill assays. 
Mechanism of action of essential oils 
To ascertain the surface and ultrastructural changes produced by oils against yeasts and 
filamentous fungi, the cinnamaldehyde and eugenol were selected as test agents as being more 
inhibitory to fungal growth at lower concentrations. The morphological changes produced were 
confirmed by scanning electron microscopy (SEM) of C. albicans 04, A. fumigatus MTCC2550 
treated with sub-MICs of cinnamaldehyde or eugenol. In the SEM micrograph, the differences 
between treated and untreated Candida cells have been visualized clearly. The cell envelope of 
yeast appeared to be damaged by the oils as evident by shrinkage, nonpolar bud scars, and 
receding of cytoplasm leading to lysis of cells. In case of filamentous fungi A. fumigarus 
MTCC2550, severely collapsed and squashed hyphae due to lack of cytoplasm was evident 
Further, to ascertain whether site of action of essential oils against yeasts and filamentous fungi 
is at ceil wall, cell membrane or other intracellular structures, strains of C albicans 04, A. 
fumigatus MTCC2550 and T. rubrum IOA-9 were subjected to transmission electron microscopy 
(TEM) at sub-MICs of cinnamaldehyde or eugenol. TEM observations of treated Candida cells 
showed shrinkage of the protoplast, disruption of the cytoplasmic membrane, decomposition of 
inner organelles and even unduiant ceil wail was observed. Similarly ultrastructural analysis of 
treated cells of filamentous fungi (Aspergillus fumigatus and T. rubrum) highlighted multiple sites of 
action in fungal cell including damages to the cell wall, cell membrane, nucleus, nuclear 
membrane, cytoplasmic contents, mitochondria and other organelles indicating mechanism of 
action as disruption of overall intracellular endomembranous system. Therefore, it appears that 
cell wall and cell membrane integrity, along with other membranous structures are the target 
sites for essential oils or active compounds. 
Further additional level of evidence on mechanism of action was assessed by sorbitol assay for 
detection of cell wall as target sites and K* leakage for detection of cell membrane damage and 
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assays for UV absorbing material that are released after cell death. MIC of cinnamaldehyde, 
eugenol, C verum and S. aromaticum and fluconazole (negative control) and congo red (positive 
control) were evaluated against C albicans 04 and A. fumigatus MTCC2550 in the presence of 
sorbitol. There was no increase in MIC of test agents against C. albicans 04 and A. fumigatus 
MTCC2550 except eugenol and cinnamaldehyde exhibiting increase in MIC up to two and four-
folds, respectively. This marginal increase in MIC is not enough to conclude the cell wall as 
target site by these compounds. Therefore, it may be suggested that primary target of these 
compounds would not be the cell wall synthesis or assembly. 
However, the morphological changes observed in the treated fungi lead to suggest that fungal 
membrane could be the target for them. Therefore, further experiments such as absorbance of 
cytoplasmic content leakage, effect on ergosterol biosynthesis or activity were performed to 
ensure the mode of action of these compounds. Effect of these oils on to cell permeability was 
clearly evident from data obtained in 260 nm absorbing materials and K* leakage assays. The 
data obtained for test oils were at par with positive control drug amphotericin B, a membrane 
disruptive-agent known to affect ceil permeability and lethal action against fungal cell. The result 
showed that concentration and time dependent increase in release of cytoplasmic content 
(increase in absorbance values at 260 nm compared to untreated control) is accompanied with 
change in K'^  concentration in cell membrane (evident from increased extracellular 
concentration in oil/drug treated supernatant) and leads to cell death at higher concentrations of 
these test oils. In our study substantial leakage of K^  from treated cell has indicated that 
cytoplasmic membrane is targeted by test oils and its fluidity and permeability is changed leading 
to leakage of cytoplasmic material. Loss of significant amount of 260 nm absorbing material 
suggests that nucleic acids were lost through damaged cytoplasmic membrane. Marked leakage 
of cytoplasmic material is considered as indicative of gross and irreversible damage to the 
cytoplasmic membrane. 
Further, to confirm membrane damage or lesion the flow cytometry of treated fungal cells were 
performed using propidium iodide (PI) as fluorescent marker. In a dose dependent manner 
eugenol at 4X MIC resulted in 50.90% dead cells, with an edge over cinnamaldehyde (40.21%) 
and amphotericin B (30.42%), an ergosterol-binding fungicidal antifungal agent Since the 
membrane damaging effects may be resulting from different mechanisms of activity involving 
direct binding to ergosterol (as by amphotericn B) or indirectly inhibiting the ergosterol 
biosynthesis (as by fluconazole). Therefore, additional experiments for differentiating these kinds 
of mechanism, ergosterol quantitation and ergosterol binding assays were performed for 
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Candida cells in the presence of test oils. Our studies revealed a dose dependent decrease in the 
synthesis of ergosterol content at sub-MICs of C. verum, S. aromaticum, cinnamaldehyde and 
eugenoi, and the effect was far greater than fluconazole. These oils at MICs blocked the 
ergosterol synthesis almost completely in the order of eugenoi (97.07%) >cinnamaldehyde 
(92.84) >S. aromaticum (87.95) > C. verum (82.09).The effect on membrane integrity, thus, 
appears to originate from the inhibition of ergosterol biosynthesis in a manner similar to 
fluconazole or other ergosterol synthesis inhibitors. However, when these oils were tested for 
their ability to bind ergosterol resulted in increase in MIC against Candida albicans cells in the 
presence of increasing concentration of ergosterol in a manner similar to amphotericin B. 
Antifungal activity of essential oils in combination with antifungal drugs against 
drug-resistant strains of C. albicans and other filamentous fungi 
The essential oils viz. C copticum, C. dtratus, C. martini, C verum, S. aromaticum, T. vulgaris, 
cinnamaldehyde, citral, eugenoi and geraniol exhibiting promising antifungal activity alone against 
Candida spp, Aspergillus spp and Trichophyton rubrum were also tested in combination with 
antifungal drugs viz. amphotericin B and fluconazole to explore more effective approach in terms 
of synergistic interaction. A checkerboard microtiter test was performed to evaluate these 
interactions in vitro. In the present study, eugenoi, citral and T. vulgaris being promising anti-
candidai agent alone, also exhibited synergistic interaction with both fluconazole and 
amphotericin B against tested strains of C albicans. Although, oil of C martini was an effective 
anti-candidal agent alone, but in combination was indifferent with both fluconazole and 
amphotericin B. Geraniol exhibited moderate anti-candidal activity alone, and also showed a 
significant level of synergy with both fluconazole and amphotericin B. Also, a relatively higher 
limit of tolerance (greater MIC) to amphotericin B and fluconazole as observed in test strains 
was reduced substantially by 16- to 32-fold and, thereby indicated effectiveness of these 
combinations. On the other hand, ail test combinations showed synergistic interactions against 
the test strains of filamentous fungi except the oils of C. martini and geraniol against A. fumigatus. 
Cinnamaldehyde was most effective in the combination showing strongest synergy with 
fluconazole against both A fumigatus and T. rubrum. Cinnamaldehyde also reduced the MIC of 
fluconazole up to eight-fold and its MIC decreased up to 16- and 32-fold. 
Inhibition of virulence factors production/activity in drug-resistant strains of Candida 
spp and other filamentous fungi by essential oils 
In the present study, oils C copticum, C. verum, C citratus, C martini, S. aromaticum, T. vulgaris, 
eugenoi, cinnamaldehyde, citral and geraniol exhibiting significant antifungal activity were 
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assessed at sub-MICs (0.5X and 0.25X MIC) for their ability to reduce the production of 
virulence factors namely germ tube formation, cell surface hydrophobicity, proteinase and 
haemolysin in drug-resistant strains of C albicans, and keratinase and elastase production/activity 
in drug-resistant strains of Aspergillus spp and Trichopliyton spp. The order of GTF in the 
presence of 0.5X MIC of these oils was C copticum <T. vulgaris =eugenol <cinnamaldehyde < S. 
aromaticum <C. verum. Except C. martini, all other test oils significantly (PSO.05) reduced the CSH 
at both 0.5X and 0.25X MIC in one or other strains of Candida spp. Percent reduction in the 
proteinase production by C. albicans 04 at 0.5X MIC of oils was recorded in the order of T. 
vulgaris >S. aromaticum >C. verum =C copticum >C. citratus >geranioi >eugenoi >citral >C. martini 
>cinnamaldehyde. The oils C. coptocium, C. verum, T. vulgaris, cinnamaldehyde and eugenol at 
0.5X MIC showed haemolysin reduction of 560% in test strains. 
In general, test oils or compounds inhibited different virulence factors in one or other strains in 
both C albicans and non-albicans Candida in the order of efficacy of proteinase >CSH >GT 
>haemolysin. Oils C copticum, C. verum, S. aromaticum, T. vulgaris, eugenol and cinnamaldehyde 
were highly effective in reducing all the tested virulence factors at 0.5X and 0.25X MICs. Other 
oils could effectively inhibit one or two virulence factors at 0.5X MIC. Therefore, these oils 
exhibiting broad spectrum anti-virulent activity may play significant role in the management of 
fungal infections. 
To explore broad spectrum anti-virulence activity against filamentous fungi these oils were 
assessed for their inhibition of elastase and keratinase production or activities in A. fumigatus and 
T. rubrum. Oils C copticum, C. verum, T. vulgaris and cinnamaldehyde were significantly effective 
against production of elastase at 0.5X MIC. All the test oils except C citratus and citral 
significantly reduced the elastase activity whereas only C martini and geraniol were effective 
against keratinase production and activity. The ability of test oils to inhibit proteinase 
production/activity in filamentous fungi is an added advantages to the effectiveness of these oils 
as an anti-pathogenic candidate against wide range of fungal infections. 
Anti-biofilm activity of essential oils against drug-resistant strains of C. albicans 
Essential oils exhibiting potential inhibition of growth and virulence in test fungi, namely C 
copticum, C citratus, C. martini, C. verum, S. aromaticum, T. vulgaris, cinnamaldehyde, citral, eugenol 
and geraniol were also tested for their anti-biofim activity against C albicans strains. In our study, 
drug susceptibility of test strains under biofilm conditions exhibited several folds increase in 
MICs. Sessile MIC (SMiC) of amphotericin B was raised up to 16- and 512- folds in C. albicans 04 
and C albicans SC53I4, respectively. Similarly, SMIC of fluconazole was increased to 8- and 
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1024- folds, respectively. Increase in MICs of test oils/compounds against sessile cells con-ipared 
to their planktonic counterparts were only 2- folds higher for C. copticum, C. verum, S. 
aromaticum, cinnamaldehyde and geraniol and 4- folds for C. martini and citral. Remarkably, C. 
citratus, T. vulgaris, and eugenol showed no increase in SMIC compared to planktonic MIC against 
test strains. Furthermore, efficacy of test oils/compounds was evaluated in terms of the time-
dependent killing of established C. albicans biofilms. Data obtained have showed highest cidal 
activity from C citratus, geraniol and eugenol compared to other oils and antifungal drugs tested. 
Our data revealed varying level of inhibition of biofilm formation by planktonic Candida cells in 
the presence of oils and drugs in a dose dependent manner. Among the tested agents, T. vulgaris 
showed most inhibitory effect on biofilm formation at 0.5 X and 0.25 X MIC followed by C 
citratus, eugenol, C copticum, cinnamaldehyde. Other test oils and antifungal drugs were less 
effective in preventing the formation of biofilms. These findings of concentration dependent 
inhibition of formation of biofilms were visually confirmed by light microscopy and scanning 
electron microscopy of C. albicans 04. Under light microscopy, untreated cells resulted in intact 
biofilm formation in 48 h whereas treated cells exhibited disorganization of biofilm stages with 
the increasing concentration of oils at sub-MICs. In this study, SEM observations have clearly 
indicated the interference of eugenol and cinnamaldehyde with cell membrane integrity as 
evidenced by shrinkage of cell surface in planktonic cells. 
An attempt was also made to determine whether synergism of fluconazole or amphotericin B 
and phytocompounds from essential oils in combinations could be extended to C albicans 
biofilms. The compounds exhibiting strong anti-biofilm activity viz. eugenol and cinnamaldehyde 
were tested for their interaction with amphotericin B or fluconazole to examine possible 
synergy with drugs against established biofilms of C albicans. Eugenol being a potential anti-
biofiim agent against preformed biofilms as well as formation of biofilms, also exhibited 
synergistic interaction with fluconazole against biofilms formed by test strains. However, 
combination with amphotericn B was indifferent Similar interaction result was also obtained for 
cinnamaldehyde. SMIC of fluconazole was reduced substantially by 32-fold and, thereby indicated 
effectiveness of these combinational approaches. 
Conclusion 
Based on the findings of this study the following major conclusions are drawn as follows: (i) 
Occurrence of drug-resistant strains of Candida spp, Aspergilus spp and Trichophyton spp from 
different diseased conditions is a common problem, (ii) The test fungi exhibited production of 
various virulence factors namely germ tube formation, cell surface hydrophobocity, proteinases. 
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phospholipases and biofilm formation in Candida spp and production of lipases, gelatinases, 
keratlnases and elastases in filamentous fungi and thus indicated a possible role of various 
virulence factors in the pathogenicity of fungi, (iii) A fair number of common essential oils 
especially C. copticum, C. citratus, C. martini, C. verum, S. aromaticum, T. vulgaris and some of their 
major active compounds such as cinnamaldehyde, citral, eugenol and geraniol demonstrated 
promising in vitro antifungal activity against drug-resistant strains of Candida spp, Aspergillus spp, T". 
rubrum and other filamentous fungi, (iv) The mechanism of action of some of these oils primarily 
appeared to be the damage of cytoplasmic membranes by inhibiting ergosterol biosynthesis and 
or binding to ergosterol in the membrane and thereby altering the membrane fluidity and 
integrity, in a consequence they may damage cell wall as a secondary effect as observed under 
transmission electron microscopy, (v) An alternative combinational approach to antifungal 
agents, these oils exhibited synergistic interaction in a varying capacity when tested in 
combination with amphotericin B/fluconazole against drug-resistant strains of Candida spp, A. 
fumigatus and T. rubrum. This has indicated their possible effective exploitation in combination 
approach to combat mycoses caused by these drug-resistant fungi, (vi) These oils at sub-MICs 
also showed varying level of anti-virulence potential by inhibiting production of germ tubes, cell 
surface hydrophobicity, proteinase and haemolysin in Candida spp and inhibition of elastase and 
keratinase productions/activity in the strains of Aspergillus sp and Trichophyton sp. This is an 
indicative of their possible role in reducing the virulence of pathogenic fungi, (vii) Varying level of 
anti-biofilm activity of these oils against preformed biofilms or formation of biofilms alone and or 
in combination with fluconazole in C albicans further indicated their potential role in inhibition 
of biofilm on medical implants in the host tissue. This also justify their effective use in combating 
the problems of drug-resistance associated with the biofilm mode of growth. 
Future direction 
The broad spectrum antifungal and anti-pathogenic activities of these test oils/compounds needs 
to be evaluated in vivo alone and in combination with antifungal drugs to uncover their 
therapeutic potential against fungal infections caused by strains of Candida spp, Aspergillus spp and 
Trichophyton spp. Biochemical and molecular mechanism of anti-virulence activity of these oils 
need to be explored and also to check loss of virulence in animal model. 
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Objectives: The aim of this study was to evaluate four phytocompoufKis (cinnamoldehyde, citral, eugenol and 
geraniol) for their in vitro inhibitory activity ogainst pre-formed biofilms of Candida dbicans alone or in combin- 75 
otion with fluconazole and amphotericin B. These compounds were also tested at subinhibitory concentrations 
for their ability to inhibit biofilm formation. 
Methods: The XTT reduction assay, light microscopy and scanning electron microscopy (SEM) were employed to 
determine the inhibitory effect of the test compounds on biofilms. A chequerboord method was used for com-
birration studies. 
80 
Results: Both clinical and reference strains of C. albicans (C albicans 04 end C. albicans SC5314, respectively) 
25 displayed formation of strong biofilms. Pre-formed Candida biofilms showed >1024x increosed resistance to 
antifungal drugs and 2x increased resistance to cinnamoldehyde and geraniol, but no increased tolerarKe of 
eugenol. The test compounds were more active against pre-formed biofilms than amphotericin B and flucon- 85 
azole. At 0.5x MIC, eugenol and cinnamoldehyde were the most inhibitory compounds against biofilm forma-
tion. Light and electron microscopic studies revealed the deformity of three-dimensional staictures of biofilms 
30 formed in the presence of sub-MICs of eugenol and c innomaldef^e. The cell membrane appeared to be the 
target site of compounds in both planktonic and sessile C. albicans cells, as observed by SEM. Combination 
studies showed that synergy was highest between eugenol ond fluconazole (fractional inhibitory concentration 90 
index=0.14) against pre-formed biofilms of C. albicans SC5314. 
Conclusions: Promising antibiofilm activity was disployed by eugenol and cinnomaldehyde, which also showed 
synergy with fluconazole in vitro. Further evaluation in in vivo systems is required to determine whether these 
findings con be exploited in treating biofilm-associated candidiasis. 
Keywords: eugenol, cinnamoldehyde, scanning electron microscopy, XTT reduction assay 
Introduction resistance associated with nnonotherapy, two-drug combination 
strategies have been attempted both for planktonic and biofilm 
95 
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The majority of manifestations of candidiasis are associated in cells of C dbicans, but disporate effects hove been observed. 
•^ 5 one way or another with the formation of Candida biofilms on Given these concerns, identifying antifungal agents that are 
the surfaces of Inert or biological surfaces.' Sessile (biofilm) effective agoinst Cond/do biofilms olone or in synergy with flucon-
celts display unique phenotypic traits in comparison with plank- azole or amphotericin B is of great importance. Plants are known ^°^ 
tonic cells. The most notable of these is that sessile cells are to produce phytochemicals that attenuate biofilm development 
notoriously resistant to antimicrobial agents ond withstand through specific mechanisms.''Therefore, in this study, we evol- Q2 
50 host immune defences,' and this is the main reoson why uated four phytocompounds of different chemical nature 
biofilm-associated infections are frequently refractory to conven- [phenyl aldehyde (cinnamoldehyde; 3-phenytprop-2-enal), 
tionol antibiotic therapy. The decreased susceptibility of sessile phenyl proponoid (eugenol; 4-Qllyl-2-methoxyphenol) and i io 
cells to antimicrobial agents, including amphotericin B, flucon- terpenoid (citral; 3,7-dimethylocta-2,6-dienal and geraniol; 
azole, itroconazole and ketoconozole, compared with that of 3,7-dimethyloctG-2,6-dien-l-ol)] for their ability to eradicate 
55 planktonic cells has been reported extensively over the past established biofilms and to inhibit biofilm formation at 
decade. To overcome the problem of host toxicity and drug sub-MICs in strains of C. dbicans. The antifungal drugs 
(• The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrot»al Chemotherapy. Ml rights reserved. 
For Permissions, please e-mail: journals.permissions@oup.com 
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In vitro antifungal, anti-elastase and anti-keratinase activity of essential oils of 
Cinnamomum-, Syzygium- and Cymbopogon-spedes against Aspergillus fumigatus 
and Trichophyton rubrum 
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A B S T R A C T 
This study was aimed to evaluate effects of certain essential oils namely Gnnamomum verum, Syzygium 
aromaticujtt. Cymbopogon citratus, Cymbopogon martini and their major components cinnamaldehyde. 
eugenol, citral and geraniol respectively, on growth, hyphal ultrastructure and virulence factors of 
/tspei;g)//us^m^atus and Trichophyton nibmm. The antifungal activity of essential oi Is and thei r major con-
stituents was in the order of cinnamaldehyde > eugenol > geraniol - C. verum > citral > S. aromaticum > C. 
citratus > C. martini, both in liquid and solid media against T. rubmm and A.fiimigatus. Based on promising 
antifungal activity of eugenol and cinnamaldehyde, these oils were further tested for their inhibitory 
activity against ungerminated and germinated oonidia in test fungi. Cinnamaldehyde was found to be 
more active than eugenol. To assess the possible mode of action of cinnamaldehyde, electron micro-
scopic studies were conducted. The observations revealed multiple sites of action of cinnamaldehyde 
mainly on cell membranes and endomembranous structures of the fungal cell. Further, test oils were also 
tested for their anti-virulence activity. More than 70% reduction in elastase activity was recorded in A 
fumigatus by the oils of C verum, C martini, eugenol, cinnamaldehyde and geranioL Similar reduction in 
keratinase activity in A. niger was recorded for the oils of C martini and geraniol. Maximum reduction 
(96.56%) in elastase activity was pnxiuced by cinnamaldehyde whereas; geraniol caused maximum inhi-
bition (97.31%) of keratinase activity. Our findings highlight anti-elastase and anti-keratinase activity of 
above mentioned essential oils as a novel property to be exploited in controlling invasive and supaficial 
mycoses. 
€> 2011 Elsevier GmbH. All rights reserved. 
IntitMluction 
Fungal infections caused by various pathogenic and opportunis-
tic groups are on the rise in the different parts of the world. Invasive 
aspergillosis caused by ^ spcrgiMiis is considered as a major cause of 
morbidity and mortality in immunocompromised hosts and mor-
tality rates may range from 40 to 90% in high risk populations 
(Dagenais and Keller 2009). Other chronic infections associated 
with the immunocompromised patients are caused by dermato-
phytes mainly rridiopftyton sp, and had shown increased incidence 
in recent years especially in the tropical countries (Venkatesan et al. 
2007). With the increasing number of immunosuppressed patients 
at an unprecedented rate, the management of these fimgal infec-
tions would be a definite challenge to mankind. 
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Current antiftmgal therapy for such fungal infections has been 
threatened by the development of drug resistant strains, host tox-
icity of available polyenes and fungistatic mode of action of azoles 
(Barker and Rogers 2006). Therefore, development of nevrer d n ^ 
with improved efficacy and safety or alternative mode of combat-
ing infections is needed. Recent developments in fungal genomics 
have provided unprecedented opportimities for identifying new 
antifungal drug targets and subsequently exploiting in disease con-
trol Targeting virulence and pathogenicity are now considered 
as valuable anti-pathogenic approaches (Gauwerky et ai. 2009). 
Establishment of infection by fungi depends on the host-cell inter-
action with complex interplay of secretion of virulence factors 
mainly proteinases including elastinases. keratinases. gelatinases, 
lipases and phospholipases. These extracellular enzymes are prob-
ably essential for these organisms to degrade structural barrier 
and to obtain nutrient and in establishing infections (Voltan et al. 
2008). Plant products traditionally being used in ethnomedicine 
have been expected to deliver newer antifungal compounds. Anti-
fungal activities of the essential oils or their major constituents 
against Aspergillus and Trichophyton spp. have been reported by 
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oils of Cinnamomum-, Syzygium- and Cymbopogon-spedes against Aspergilhis fiiimgatus and TricbopftytDn nibrum. Phytomedicine (2011), 
doi: 101016/j.phymed.2011.07.005 
Medical Mycology Month 2011, Early Online, 
-10 
informa 
hedlthcare 
Anti-candidal activity of essential oils alone and in 
combination with amphotericin B or fluconazole against 
multi-drug resistant isolates of Candida albicans 
MOHD SAJJAD AHMAD KHAN*,ABIDA MALIKf & IQBAL AHMAD* 
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Therapy for candidiasis is becomine problemalic due to the loxicities of currenlly 
available antifungal agents and the increasing pre\alence of resistance among the etio-
logic agents. Therefore, new antifungals and alternative approaches are needed. In this 
study, 20 fluconazole-resistant strains of Cundhln albicans were found to have varying 
levels of resistance to other azoles, i.e.. itraconazole (MIC of 4-128 |ig/ml) and keloco-
nazole (2-256 ^g/ml). In addition. 13 of these isolates appeared resistant to amphotericin 
B (32-128 |ag/ml). A total of 21 plant essential oils were screened for their antifungal 
activity against these multi-drug resistant isolates. The oils of Cymhopogon martini, 
i.e.. citral and cinnanialdehyde, exhibited strong inhibitory activity with minimum 
inhibitory concentrations (MIC-^) ranging from 90-100 ug/ml. The test oils were more 
effective than fluconazole and amphotericin B in inhibiting azoic- and amphotericin 
B-resislant, as well as amphotericin B-suscept:blc isolates. The test oils and especially 
eugcnol, exhibited signilicani syncrg}' u'iih ilrcoiiazole or amphotericin B against (he 
test isolates. These findings suggest the possible effective use of certain oils alone or in 
combination wuh (luconazole or amphotericin B. against multi-drtig resistant isolates of 
C. albicans. 
Keywords Candida albicans, drug resistance, essential oils, synergy, fluconazole, 
amphotericin B 
Introduction 
Fungal infections have been increasing in recent years 
as a consequence of the growing ntmiber of unniunocom-
promised patients due to HIV infection, cancer chemo-
therapy and organ or bone niaiTow transplantations f I ]. 
In such persons. Candida infections are very common 
causing oral, \aginal and/or systemic candidiasis. Oropha-
lyngeal candidiasis is generally frequently enountered in 
,-\lD.S patients who do not have access to highly active 
antii'etro\iral therapy (HAART) |2|. whereas oral candidi-
asis often affects cancer patients undergoing chemotherapy 
and/or radiotherapy [3]. 
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Polyenes and azoles have been the antifungals of choice 
in the treatment of these fungal infections. Flowever, many 
problems remain to be solved for most of the available 
antifungal drugs such as nephrlJ- and hepato-to.xicity 
associated with the use of tuiiphotericin B [4|. A lipid for-
mulation of amphotericin B is less toxic but more costly 
14.5]. .A/oles. particularly (luconazole, are less toxic after 
oral or intra\enous adniinisiralion and consequently are 
often employed |4|. However, azole therapy failures 
have been obsei\ed due to intrinsic resistance in Candida 
spp. such as C kriisci and C. f^lubnita and acquired resis-
tance in previousl)' susceptible strains of C. albicans due 
to their continual use in .AID-S and cancer patients [6|. 
.About 3.6-7.2 o- of (\ albicans isolates from women with 
\'aginitis are resistant to lluconazole |7 | and. oropharangeal 
candidia.sis due lo Ihe llucona/ole-resistanl Candida has 
long been a pri>blem for HIV patients 18.9]. Since the 
imniunocompio nised population is increasing in number. 
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Abstract The aim of this study was to screen certain plant 
essential oils and active compounds for antifungal activity 
and their in vitro interaction with fluconazole against drug-
resistant pathogenic fungi. The methods employed in this 
work included disc diflftision, broth macrodilution, time kill 
methods and checkerboard microliter tests. Oil compositions 
were evaluated by gas chromatography-mass spectrometry 
(GC-MS) analysis. Transmission electron microscopy was 
used to assess the effect of essential oils on cellular structures 
of test fiingi. Test fungal strains exhibited resistance to at least 
two drugs (fluconazole and itraconazole). Among the 21 
essential oils or active compounds tested, ten showed 
promising antifungal activity. GC-MS analysis revealed the 
presence of major active compounds in the essential oils used 
Cinnamaldehyde showed the most promising antifungal 
activity and killing potency against Aspei-gillus fiimigatiis 
NfTCC2550 and Trichophyton rubrum IOA-9. Cinnamalde-
hyde showed strongest synergy with fluconazole against A. 
fumigatus and T. rubrum by reducing the minimum 
inhibitory concentration of fluconazole up to 8-fold. Zones 
of lysis of the cdl wall and cell memlwane appeared to be 
where cinnamaldehyde acted on fiingi. This study highlights 
the broad spectrum antifungal activity of essential oils and 
active compounds and their synergy with fluconazole against 
drug-resistant fiingi. 
Keywords Antifiingal drugs • Drug resistance - Essential 
oils • GC-MS • Synergy • Transmission electron microscopy 
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Introduction 
Incidence of microbial infections has increased in recent 
decades, especially mycoses which account for a high rate 
of death among patients with a weakened immune system. 
Opportunistic fungal infections are a serious threat to such 
patients and have been reported to occur at an alarming rate 
(Pinto et al. 2006). Infections of alveolar tissues by 
members of genus .Aspergillus produce a spectrum of lung 
diseases known as aspergilloses. The disease involves 
pulmonary aspergilloma, invasive aspergillosis and allergic 
bronchopulmonary aspergillosis and is mainly caused by 
Aspergillus fumigatus and A. niger and less frequently by 
A. flams and A. clavatus. Invasive aspergillosis in 
immunosuppressed individuals often results in death and 
has become a major concern among public health officials 
(Lutz et al. 2003; Sin^ and Paterson 2005; Erjavec et al. 
2009; Leventakos et al. 2010; Pfaller and Diekema 2010). 
Also, infections of hair, skin and nails have increased 
considerably among pediatric and geriatric populations 
(Mukherjee et al. 2003; Monod 2008). Such infections are 
primarily caused by Trichophyton rubrum and other 
dermatophytes and are not life-threatening; however, both 
immunocompetent and immunosuppressed persons are 
affected (Vermount et al. 200S). Chronic infections of skin 
carry considerable morbidity and can become serious in 
immunocompromised patients resulting in invasive infections 
(Sokovic et al. 2006). 
The antifungal drugs most commonly used against these 
diseases include amphotericin B, ketoconazolc, fluconazole, 
terbinafine and flucytosine. Adverse side effects are associated 
with the use of available antifungal dmgs including nephro-
toxicity, hepatotoxicity and neurotoxicity (Andriole l*^ W4). 
Also, therapeutic response is slow in immunocompromised 
patients. Fluconazole is considered to be one of the safest 
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Abstract 
Plants have been one of the major sources of med-
icines since the dawn of human civilization. The con-
tribution of plant-derived drugs in modern times is still 
significant and much interest has been focused on 
exploiting the vi/ide diversity of medicinal plants in both 
traditional systems of medicine and modern drug 
development. In this review, we assess three plants, 
namely Punica granatum L., Curcuma longa L and 
Zingiber officinale Rose, for their biological activities, 
i Recent trends in phytochemical investigation and 
i study of the pharmacological actions of all P. grana' 
I turn components (juice, seeds, leaf, pericarp) suggest 
I possible clinical application for the treatment and pre-
i vention of cancer and other diseases where chronic 
inflammation is believed to play an essential etiologi-
cal role. C. longa extracts and active constituents have 
a potential role in the prevention of cancer and the 
nianagement of infectious and chronic diseases. Z. 
officinale extracts and active constituents have potent 
antioxidant, antiinflammatory, antimutagenic and 
antimicrobial activities, and some of them have shown 
anticancer activity in experimental models of carcino-
genesis. Z officinale has also been found to be effec-
tive against pregnancy-induced and postoperative 
nausea and vomiting, and has proved useful for treat-
ing motion sickness and arthritis symptoms. 
Introduction 
Herbs, spices, medicinal plants and their preparations 
have been used to treat ailments since prehistonc times. 
The treatment of various diseases using plant-based med-
icines has remained an integral part of many cultures 
across the globe. The World Health Organization (WHO) 
estimates that 80°c of the people living m developing 
countries almost exclusively use traditional medicine 
Such medicines, derived directly or indirectly from plants 
constitute 25°o of the pharmaceutical armamentarium. 
India has been identified as one of the top 12 mega-diver-
sity centers n the world, with immensely rich medicinal 
and aromatic plants occurring in diverse ecosystems 
These medicinal plants are used both for pnmary health-
care and for treating chronic diseases such as AIDS, can-
cer, hepatic and cardiac disorders and age-related dis-
eases such as memory loss, osteoporosis and diabetes. 
In the Indian coded system. Ayurveda currently uses as 
many as 1,003 single drugs and over 8.000 compound for-
mulations of recognized merit Similarly 600-700 plants 
are used by Dther systems, such as Unani. Siddha ana 
Amchi (1). 
The use of medicinal plants and other natural prod-
ucts with therapeutic properties is as ancient as human 
civilization ar^d lor centuries natural products were the 
main source of drugs. About 25°o of the drugs prescribed 
worldwide sli I come from plants, with 121 such com-
pounds Still currently in use. At the beginning of the 21s' 
century. 11% of the 252 drugs considered basic and 
essential by the WHO were exclusively of flowering plant 
origin. In recent years, there has been serious rethinking 
on the use of medicinal plants and traditional medicines 
as a source of new bioactive compounds lor the treat-
ment of various ailments (2-5) This is primarily due to the 
slow progress in drug development from synthetic and 
other modern approaches and the acceptance of herbal 
medicine in both developed and developing countries. 
Traditional medicinal practices form an integral part of 
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Intrinsic drug-resistance and persistent infections of Candida biofilms has necessitated 
the search for new strategies to combat such infections. In the present study, 16 out of 
18 multidrug-resistant strains of Candida albicans formed biofilms. Preformed Candida 
biofilms showed up to 512 times increased tolerance to antifungal drugs compared to 
essential oils (up to 4 times). Test oils were also found more cidal in nature cidal in nature 
compared to antifungal drugs. At 1/2 MIC, eugenol and cinnamaldehyde were most 
inhibitory against biofilm formation as also evident from electron microscopic studies. Our 
findings suggest a novel approach to use essential oils especially eugenol and cinnamaldehyde 
in treating biofilm associated candidiasis. 
